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Abstract
Meta-analysis has become a widely-used tool to combine findings from independent
studies in various research areas. This thesis deals with several important statisti-
cal issues in systematic reviews and meta-analyses, such as assessing heterogeneity in
the presence of outliers, quantifying publication bias, and simultaneously synthesizing
multiple treatments and factors. The first part of this thesis focuses on univariate
meta-analysis. We propose alternative measures to robustly describe between-study
heterogeneity, which are shown to be less affected by outliers compared with traditional
measures. Publication bias is another issue that can seriously affect the validity and
generalizability of meta-analysis conclusions. We present the first work to empirically
evaluate the performance of seven commonly-used publication bias tests based on a
large collection of actual meta-analyses in the Cochrane Library. Our findings may
guide researchers in properly assessing publication bias and interpreting test results for
future systematic reviews. Moreover, instead of just testing for publication bias, we
further consider quantifying it and propose an intuitive publication bias measure, called
the skewness of standardized deviates, which effectively describes the asymmetry of the
collected studies’ results. The measure’s theoretical properties are studied, and we show
that it can also serve as a powerful test statistic.
The second part of this thesis introduces novel ideas in multivariate meta-analysis.
In medical sciences, a disease condition is typically associated with multiple risk and
protective factors. Although many studies report results of multiple factors, nearly
all meta-analyses separately synthesize the association between each factor and the
disease condition of interest. We propose a new concept, multivariate meta-analysis
of multiple factors, to synthesize all available factors simultaneously using a Bayesian
hierarchical model. By borrowing information across factors, the multivariate method
can improve statistical efficiency and reduce biases compared with separate analyses. In
addition to synthesizing multiple factors, network meta-analysis has recently attracted
much attention in evidence-based medicine because it simultaneously combines both
direct and indirect evidence to compare multiple treatments and thus facilitates better
decision making. First, we empirically compare two network meta-analysis models,
ii
contrast- and arm-based, with respect to their sensitivity to treatment exclusions. The
arm-based method is shown to be more robust to such exclusions, mostly because it
can use single-arm studies while the contrast-based method cannot. Then, focusing on
the currently popular contrast-based method, we theoretically explore the key factors
that make network meta-analysis outperform traditional pairwise meta-analyses. We
prove that evidence cycles in the treatment network play critical roles in network meta-
analysis. Specifically, network meta-analysis produces posterior distributions identical
to separate pairwise meta-analyses for all treatment comparisons when a treatment
network does not contain cycles. This equivalence is illustrated using simulations and
a case study.
iii
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Chapter 1
Introduction
Systematic reviews and meta-analyses have been frequently used to synthesize findings
from multiple independent studies in many areas, including but not limited to evidence-
based medicine and health care [1–5]. On an Internet Web search, the term ‘meta-
analysis’ had 112,071 hits in PubMed dated on September 1, 2016, with 62,279 hits
within last five years. This thesis deals with several important problems in meta-
analysis: assessing heterogeneity (Chapter 2) and publication bias (Chapters 3 and 4),
synthesizing multiple risk/protective factors (Chapter 5), and simultaneously comparing
multiple treatments (Chapters 6 and 7).
The collected studies in a meta-analysis are called homogeneous if they share a
common underlying true effect size; otherwise, they are called heterogeneous. A fixed-
effect model is customarily used for studies deemed to be homogeneous, while a random-
effects model is used for heterogeneous studies [6, 7]. Assessing heterogeneity is thus a
critical issue in meta-analysis because different models may lead to different estimates
of overall effect size and different standard errors. Also, the perception of heterogeneity
or homogeneity helps clinicians make important decisions, such as whether the collected
studies are similar enough to integrate their results and whether a treatment is applicable
to all patients [8].
The classical statistic for testing between-study heterogeneity is Cochran’s χ2 test
[9], also known as the Q test [10]. However, this test suffers from poor power when the
number of collected studies is small, and it may detect clinically unimportant hetero-
geneity when many studies are pooled [11, 12]. More importantly, since the Q statistic
1
2and estimators of between-study variance depend on either the number of collected
studies or the scale of effect sizes, they cannot be used to compare degrees of het-
erogeneity between different meta-analyses. Accordingly, Higgins and Thompson [13]
proposed several measures to better describe heterogeneity. Among these, I2 measures
the proportion of total variation between studies that is due to heterogeneity rather than
within-study sampling error, and it has been popular in the meta-analysis literature.
Higgins and Thompson [3] empirically provided a rough guide to interpretation of I2:
0 ≤ I2 ≤ 0.4 indicates that heterogeneity might not be important; 0.3 ≤ I2 ≤ 0.6 may
represent moderate heterogeneity; 0.5 ≤ I2 ≤ 0.9 may represent substantial heterogene-
ity; and 0.75 ≤ I2 ≤ 1 implies considerable heterogeneity. These ranges overlap because
the importance of heterogeneity depends on several factors and strict thresholds can be
misleading [3].
Ideally, if heterogeneity is present in a meta-analysis, it should permeate the entire
collection of studies instead of being limited to a small number of outlying studies. With
this in mind, we may classify meta-analyses into four groups: (i) all collected studies are
homogeneous; (ii) a few studies are outlying and the rest are homogeneous; (iii) hetero-
geneity permeates the entire collection of studies; and (iv) a few studies are outlying and
heterogeneity permeates the remaining studies. Outlying studies can have great impact
on conventional heterogeneity measures and on the conclusions of a meta-analysis. Sev-
eral methods have been recently developed for detecting outliers and influential data
in meta-analysis [14, 15]. However, no widely accepted guidelines exist for handling
outliers in the statistical literature, including the area of meta-analysis. Hedges and
Olkin [16] specified two extreme positions about dealing with outlying studies: (i) data
are ‘sacred’, and no study should ever be set aside for any reason; or (ii) data should
be tested for outlying studies, and those failing to conform to the hypothesized model
should be removed. Neither seems appropriate. Alternatively, if a small number of stud-
ies is influential, some researchers usually present sensitivity analyses with and without
those studies. However, if the results of sensitivity analysis differ dramatically, clinicians
may reach no consensus about which result to use to make decisions. Because of these
problems caused by outliers, ideal heterogeneity measures are expected to be robust:
they should be minimally affected by outliers and accurately describe heterogeneity.
Chapter 2 will introduce new heterogeneity measures that are less affected by outliers
3than conventional measures.
Like outliers and high heterogeneity between studies, publication bias also seriously
threatens the validity and generalizability of conclusions of systematic reviews—studies
with statistically significant findings are more likely to be published than those re-
porting statistically non-significant findings—thus the overall treatment effect may be
overestimated [17–21]. Therefore, assessing publication bias has been a critical topic in
systematic review and meta-analysis.
A traditional and intuitive method for assessing publication bias is to examine the
asymmetry of a funnel plot, which usually plots effect sizes vs. their corresponding
precisions or standard errors [22,23]. In the presence of publication bias, the funnel plot
is expected to be asymmetric. However, the visual examination is usually subjective.
Based on the funnel plot, Begg’s rank test, Egger’s regression test, and the trim and fill
method have been proposed to statistically test publication bias, and they are widely
applied [24–26]. The trim and fill method is attractive because it not only detects but
also adjusts for publication bias; nevertheless, it makes rather strong assumptions about
the treatment effects of potentially suppressed studies, and the adjusted overall effect
estimate is generally recommended as a form of sensitivity analysis [27]. Begg’s and
Egger’s tests aim at examining the association between the observed treatment effects
and their standard errors; a strong association leads to an asymmetric funnel plot and
implies publication bias. The original Egger’s test regresses the standardized treatment
effect (i.e., effect size divided by its standard error) on the corresponding precision
(i.e., the inverse of standard error). This regression can be shown to be equivalent to
a weighted regression of the treatment effect on its standard error, weighted by the
inverse of its variance [28]. The weighted regression version has become more familiar
among meta-analysts, probably because it directly links the treatment effects to their
precisions without standardizing. Several modifications of Egger’s test also use the
technique of weighted regression—the dependent variable is still the treatment effect,
but the independent variable differs. For example, Tang and Liu [29] suggested an
alternative test motivated by the sample-size-based funnel plot, in which the treatment
effect is presented against the total sample size of each study. Tang’s regression test
basically performs weighted regression of the treatment effect on the inverse of the
square root of study-specific sample size.
4When study outcomes are binary, the commonly-used effect size, log odds ratio, is
mathematically associated with its standard error, even in the absence of publication
bias [30,31]. Although it is infeasible to accurately evaluate this association’s strength,
several authors have concerns that Begg’s and Egger’s methods may have inflated type I
error rates for binary outcomes due to the potential association, and alternative regres-
sion tests have been designed specifically to deal with this issue [31–33]. For example,
Macaskill et al. [32] regressed the log odds ratio on the study-specific total sample
size. Deeks et al. [31] used the ‘effective sample size’ (see its definition in Table 3.1) as
the regression independent variable, and Peters et al. [33] slightly modified Macaskill’s
regression and used the inverse of the total sample size as the independent variable. Ta-
ble 3.1 briefly describes these approaches; more details are provided by Sterne et al. [34].
The various approaches have been widely applied to assess publication bias in sys-
tematic reviews, and some of them have been compared in extensive simulation stud-
ies [33,35,36]. It is generally recognized that Begg’s rank test has lower statistical power
than the others based on their performance in simulations [28, 30, 32]. However, most
meta-analysis articles only perform one or two publication bias tests, and so far the
performance of the various tests has not been systematically and comprehensively eval-
uated using published meta-analysis datasets. In addition, some simulation settings can
be fairly unrealistic; for example, studies may be suppressed because of non-significant
P -values [24], or negative effect sizes [26], or other obscure editorial criteria, and the
exact mechanism of publication bias in a real meta-analysis can never be reproduced by
simulations. Instead of just conducting simulation studies, Chapter 3 evaluates seven
commonly-used publication bias tests using a large collection of actual meta-analyses
published in the Cochrane Library.
Besides the aforementioned funnel-plot-based methods, another class of approaches
to detecting publication bias is based on selection models. These approaches typically
use weighted distribution theory to model the selection (i.e., publication) process and
develop estimation procedures that account for the selection process; see, e.g., [37–40].
Sutton et al. [41] provide a comprehensive review. The selection models are usually
complicated, limiting their applicability. Moreover, they incorporate weight functions
in an effort to correct publication bias, but strong and largely untestable assumptions
are often made [41]. Therefore, the validity of their adjusted results may be doubtful,
5and these methods are usually employed as sensitivity analyses.
In addition to detecting publication bias using selection models and funnel-plot-
based methods, it is also important to quantify publication bias by measures that permit
comparisons between different meta-analyses. A candidate measure is the intercept of
the regression test [25]. However, as a measure of asymmetry of the collected study
results, the regression intercept lacks a clear interpretation; for example, it is difficult to
provide a range guideline to determine mild, moderate, or substantial publication bias
based on the regression intercept. Due to this limitation, meta-analysts usually report
the P -value of Egger’s regression test, but not the magnitude of the intercept. We
will show that the regression intercept basically estimates the average of study-specific
standardized deviates; it does not account for the shape of the deviates’ distribution,
which is skewed in the presence of publication bias. This may limit the statistical power
of Egger’s regression test. Chapter 4 introduces a new measure of publication bias: the
skewness of the standardized deviates. It not only has an intuitive interpretation as the
asymmetry of the collected study results but also can serve as a powerful test statistic.
Beyond univariate meta-analysis, statistical methods for multivariate meta-analysis
are increasingly popular in the era of big data. This thesis will introduce innovative ideas
when synthesizing multiple factors and treatments. As a disease condition is typically
associated with many risk and protective factors in medical sciences, many randomized
controlled trials and observational studies considered multiple factors [42–45]. Reliable
summaries of association between each factor and the disease condition are crucial for the
design of a multi-factor intervention program. The growth of interest in evidence-based
medicine has led to a dramatic increase in attention paid to systematic reviews and meta-
analyses. In prevention studies, it has become increasingly popular to perform meta-
analyses on multiple risk and protective factors to summarize existing evidence; however,
currently, nearly all meta-analyses are performed on each factor separately [46–48].
Different studies usually focus on different subsets of all risk and protective factors,
and may only selectively report some significant factors in peer-reviewed articles; some
factors may be reported by only a few studies. Hence, if we organize the collected data
in a matrix with rows and columns indexing studies and factors respectively, then the
data matrix is expected to contain many missing entries; see the example in Table 5.1.
A conventional meta-analysis separately estimates each factor’s association with the
6disease condition, so it cannot borrow information from the correlations between factors.
Moreover, results from separate meta-analyses may not be directly comparable because
they may be based on different subpopulations. This limits medical investigators as they
select most important factors for the design of a multi-factor intervention program.
Recently, Serghiou et al. [49] introduced field-wide systematic review and meta-
analysis to report and assess the entire field of putative factors for a disease condition.
Based on this concept, researchers can learn the selective availability and different ad-
justments of factors and the patterns of modeling. Although multiple factors were
collected, the authors pooled the results for each factor separately; this is not efficient
to analyze the multivariate data from a field-wide systematic review. Chapter 5 pro-
poses multivariate meta-analysis of multiple factors to jointly synthesize all risk and
protective factors in the field-wide systematic review. This method is shown to produce
better estimates of association measures between the factors and the disease condition,
compared with separate meta-analyses.
A disease condition can also have multiple treatments in medical sciences. Com-
parative effectiveness research is aimed at informing health care decisions concerning
the benefits and risks of different diagnostic and intervention options. The growing
number of treatment options for a given condition, as well as the rapid escalation in
their cost, has created a greater need for rigorous comparisons of multiple treatments
in clinical practice. To simultaneously compare multiple treatments for a given condi-
tion, network meta-analysis methods, also known as mixed treatment comparisons, have
recently been developed, expanding the scope of conventional pairwise meta-analysis.
Network meta-analysis simultaneously synthesizes both direct comparisons of interven-
tions within randomized controlled trials and indirect comparisons across trials [50–56].
Based on an Internet Web search, the prestigious medical journals BMJ, JAMA, and
Lancet have published more than 100 research articles with the term ‘network meta-
analysis’ in their titles since 2010.
Currently, much effort in network meta-analysis has been devoted to contrast-based
approaches, which focus on investigating relative treatment effects, such as odds ratios
when the outcome is binary. However, population-averaged absolute risks may be pre-
ferred in some situations such as cost-effectiveness analysis [57,58]. In addition, relative
treatment effects are sometimes insufficient for patients to make decisions. For instance,
7consider a patient’s choice between treatments A and B with the following two sets of
one-year survival rates: (i) piA = 0.8 vs. piB = 0.5; (ii) piA = 0.004 vs. piB = 0.001. Most
likely, patients will strongly prefer treatment A in scenario (i) but have little preference
in scenario (ii), yet both have odds ratio 4.0.
Contrast-based network meta-analysis can back-transform odds ratios to population-
averaged absolute risks only if the absolute risk of a given reference treatment group
can be accurately estimated from external data, or can be estimated using a separate
model to analyze responses for the reference arm from the network [57, 58]. Both ap-
proaches depend on strong assumptions. For the approach using external data, even
if such external data are available, they may come from a population different from
the one represented in the network meta-analysis, and the assumption of transitivity
of relative effects on the odds ratio scale (i.e., that treatment effects are independent
of baseline risks) is rather strong. The choice of the odds ratio scale is generally ar-
bitrary or conventional, and there is no particular reason to expect effects in different
trials to be exchangeable on the odds ratio scale. For the approach using a distinct
model for the reference arm, under the theory of missing data, this analysis is unbiased
only under a strong assumption of missing completely at random, i.e., that each study
randomly chooses which treatment arms to include. In addition, if the estimation of
absolute effects uses a subset of the same trials used for the estimation of relative ef-
fects, then the estimated absolute and relative effects are not independent. Thus, one
would need to model the correlations among the two sets of estimates, which is not
straightforward. Finally, the back-transformed relative risks and risk differences can be
noticeably different depending on which treatment is chosen as the reference group, even
with exactly the same model and priors (Appendix A.7 gives an example). These con-
siderations suggest methodological limitations in contrast-based methods for estimating
population-averaged absolute risks.
When performing a network meta-analysis, selecting appropriate treatments for the
systematic review is crucial, as this will influence the validity and generalizability of both
the direct and indirect evidence summarized in the analysis. However, no guidelines exist
for treatment selection. Because the control treatment may not be defined consistently
across trials, some have suggested excluding such control treatments from a network
meta-analysis [59–61], but others have argued that having no comparison between an
8active intervention and placebo is problematic [62–64]. Moreover, the treatments of
interest may differ in different countries, and may vary over time due to introduction
of new drugs [65]. Therefore, the treatment arms included in a network meta-analysis
usually consist of a subset of a more extensive network. Using a contrast-based network
meta-analysis [50,51], Mills et al. [66] examined the sensitivity of estimated effect sizes
such as odds ratio to removal of certain treatments. They concluded that excluding a
treatment sometimes has substantial influence on estimated effect sizes. Consequently,
selection of treatment arms should be carefully considered when applying network meta-
analysis.
Chapter 6 examines the sensitivity to treatment exclusion of an alternative arm-
based approach to network meta-analysis, which has recently been developed from the
perspective of missing data analysis [67]. The difference between the contrast- and arm-
based approaches is substantial, and it is almost entirely due to single-arm trials. When
a treatment is removed from a contrast-based network meta-analysis, it is necessary
to exclude other treatments in two-arm studies that investigated the excluded treat-
ment; such exclusions are not necessary in arm-based network meta-analysis, leading to
substantial gain in performance.
As mentioned above, the Lu–Ades contrast-based Bayesian hierarchical model [51,54]
is still the most popular method to implement network meta-analysis, and it is generally
considered more powerful than conventional pairwise meta-analysis, leading to more
accurate effect estimates with narrower confidence intervals. However, the improvement
of effect estimates produced by Lu–Ades network meta-analysis has never been studied
theoretically. Chapter 7 shows that such improvement depends highly on evidence
cycles in the treatment network. Specifically, Lu–Ades network meta-analysis produces
posterior distributions identical to separate pairwise meta-analyses for all treatment
comparisons when a treatment network does not contain cycles. Even in a general
network with cycles, treatment comparisons that are not contained in any cycles do
not benefit from Lu–Ades network meta-analysis. Simulations and a case study will
be used to illustrate the equivalence of Lu–Ades network meta-analysis and pairwise
meta-analysis in certain networks.
Chapter 8 summarizes the major findings in this thesis and introduces some related
future topics.
Chapter 2
Alternative Measures of
Between-Study Heterogeneity in
Meta-Analysis: Reducing the
Impact of Outlying Studies
This chapter introduces several new heterogeneity measures, which are designed to be
less affected by outliers than conventional measures. The basic idea comes from least
absolute deviations (LAD) regression, which is known to have significant robustness ad-
vantages over classical least squares (LS) regression [68]. Specifically, LS regression aims
at minimizing the sum of squared errors
∑
(yi −xTi β)2, where xi represents predictors,
yi is the response, and β contains the regression coefficients. LAD regression minimizes
the sum of absolute errors
∑ |yi − xTi β|. The impact of outliers is diminished by using
absolute values in LAD regression, compared to using squared values in LS regression.
In meta-analysis, the conventional Q statistic has the form Q =
∑
wi(yi−µ¯)2, where the
yi’s are the observed effect sizes, the wi’s are study-specific weights, and µ¯ is the weighted
average effect size. Analogously, we consider a new measure Qr =
∑√
wi|yi− µ¯|, which
is expected to be more robust against outliers than the conventional Q. An estimate of
the between-study variance can be obtained based on Qr. Also, since Qr depends on
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the number of collected studies, we further derive two statistics to quantify heterogene-
ity, which are counterparts of I2 and another statistic H also proposed by Higgins and
Thompson [13].
This chapter is organized as follows. Section 2.1 gives a brief review of conventional
measures and discusses the dilemma of handling outliers in meta-analysis. Section 2.2
proposes several new heterogeneity measures designed to be robust to outliers. Sec-
tion 2.3 uses theoretical properties to compare the proposed and conventional measures.
Section 2.4 presents simulations to compare the various approaches empirically, and Sec-
tion 2.5 applies the approaches to two actual meta-analyses. Section 2.6 provides a brief
discussion.
2.1 The conventional methods
2.1.1 Measures of between-study heterogeneity
Suppose that a meta-analysis contains n independent studies. Let µi be the underlying
true effect size, such as log odds ratio, in study i (i = 1, . . . , n). Typically, published
studies report estimates of the effect sizes and their within-study variances, which we
will call yi and s
2
i . It is customary to assume that the yi’s are approximately normally
distributed with mean µi and variance σ
2
i , respectively. Since the unknown σ
2
i can be
estimated by s2i , these data are commonly modeled as yi ∼ N(µi, s2i ) with s2i treated
as known. Also, we assume that the true µi’s are independently distributed as µi ∼
N(µ, τ2), where µ is the true overall mean effect size across studies and τ2 is the between-
study variance. The collected n studies are defined to be homogeneous if their underlying
true effect sizes are equal, that is, µi = µ for all i = 1, . . . , n, or equivalently τ
2 = 0. On
the other hand, the studies are heterogeneous if their underlying true effect sizes vary,
that is, τ2 > 0.
To test the homogeneity of the yi’s (i.e., H0: τ
2 = 0 vs. HA: τ
2 > 0), the well-known
Q statistic [10] is defined as
Q =
n∑
i=1
wi(yi − µ¯)2,
which follows a χ2n−1 distribution under the null hypothesis. Here, wi = 1/s2i is the
reciprocal of the within-study variance of yi, and µ¯ =
∑n
i=1wiyi/
∑n
i=1wi is the pooled
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fixed-effect estimate of µ. Based on the Q statistic, DerSimonian and Laird [69] intro-
duced a method of moments estimate of the between-study variance,
τ̂2DL = max
{
0,
Q− (n− 1)∑n
i=1wi −
∑n
i=1w
2
i /
∑n
i=1wi
}
.
Note that the Q statistic depends on the number of collected studies n and the
estimate of between-study variance depends on the scale of effect sizes. Hence, neither
Q nor τ̂2DL can be used to compare degrees of heterogeneity between different meta-
analyses. To allow such comparisons, Higgins and Thompson [13] proposed the measures
H and I2:
H =
√
Q/(n− 1), I2 = [Q− (n− 1)]/Q.
The H statistic is interpreted as the ratio of the standard deviation of the estimated
overall effect size from a random-effects meta-analysis compared to the standard de-
viation from a fixed-effect meta-analysis; I2 describes the proportion of total variance
between studies that is attributed to heterogeneity rather than sampling error. In prac-
tice, meta-analysts truncate H at 1 when H < 1 and truncate I2 at 0 when I2 < 0;
therefore, H ≥ 1 and I2 lies between 0 and 1. Since I2 is interpreted as a proportion, it
is usually expressed as a percent. Both measures have been widely adopted in practice.
2.1.2 Outlier detection
As in many other statistical applications, outliers frequently appear in meta-analysis.
Outliers may arise from at least three sources:
(i) The quality of collected studies and systematic review. The published results
(yi, s
2
i ) in a clinical study could be outlying due to errors in the process of record-
ing, analyzing, or reporting data. Also, the populations in certain clinical studies
may not meet the systematic review’s inclusion criteria; hence, such studies may
be outlying compared to most other collected studies.
(ii) A heavy-tailed distribution of study-specific underlying effect sizes. Conventionally,
at the between-study level, the study-specific underlying effect sizes µi are assumed
to have a normal distribution. However, the true distribution of the µi’s may
greatly depart from the normality assumption and have heavy tails, such as the
t-distribution with small degrees of freedom.
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(iii) Small sample sizes in certain studies. The true within-study variances σ2i could
be poorly estimated by the sample variances s2i if the sample sizes are small. In
some situations, effect sizes in small studies may be more informative than large
studies due to ‘small study effects’ [70]; if their true within-study variances σ2i are
seriously underestimated, then small studies could be outlying.
Hedges and Olkin [16] and Viechtbauer and Cheung [14] introduced outlier detection
methods for fixed-effect and random-effects meta-analyses, respectively. Both methods
use a ‘leave-one-study-out’ technique so that a potential outlier could have little influence
on the residuals of interest. Specifically, the residual of study i is calculated as ei =
yi − µ¯(−i). Here, µ¯(−i) is the estimated overall effect size using the data without study
i; that is, µ¯(−i) =
∑
j 6=i yj/s
2
j∑
j 6=i 1/s
2
j
under the fixed-effect setting, and µ¯(−i) =
∑
j 6=i yj/(s
2
j+τ̂
2
(−i))∑
j 6=i 1/(s
2
j+τ̂
2
(−i))
under the random-effects setting, where τ̂2(−i) can be the DerSimonian and Laird estimate
using the data without study i. The variance of ei is estimated as vi = s
2
i+(
∑
j 6=i 1/s
2
j )
−1
and vi = s
2
i + τ̂
2
(−i) + [
∑
j 6=i 1/(s
2
j + τ̂
2
(−i))]
−1 under the fixed-effect and random-effects
settings, respectively. The standardized residuals i = ei/
√
vi are expected to follow the
standard normal distribution and studies with i’s greater than 3 in absolute magnitude
are customarily considered outliers.
Outliers may be masked if the above approaches are used in an inappropriate setting.
For example, Figures 2.3(b) and 2.3(d) in Section 2.5 show standardized residuals of
two actual meta-analyses; different outlier detection methods identify different outliers.
Hence, one must assess the heterogeneity of collected studies to correctly apply the
foregoing approaches to detect outliers. However, outliers may cause heterogeneity
to be overestimated and thus affect procedures to detect them. Additionally, even if
outliers are identified, there is no consensus in the statistical literature on what to do
about them unless these studies are evidently erroneous [71]. To avoid the dilemmas of
detecting and handling outliers, we propose robust measures to assess heterogeneity.
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2.2 The proposed alternative heterogeneity measures
2.2.1 Measures based on absolute deviations and weighted average
In linear regression, it is well-known that least absolute deviations regression is more
robust to outliers than classical least squares regression [68]. The former method mini-
mizes
∑ |yi−xTi β| and the latter minimizes∑(yi−xTi β)2, where xi and yi are predictors
and response respectively and β contains the regression coefficients. In the context of
meta-analysis, the conventional Q statistic is analogous to least squares regression, be-
cause Q is a weighted sum of squared deviations. To reduce the impact of outlying
studies, we propose a new measure Qr which is analogous to least absolute deviations
regression. This measure is the weighted sum of absolute deviations, and is defined as
Qr =
n∑
i=1
√
wi|yi − µ¯|.
For random-effects meta-analysis, E[Qr] =
∑n
i=1
√
2vi/pi, where vi = 1−wi/
∑n
j=1wj +
τ2[wi − 2w2i /
∑n
j=1wj + wi
∑n
j=1w
2
j/(
∑n
j=1wj)
2].
DerSimonian and Laird [69] derived an estimate of the between-study variance τ2
based on the Q statistic by the method of moments, i.e., equating the observed Q with
its expectation. We can similarly obtain a new estimate of τ2, denoted as τ̂2r , from the
proposed Qr statistic. Specifically, τ̂
2
r is the solution to the following equation in τ
2:
Qr
√
pi
2
=
n∑
i=1
{
1− wi∑n
j=1wj
+ τ2
[
wi − 2w
2
i∑n
j=1wj
+
wi
∑n
j=1w
2
j
(
∑n
j=1wj)
2
]}1/2
. (2.1)
If this equation has no nonnegative solution, set τ̂2r = 0. Note that the right-hand side
of Equation (2.1) is monotone increasing in τ2, so the solution is unique.
The Qr statistic, like Q, is dependent on the number of studies; τ̂
2
r , like τ̂
2
DL, is
dependent on the scale of effect sizes. Following the approach of Higgins and Thomp-
son [13], we tentatively assume that all studies share a common within-study variance
σ2 and explore heterogeneity measures that are independent of both the number of
studies and the scale of effect sizes, so that they can be used to compare degrees of
heterogeneity between meta-analyses. Suppose the target heterogeneity measure can
be written as f(µ, τ2, σ2, n), which is a function of the true overall mean effect size µ,
the between-study variance τ2, the within-study variance σ2, and the number of studies
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n. Higgins and Thompson [13] suggested that this measure should satisfy the following
three criteria:
(i) (Dependence on the magnitude of heterogeneity) f(µ, τ ′2, σ2, n) > f(µ, τ2, σ2, n)
for any τ ′2 > τ2. This criterion is self-evident.
(ii) (Scale invariance) f(a+ bµ, b2τ2, b2σ2, n) = f(µ, τ2, σ2, n) for any constants a and
b. This criterion ‘standardizes’ comparisons between meta-analyses using different
scales of measurement and different types of outcome data.
(iii) (Size invariance) f(µ, τ2, σ2, n′) = f(µ, τ2, σ2, n) for any positive integers n and
n′. This criterion indicates that the number of studies collected in meta-analysis
does not systematically affect the magnitude of the heterogeneity measure.
Monotone increasing functions of ρ = τ2/σ2 can be easily shown to satisfy these three
criteria. Plugging wi = 1/σ
2 into Equation (2.1), we have ρ + 1 = piQ2r/[2n(n − 1)].
This implies that
H2r =
piQ2r
2n(n− 1)
is a candidate measure. Further, considering ρ/(ρ+1) = τ2/(τ2 +σ2), commonly called
the intraclass correlation, Equation (2.1) yields another candidate:
I2r =
Q2r − 2n(n− 1)/pi
Q2r
.
In practice, Hr would be truncated at 1 when Hr < 1 and I
2
r would be truncated at
0 when I2r < 0. These two measures, H
2
r and I
2
r , are analogous to and have the same
interpretations as H2 and I2, respectively. Higgins and Thompson [13] also introduced
a so-called R2 statistic; since it has interpretation and performance similar to H2, we
do not present a version of R2 based on the new Qr statistic.
Since standard deviations are used more frequently in clinical practice, Higgins and
Thompson [13] suggested reporting H, instead of H2, for meta-analyses. For the pro-
posed measures, we also recommend reporting Hr rather than H
2
r . However, we suggest
presenting I2 and I2r instead of their square roots because their interpretation of ‘pro-
portion of variance explained’ is widely familiar to clinicians. Hr = 1 or I
2
r = 0 implies
perfect homogeneity. Also, since the expressions for Hr and I
2
r only involve Qr and
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n but not within-study variances, these two measures can be easily generalized to a
situation where the within-study variances s2i vary across studies.
2.2.2 Measures based on absolute deviations and weighted median
The proposed Qr statistic uses the weighted average µ¯ to estimate overall effect size
under the null hypothesis; it may be sensitive to potential outliers. To derive an even
more robust heterogeneity measure, we may replace the weighted average with the
weighted median µ̂m, which is defined as the solution to the following equation in θ:
n∑
i=1
wi [I(θ ≥ yi)− 0.5] = 0, (2.2)
where I(·) is the indicator function. This weighted median leads to a new test statistic,
Qm =
∑n
i=1
√
wi|yi−µ̂m|. Note that the solution to Equation (2.2) may be not unique; to
avoid this problem, we will approximate the indicator function by a monotone increasing
smooth function [72]. Section 2.2.3 introduces the details.
The expectation of Qm may not be explicitly calculated because the distribution of
weighted median of finite samples is unclear. By the theory of M-estimation [73], the
weighted median is a
√
n-consistent estimator of the true overall effect size µ. Suppose
that the weights wi have finite first-order moment, then it can be shown that∣∣∣∣∣Qm/n− 1n
n∑
i=1
√
wi|yi − µ|
∣∣∣∣∣ ≤ |µ̂m − µ| · 1n
n∑
i=1
√
wi = Op(n
−1/2).
Therefore, when the number of collected studies n is large,
E[Qm/n] ≈ 1
n
E
[
n∑
i=1
√
wi|yi − µ|
]
=
1
n
√
2/pi
n∑
i=1
√
(s2i + τ
2)/s2i .
By equating the Qm statistic to its approximated expectation, a new estimator of
between-study variance τ̂2m can be derived as the solution to
Qm
√
pi/2 =
n∑
i=1
√
(s2i + τ
2)/s2i
in τ2. If all within-study variances are further assumed to be equal to a common value
σ2 as in Section 2.2.1, E[Qm/n] ≈
√
2/pi
√
(σ2 + τ2)/σ2. Based on Qm, the counterparts
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of H2r and I
2
r—which assess (σ
2 + τ2)/σ2 and τ2/(σ2 + τ2) respectively—are defined as
H2m =
piQ2m
2n2
, I2m =
Q2m − 2n2/pi
Q2m
.
Note that many meta-analyses only collect a small number of studies; however, the
derivation of τ̂2m, H
2
m, and I
2
m assumes a large n. The finite-sample performance of
these heterogeneity measures will be studied using simulations.
2.2.3 Calculation of P -values and confidence intervals
Due to the difficulty caused by summing the absolute values of correlated random vari-
ables in the expression of Qr and the intractable distribution of weighted median in Qm,
it is not feasible to explicitly derive the probability and cumulative density functions for
the proposed statistics. Instead, resampling method can be used to calculate P -values
and 95% confidence intervals (CIs). Since the weighted median in Qm is discontinuous
and may be not unique due to the indicator function in Equation (2.2), we apply the
approach by Horowitz [72] to approximate the indicator function I(t > 0) by a smooth
function J(t) in the following simulations and case studies. For example, J(t) can be
the scaled expit function J(t) = 1/[1 + exp(−t/)], where  is a pre-specified small
constant. We use  = 10−4; various choices of  are shown to produce stable results in
Appendix A.1.
Parametric resampling can be used to calculate a P -value for Qr; similar procedures
can also be used for Q and Qm. First, estimate the overall effect size µ¯ under H0 : τ
2 = 0
(i.e., the fixed-effect setting) and calculate the Qr statistic based on the original data.
Second, draw n samples under H0, y
?
i ∼ N(µ¯, s2i ), and repeat this for B (say 10,000)
iterations. Here, the weighted average µ¯ is used to estimate µ because it is unbiased and
may have smaller variance than the weighted median under the null hypothesis. Third,
based on the B sets of bootstrap samples, calculate the Qr statistic as Q
(b)
r for b =
1, . . . , B. Finally, the P -value is calculated as P =
[∑B
b=1 I(Q
(b)
r > Qr) + 1
]
/(B + 1).
Here, 1 is added to both numerator and denominator to avoid calculating P = 0. To
derive 95% CIs for the various heterogeneity measures, the nonparametric bootstrap can
be used by taking samples of size n with replacement from the original data {(yi, s2i )}ni=1
and calculating 2.5% and 97.5% quantiles for each of the measures over the bootstrap
samples.
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2.3 The relationship between I2, I2r , and I
2
m
2.3.1 When the number of studies is fixed
Since I2r and I
2
m are designed to be robust compared to the conventional I
2, they are
expected to be smaller than I2 in the presence of outliers. Applying the Cauchy-Schwarz
Inequality, Q2r ≤ nQ, and the equality holds if and only if each wi(yi − µ¯)2 equals a
common value for all studies, in which case outliers are unlikely to appear. The foregoing
inequality further implies Hr ≤ H
√
pi/2 and I2r ≤ I2 + (1− 2/pi) (1 − I2). Therefore,
the proposed Hr and I
2
r are not always smaller than H and I
2, respectively; I2r may
be greater than I2 by up to (1 − 2/pi)(1 − I2). Appendix A.2 provides artificial meta-
analyses to illustrate how the proposed measures may have better interpretations even
when no outliers are present; I2r and I
2
m are larger than I
2 in those examples. As I2m
is based on the intractable weighted median, determining its relationship with I2 and
I2r is not feasible in finite samples except by simulations. Alternatively, the asymptotic
values of the three measures can be derived as n→∞; Section 2.3.2 considers this case.
2.3.2 When the number of studies becomes large
This section focuses on the asymptotic properties of the three heterogeneity measures as
the number of collected studies n→∞. Denote P−→ as convergence in probability, and
let Φ(·) be the cumulative distribution function of the standard normal distribution.
We have the following two propositions if no outliers are present.
Proposition 1. Under the fixed-effect setting, the observed effect sizes are yi ∼ N(µ, s2i ).
Assume that the weights wi = 1/s
2
i are independent and identically distributed with fi-
nite positive mean, and independent of the yi’s. Then I
2, I2r , and I
2
m converge to 0 in
probability as n→∞.
Proposition 2. Assume that all studies share a common within-study variance σ2.
Under the random-effects setting, the observed effect sizes are yi ∼ N(µi, σ2) and
µi ∼ N(µ, τ2); hence, the true proportion of total variation between studies due to
heterogeneity is I20 = τ
2/(σ2 + τ2). Then I2, I2r , and I
2
m converge to the true I
2
0 in
probability as n→∞.
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Propositions 1 and 2 show that, for either homogeneous or heterogeneous studies,
all three heterogeneity measures converge to the true value and correctly indicate ho-
mogeneity or heterogeneity. Proposition 1 does not require that the n studies have a
common within-study variance; Proposition 2 makes this assumption to facilitate defi-
nition of the true I20 . The following proposition compares the three measures when the
collection of studies is contaminated by a certain proportion of outlying studies.
Proposition 3. Assume that all studies share a common within-study variance σ2. The
observed effect sizes are yi ∼ N(µi, σ2). The meta-analysis is supposed to focus on a
certain population of interest, and in this population, the study-specific underlying effect
sizes are µi ∼ N(µ, τ2); therefore, the true proportion of total variation between studies
in this population that is due to heterogeneity is I20 = τ
2/(σ2 + τ2). However, 100η
percent of the n studies are mistakenly included, having been conducted on inappropriate
populations; their study-specific underlying effect sizes are µi ∼ N(µ+ C, τ2), where C
is a constant, representing the discrepancy of outliers. Then, as n→∞,
I2
P−→ 1− [(1− I20 )−1 + r1r2]−1;
I2r
P−→ h(r1, r2; η, I20 );
I2m
P−→ h(s1, s2; η, I20 ).
Here, h(·, ·; η, I20 ) is a function depending on η and I20 defined as
h(t1, t2; η, I
2
0 ) = 1−
{
η
[
(1− I20 )−1/2 exp
(
−1
2
t21(1− I20 )
)
+
√
pi
2
t1
(
1− 2Φ
(
−t1(1− I20 )1/2
))]
+ (1− η)
[
(1− I20 )−1/2 exp
(
−1
2
t22(1− I20 )
)
−
√
pi
2
t2
(
1− 2Φ
(
t2(1− I20 )1/2
))]}−2
;
also, r1 = (1− η)C/σ, r2 = ηC/σ, s2 = C/σ − s1, and s1 is the solution to
ηΦ
(
−s1(1− I20 )1/2
)
+ (1− η)Φ
(
(C/σ − s1)(1− I20 )1/2
)
= 0.5.
Appendix B.1 gives proofs of the three propositions. Proposition 3 suggests that
all three heterogeneity measures are affected by outlying studies, though to different
degrees. Specifically, their asymptotic values are determined by three factors: the true
proportion of total variation between studies that is due to heterogeneity I20 , the pro-
portion of outliers η, and the ratio of the discrepancy of the outliers C compared to the
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within-study standard deviation σ, that is, R = C/σ. Outliers are usually present in
small quantities, so the proportion of outliers η is usually not large. Also, an observation
is customarily considered an outlier if the distance to the overall mean is greater than
three times the standard deviation σ; therefore, the ratio R is usually greater than 3.
Figure 2.1 compares the asymptotic values of the three heterogeneity measures de-
rived in Proposition 3. The upper panels show the setting of true homogeneity (I20 = 0)
and the lower panels show the setting of true heterogeneity (I20 = 0.5). Under each
setting, the proportion of outliers is 1%, 5%, or 10%. Clearly, all panels present a com-
mon trend: the three heterogeneity measures increase as R increases. When η is 1%,
I2r and I
2
m are much less affected by outliers than I
2, indicating the robustness of the
proposed measures. Also, I2m is a bit smaller than I
2
r . As η increases, the difference
between I2 and I2r becomes smaller, while the difference between I
2
r and I
2
m becomes
larger though it is never substantial. This implies that I2m is the most robust measure
when a meta-analysis is contaminated by a large proportion of outliers.
2.4 Simulations
Simulations were conducted to investigate the finite-sample performance of the various
approaches to assessing heterogeneity. Without loss of generality, the true overall mean
effect size was fixed as µ = 0. The number of studies in these simulated meta-analyses
was set to n = 10 or 30, and the between-study variance was τ2 = 0 (homogeneity)
or 1 (heterogeneity). Under the homogeneity setting, the within-study standard errors
si were sampled from U(0.5, 1); under the heterogeneity setting, we sampled si’s from
U(smin, smax), where (smin, smax) = (0.5, 1), (1, 2), or (2, 5) to represent different pro-
portions of total variation between studies that is due to heterogeneity. The observed
effect sizes were drawn from yi ∼ N(µi, s2i ), where µi’s are study-specific underlying
effect sizes. Regarding the µi, we considered the following two different scenarios to
produce outliers.
(I) (Contamination) The µi’s are normally distributed, µi ∼ N(µ, τ2); however, m
out of the n studies were contaminated by a certain outlying discrepancy, as in
Proposition 3. We set m = 0, 1, 2, and 3, and five outlier patterns were considered:
the m studies were created as outliers by artificially adding C, (C,C), (C,−C),
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(C,C,C), or (C,C,−C) to the original effect sizes for m = 1, 2, 2, 3, and 3
respectively. The discrepancy of outliers was set to C = 3
√
s2max + τ
2.
(II) (Heavy tail) The µi’s are drawn from a heavy-tailed distribution. We considered
a location-scale transformed t distribution with degrees of freedom df = 3, 5, and
10; that is, µi = µ + zi
√
(df− 2)/df, where zi ∼ tdf. Note that the between-
study variance τ2 = Var[µi] = 1 in this scenario, so the generated studies are
heterogeneous. Also, as degrees of freedom increases, the distribution of µi’s
converges to the normal distribution and outliers are less likely.
Table 2.1 presents some results for n = 30, including statistical sizes (type I error
rates) and powers of the statistics Q, Qr, and Qm for testing H0 : τ
2 = 0 vs. HA : τ
2 > 0,
and the root mean squared errors (RMSEs) and coverage probabilities of 95% CIs of τ̂2DL,
τ̂2r , and τ̂
2
m. Appendix A.3 contains complete simulation results. When the studies are
homogeneous, each of the three test statistics controls type I error rate well if no outliers
are present. Also, the RMSEs of the three estimators of τ2 are close and their coverage
probabilities are fairly high. However, when outliers appear, the type I error rate of
Q inflates dramatically compared to Qr and Qm. The RMSE of τ̂
2
DL becomes larger
than those of τ̂2r and τ̂
2
m; also, the coverage probability of τ̂
2
DL is lower, especially when
m = 3. As the number of outliers increases, the weighted-median-based τ̂2m has smaller
RMSE and its 95% CI has higher coverage probability than the weighted-mean-based
τ̂2r .
For heterogeneous studies, the conventional Q statistic is more powerful than Qr or
Qm, but the differences are not large; this is expected because Q sacrifices type I error
in the presence of outliers. In spite of this disadvantage of Qr and Qm, the proposed
estimators of τ2 still perform better than the conventional τ̂2DL in both Scenarios I and
II.
Figure 2.2 compares the impact of a single outlier in Scenario I with m = 1 on
the heterogeneity measures I2, I2r , and I
2
m. As expected, these heterogeneity measures
generally increase due to the outlying study, so their changes are mostly greater than 0.
However, for both homogeneous and heterogeneous studies, the changes of I2r and I
2
m
are generally smaller than the changes of I2, indicating that the proposed measures are
indeed less affected by outliers than the conventional I2.
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2.5 Two case studies
2.5.1 Homogeneous studies with outliers
Ismail et al. [74] reported a meta-analysis consisting of 29 studies to evaluate the effect
of aerobic exercise (AEx) on visceral adipose tissue (VAT) content/volume in overweight
and obese adults, compared to control treatment. Figure 2.3(a) shows the forest plot
with the observed effect sizes and their within-study 95% CIs; studies 1, 3, 19, and 29
seem to be outlying. If these four studies are removed, the remaining studies are much
more homogeneous. Figure 2.3(b) presents the standardized residuals using both the
fixed-effect and random-effects approaches described in Section 2.1.2. Studies 1, 19, and
29 have standardized residuals (under the fixed-effect setting) greater than 3 in absolute
magnitude; hence, they may be considered outliers. We conducted sensitivity analysis
by removing the following studies: (i) 1; (ii) 19; (iii) 29; (iv) 1 and 19; (v) 1 and 29;
(vi) 19 and 29; and (vii) 1, 19, and 29.
Table 2.2 presents the results for the original meta-analysis and for alternate meta-
analyses removing certain outlying studies. For the original meta-analysis, I2r = 0.44
and I2m = 0.45, compared to I
2 = 0.59. Also, τ̂r and τ̂m are smaller than τ̂DL. To test
H0 : τ
2 = 0 vs. HA : τ
2 > 0, the P -value of the Q statistic is smaller than 0.001, and
those of the Qr and Qm statistics are 0.013 and 0.006, respectively. When study 29 is
removed, the Q statistic is still significant (P -value = 0.008), while the P -values of the
Qr and Qm statistics are larger than the commonly used significance level α = 0.05.
After removing all three outlying studies, the P -values of the three test statistics are
much larger than 0.05; also, I2r = I
2
m = 0 and I
2 = 0.11. Hence, the heterogeneity
presented in the original meta-analysis is mainly caused by the few outliers. Note that
I2r and I
2
m are still noticeably smaller than I
2 after removing the three identified outliers.
This may be because some studies other than studies 1, 19, and 29 are potentially
outlying. Figure 2.3(b) shows that the absolute values of the standardized residuals
of studies 3 and 28 are fairly close to 3. Although some outliers may not be clearly
detected, I2r and I
2
m automatically reduce their impact without removing them.
22
2.5.2 Heterogeneous studies with outliers
Haentjens et al. [75] investigated the magnitude and duration of excess mortality after
hip fracture among older men by performing a meta-analysis consisting of 17 studies.
Figure 2.3(c) shows the forest plot with the observed effect sizes (log hazard ratios) and
their 95% within-study CIs. The forest plot indicates that the collected studies tend to
be heterogeneous. Despite this, we used both the fixed-effect and random-effects diag-
nostic procedure in Section 2.1.2 to detect potential outliers. Figure 2.3(d) shows the
study-specific standardized residuals, indicating that study 17 is apparently outlying.
Although study 9’s standardized residual is smaller than 2 in absolute magnitude when
using the random-effects approach, its standardized residual under the fixed-effect set-
ting is fairly large. To take all potential outliers into account, we conducted sensitivity
analysis by removing the following studies: (i) 9; (ii) 17; and (iii) 9 and 17.
The results are in Table 2.2. For the original meta-analysis, the P -values of all three
test statistics are smaller than 0.001, rejecting the null hypothesis of homogeneity. Also,
I2 = 0.74, I2r = 0.66 and I
2
m = 0.63, indicating substantial heterogeneity. If study 9 is
removed, the results seem to change little, implying that this study is not influential.
If study 17 is removed, the P -values of the test statistics change noticeably; also, each
of I2, I2r , and I
2
m is reduced by more than 0.10. The three heterogeneity measures are
still fairly high (larger than or close to 0.5); therefore, meta-analysts may keep paying
attention to the heterogeneity of the remaining studies.
2.6 Discussion
This paper proposed several alternative measures of heterogeneity in meta-analysis.
Large-sample properties and finite-sample studies showed that the new measures are
robust to outliers compared with conventional measures. Since outliers frequently ap-
pear in meta-analysis and may not simply be removed without sound evidence, the
proposed robust measures can provide useful information describing heterogeneity. The
robustness of the new approaches mainly arises from using the absolute deviations in
the Qr and Qm statistics; Qr summarizes the deviations using the weighted average,
and Qm summarizes the deviations using the weighted median. Note that the number
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of studies is assumed to be large in deriving τ̂2m, Hm, and I
2
m. However, many meta-
analyses may only collect a few studies [76]; these three measures need to be used with
caution for small meta-analyses.
When study-level covariates are collected in meta-analysis, meta-regression is widely
applied to investigate whether study characteristics explain heterogeneity [77]. To im-
prove robustness to outliers, instead of performing least squares regression, researchers
may consider least absolute deviations regression [68], which is related to the hetero-
geneity measures proposed in this chapter.
Heterogeneity measures are customarily used to select a fixed-effect or random-effects
model, but both models have limitations in certain situations. Some researchers believe
that heterogeneity is to be expected in any meta-analysis because the collected studies
were performed by different teams in different places using different methods [78]. Also,
the fixed-effect model produces confidence intervals with poor coverage probability when
the collected studies have different true effect sizes [79], so some researchers recommend
routinely using the random-effects model to yield conservative results [80]. However,
the random-effects model is not always better than the fixed-effect model, especially in
the presence of publication bias [81–83]. Besides robustly assessing heterogeneity, alter-
native approaches to robustly estimating overall effects size in the presence of outliers
remain to be studied.
The R code for the proposed methods are organized in the package ‘altmeta’ and
available at http://cran.r-project.org/package=altmeta.
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Figure 2.1: The asymptotic values of I2, I2r , and I
2
m as n → ∞. The horizontal axis
represents the ratio (R) of discrepancy of outliers (C) compared to within-study stan-
dard deviation (σ), that is, R = C/σ. The true proportion of total variation between
studies that is due to heterogeneity I20 is 0 (homogeneity, top row) or 0.5 (heterogeneity,
bottom row). The proportion of outlying studies η varies from 1% (left panels) to 10%
(right panels).
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(d) Impact of an outlier on heterogeneous studies
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Figure 2.2: Scatter plots of the changes of I2r and I
2
m due to an outlier against the
changes of I2. For the upper panels, τ2 = 0 (homogeneous studies) and si ∼ U(0.5, 1);
for the lower panels, τ2 = 1 (heterogeneous studies) and si ∼ U(1, 2). The left panels
compare I2r with I
2; the right panels compare I2m with I
2.
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Figure 2.3: Forest plots and standardized residual plots of two actual meta-analyses.
The upper panels show the meta-analysis conducted by Ismail et al.; the lower panels
show that conducted by Haentjens et al. In (a) and (c), the columns ‘Lower’ and ‘Upper’
are the lower and upper bounds of 95% CIs of the effect sizes within each study. In (b)
and (d), the filled dots represent standardized residuals obtained under the fixed-effect
setting; the unfilled dots represent those obtained under the random-effects setting.
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Table 2.1: Type I error rates and powers of three heterogeneity tests for the simulated
meta-analyses containing 30 studies.
Outlier pattern
Size/power† RMSE CP (%)
Q‡ Qr Qm τ̂2DL τ̂
2
r τ̂
2
m τ̂
2
DL τ̂
2
r τ̂
2
m
Scenario I (contamination) with τ2 = 0 (homogeneity) and si ∼ U(0.5, 1):
No outliers 0.05 (0.06) 0.05 0.05 0.10 0.12 0.10 98 99 99
C 0.55 (0.55) 0.27 0.25 0.37 0.24 0.20 97 97 98
(C,C) 0.89 (0.89) 0.66 0.60 0.63 0.42 0.35 88 90 94
(C,−C) 0.92 (0.92) 0.61 0.61 0.68 0.40 0.36 89 90 94
(C,C,C) 0.98 (0.98) 0.90 0.87 0.88 0.64 0.53 65 74 83
(C,C,−C) 0.99 (0.98) 0.89 0.88 0.99 0.61 0.55 64 73 83
Scenario I (contamination) with τ2 = 1 (heterogeneity) and si ∼ U(0.5, 1):
No outliers 0.98 (0.99) 0.98 0.98 0.40 0.43 0.41 88 93 91
C 1.00 (1.00) 1.00 1.00 0.84 0.63 0.55 97 97 98
(C,C) 1.00 (1.00) 1.00 1.00 1.37 1.00 0.85 93 94 96
(C,−C) 1.00 (1.00) 1.00 1.00 1.45 0.97 0.85 93 94 96
(C,C,C) 1.00 (1.00) 1.00 1.00 1.86 1.44 1.22 76 83 90
(C,C,−C) 1.00 (1.00) 1.00 1.00 2.05 1.40 1.25 77 84 91
Scenario I (contamination) with τ2 = 1 (heterogeneity) and si ∼ U(1, 2):
No outliers 0.48 (0.49) 0.42 0.43 0.74 0.81 0.75 89 93 91
C 0.89 (0.89) 0.78 0.77 1.97 1.36 1.17 98 97 98
(C,C) 0.99 (0.99) 0.94 0.94 3.33 2.29 1.93 91 92 96
(C,−C) 0.99 (0.99) 0.94 0.94 3.50 2.17 1.93 91 92 96
(C,C,C) 1.00 (1.00) 0.99 0.99 4.60 3.41 2.85 70 80 88
(C,C,−C) 1.00 (1.00) 0.99 0.99 5.03 3.24 2.90 71 81 88
Scenario II (heavy tail) with τ2 = 1 (heterogeneity) and si ∼ U(0.5, 1):
df = 3 0.92 (0.92) 0.89 0.88 1.45 0.59 0.56 72 79 73
df = 5 0.98 (0.98) 0.95 0.95 0.55 0.45 0.45 84 90 86
df = 10 0.98 (0.98) 0.97 0.97 0.43 0.43 0.42 88 93 90
Scenario II (heavy tail) with τ2 = 1 (heterogeneity) and si ∼ U(1, 2):
df = 3 0.41 (0.40) 0.35 0.35 1.53 0.88 0.82 83 90 87
df = 5 0.46 (0.46) 0.40 0.40 0.82 0.82 0.77 88 93 90
df = 10 0.48 (0.49) 0.42 0.42 0.76 0.82 0.77 88 94 90
RMSE: root mean squared error; CP: coverage probability of 95% confidence in-
terval.
† Size (type I error rate) for homogeneous studies (τ2 = 0) and power for heteroge-
neous studies (τ2 > 0) at the significance level α = 0.05.
‡ The sizes/powers outside the parentheses are produced by the resampling method;
those inside the parentheses are obtained using Q’s theoretical distribution under
the null hypothesis.
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Table 2.2: Results of assessing heterogeneity for two actual meta-analyses.
Removed studies
P -value of testing H0 : τ
2 = 0 Estimated τ (95% CI) Heterogeneity measure (95% CI)
Q† Qr Qm τ̂DL τ̂r τ̂m I2 I2r I2m
Meta-analysis in Ismail et al. [74]:
None (Original) < 0.001 (< 0.001) 0.013 0.006 0.39 (0, 0.62) 0.29 (0, 0.58) 0.30 (0, 0.56) 0.59 (0, 0.76) 0.44 (0, 0.73) 0.45 (0, 0.72)
1 < 0.001 (< 0.001) 0.047 0.030 0.35 (0, 0.58) 0.24 (0, 0.52) 0.24 (0, 0.51) 0.55 (0, 0.75) 0.36 (0, 0.69) 0.36 (0, 0.69)
19 < 0.001 (< 0.001) 0.048 0.031 0.34 (0, 0.58) 0.24 (0, 0.52) 0.24 (0, 0.51) 0.54 (0, 0.75) 0.36 (0, 0.69) 0.36 (0, 0.68)
29 0.008 (0.007) 0.100 0.070 0.28 (0, 0.46) 0.21 (0, 0.44) 0.21 (0, 0.43) 0.44 (0, 0.66) 0.29 (0, 0.63) 0.30 (0, 0.62)
1 and 19 0.003 (0.004) 0.154 0.121 0.29 (0, 0.54) 0.18 (0, 0.45) 0.18 (0, 0.44) 0.47 (0, 0.73) 0.25 (0, 0.64) 0.24 (0, 0.63)
1 and 29 0.052 (0.052) 0.272 0.223 0.22 (0, 0.40) 0.14 (0, 0.37) 0.13 (0, 0.36) 0.33 (0, 0.60) 0.16 (0, 0.56) 0.15 (0, 0.55)
19 and 29 0.057 (0.057) 0.278 0.232 0.21 (0, 0.40) 0.13 (0, 0.38) 0.13 (0, 0.37) 0.32 (0, 0.60) 0.15 (0, 0.56) 0.14 (0, 0.55)
1, 19 and 29 0.302 (0.298) 0.547 0.504 0.11 (0, 0.30) 0 (0, 0.29) 0 (0, 0.27) 0.11 (0, 0.47) 0 (0, 0.46) 0 (0, 0.42)
Meta-analysis in Haentjens et al. [75]:
None (Original) < 0.001 (< 0.001) < 0.001 < 0.001 0.16 (0.02, 0.34) 0.15 (0, 0.37) 0.08 (0, 0.36) 0.74 (0.15, 0.86) 0.66 (0, 0.85) 0.63 (0, 0.85)
9 < 0.001 (< 0.001) 0.006 0.006 0.16 (0, 0.37) 0.13 (0, 0.42) 0.06 (0, 0.37) 0.68 (0, 0.84) 0.56 (0, 0.83) 0.52 (0, 0.81)
17 0.001 (0.001) 0.013 0.015 0.11 (0, 0.23) 0.11 (0, 0.27) 0.05 (0, 0.27) 0.60 (0, 0.76) 0.52 (0, 0.77) 0.47 (0, 0.76)
9 and 17 0.062 (0.059) 0.156 0.144 0.09 (0, 0.24) 0.07 (0, 0.27) 0.02 (0, 0.25) 0.39 (0, 0.65) 0.28 (0, 0.67) 0.23 (0, 0.65)
† The P -values outside the parentheses are produced by the resampling method; the P -values inside the parentheses are calculated using Q’s theoretical distribution
under the null hypothesis.
Chapter 3
Performance of Publication Bias
Tests in the Cochrane Library
This chapter applies seven commonly-used publication bias tests to a large collection
of published meta-analyses in the Cochrane Library, which is the leading resource for
systematic reviews in health care. We investigate the proportion of meta-analyses that
have statistically significant publication bias detected by each test. Its association with
the size of the meta-analysis is also empirically assessed. In addition, we evaluate the
agreement among various test results. These findings may guide researchers in properly
assessing publication bias and interpreting test results in future systematic reviews.
3.1 Methods
We searched complete issues in the Cochrane Library that were available in January
2016; a total of 5677 systematic reviews were collected, containing more than 180,000
meta-analyses. We only considered meta-analyses with continuous or binary outcomes.
For binary outcomes, the treatment effects were measured by the log odds ratio. When a
study contained a zero data cell in one arm only, we added a continuity correction of 0.5
to all studies’ data cells in the corresponding meta-analysis so that log odds ratios and
their variances can be estimated [3, 84]. Studies with zero data cells in both treatment
and control arms were removed from the meta-analyses because information provided by
such studies is limited [3,85,86]. For continuous outcomes, some studies did not report
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the treatment effects’ standard errors; they were also removed from the meta-analyses.
After removing the ineligible studies, we focused on meta-analyses containing at least
five studies. We finally obtained a total of 20,603 meta-analyses; among them, 6080 and
14,523 meta-analyses have continuous and binary outcomes, respectively.
For meta-analyses with continuous outcomes, we applied Begg’s rank test, the trim
and fill method, and Egger’s and Tang’s regression tests to assess publication bias; these
approaches have been proposed for all types of outcomes [24–26,29]. For meta-analyses
with binary outcomes, we also considered Macaskill’s, Deeks’, and Peters’ regression
tests, which were originally designed for log odds ratios [31–33]. As suggested by many
authors, the statistical significance level was set to 0.1 because the statistical power for
testing publication bias is generally low [24, 25, 32]. Moreover, Cohen’s κ, a coefficient
upper bounded by 1, was used to measure pairwise agreement among publication bias
tests [87]. The agreement was considered strong if κ was larger than 0.6, and weak if κ
was smaller than 0.4; the agreement was moderate when κ is between 0.4 and 0.6 [88].
Within a systematic review, multiple meta-analyses may be performed for different
outcomes, but using information from some common populations; therefore, these meta-
analyses can be correlated [89]. To reduce the impact of such correlations, we also
conducted the analysis using a restricted dataset. Specifically, the meta-analysis with
the largest number of studies was chosen from each systematic review. If a systematic
review contained at least two meta-analyses with the same largest number of studies,
the one with the largest total sample size was selected; if the total sample sizes are still
equal, one meta-analysis was randomly chosen from those having the largest number
of studies and total sample size. Again, we focused on meta-analyses containing at
least five studies. Using these criteria, 499 and 1380 meta-analyses with continuous
and binary outcomes respectively were extracted from the entire set of 5677 systematic
reviews.
3.2 Results
Figures 3.1 and 3.2 show the P -values produced by the various publication bias tests for
the Cochrane meta-analyses with continuous and binary outcomes, respectively. The
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horizontal axis presents each meta-analysis sorted by its size (i.e., the number of stud-
ies); the meta-analyses with the same size are sorted by their IDs in the Cochrane
Library. The vertical axis shows the P -values transformed by negative base 10 loga-
rithm, and three statistical significance levels, 0.01, 0.05, and 0.1, are displayed. Both
figures illustrate that the area representing small meta-analyses is much wider than that
representing large meta-analyses, and most Cochrane meta-analyses contain less than 10
studies. Specifically, among the entire 20,603 meta-analyses with continuous or binary
outcomes, 5338 meta-analyses contain 5 studies, while only 132 meta-analyses contain
20 studies. The median number of studies is 7, and the lower and upper quartiles are 5
and 10 respectively.
Overall, Table 3.1 shows that Begg’s rank test and the trim and fill method detect
statistically significant publication bias in far fewer meta-analyses than the regression
tests. In particular, for small meta-analyses, Figures 3.1 and 3.2 indicate that the P -
values produced by Begg’s rank test and the trim and fill method are generally larger
than the regression tests. For example, among the meta-analyses containing 5 studies,
most P -values produced by Begg’s rank test and all P -values produced by the trim and
fill method are greater than 0.05, while the regression tests imply extreme publication
bias with P -value < 0.01 in some meta-analyses. In addition, Begg’s rank test and the
trim and fill method are more likely to detect publication bias in large meta-analyses
than in small ones. Furthermore, note that all P -values of the trim and fill method
are discontinuous and massed at several specific values, because this method uses the
negative binomial distribution, which is discrete, to calculate P -value [26]. Many P -
values of Begg’s rank test are also massed at several specific values. This is because
the rank test calculates an exact P -value, taking certain discontinuous values, when the
number of studies is small and the treatment effects have no ties; otherwise, the P -value
is calculated using the normal approximation of the rank statistic’s distribution.
Compared with Begg’s rank test and the trim and fill method, the significance of
publication bias assessed by the regression tests seems to be less dependent on the size
of the meta-analysis. Table 3.1 shows that Egger’s test detects statistically significant
publication bias in 13.9% of meta-analyses with continuous outcomes and 16.9% of those
with binary outcomes; these proportions are higher than the other regression tests.
The numbers of meta-analyses with statistically significant publication bias detected by
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Tang’s, Deeks’, and Peters’ tests are similar for binary outcomes. Moreover, the P -value
plots of Tang’s and Deeks’ tests in Figure 3.2 are fairly similar. However, the plots of
the other regression tests are noticeably different: one test may not detect statistically
significant publication bias for a meta-analysis, while another test could lead to an
extremely small P -value for the same meta-analysis.
Table 3.2 quantifies the agreement among the tests using Cohen’s κ coefficient. The
upper table uses all extracted Cochrane meta-analyses, and the lower one is based on
the restricted dataset, which consists of the largest meta-analysis from each systematic
review. Most results in the upper and lower tables are similar. We may focus on the
lower table, in which the meta-analyses are from different systematic reviews and may
be deemed independent. Begg’s rank test and the trim and fill method have a rather
weak agreement (κ ≤ 0.40), and their agreement with the regression tests is also weak.
Egger’s test has moderate agreement with Tang’s, Deeks’, and Peters’ regression tests.
Most Cohen’s κ coefficients between Tang’s, Macaskill’s, Deeks’, and Peters’ tests are
close to 0.60, which may imply moderately strong agreement. Note that the Cohen’s
κ coefficient between Tang’s and Deeks’ tests is close to 1, implying a nearly perfect
agreement; this confirms our observation in Figure 3.2.
Categorized by the number of studies, Figure 3.3 describes the proportions of meta-
analyses having statistically significant publication bias based on the various tests, and
their Wald-type 95% confidence intervals. On the one hand, similarly to the patterns
of the P -value plots in Figures 3.1 and 3.2, the proportion tends to be greater for larger
meta-analyses, especially for binary outcomes. On the other hand, the proportions of
the Cochrane meta-analyses having statistically significant publication bias are between
approximately 10% and 30% for most sizes of meta-analyses. In addition, publication
bias is detected by at least one test in more than 20% of meta-analyses with continuous
outcomes and in more than 30% of meta-analyses with binary outcomes.
Figures A.2–A.4 in Appendix A.4 show the P -value plots and the plot of proportions
of having publication bias based on the restricted dataset. The trends in these plots are
similar to those in Figures 3.1–3.3, though the 95% confidence intervals in Figure A.4
are wider than those in Figure 3.3 because the restricted dataset contains far fewer
meta-analyses.
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3.3 Discussion
Using a large collection of meta-analyses, this chapter illustrated that publication bias
frequently appears in the Cochrane systematic reviews, so it should be routinely as-
sessed. Egger’s regression test detects statistically significant publication bias in more
meta-analyses than the others. However, this study has several limitations. For ex-
ample, the Cochrane Library only contains meta-analyses in health care, so the results
may not be generalizable to other research fields. Also, since we never know whether
a Cochrane meta-analysis truly has publication bias, the results in Table 3.1 and Fig-
ures 3.1–3.3 may not directly imply statistical powers of the tests.
Since the agreement among most publication bias tests is weak or moderate, re-
searchers need to carefully interpret the test results. Instead of reporting the result
from a single test, researchers are encouraged to use a variety of methods: different
tests make different assumptions about the association between the treatment effects
and precision measures (e.g., treatment effects’ standard error or sample size), so the
tests that yield fairly small P -values may reveal some patterns for further investigation.
Tang’s and Deeks’ regression tests are shown to have almost identical performance.
Tang’s method is motivated by examining the asymmetry of the sample-size-based fun-
nel plot for all types of outcomes, and the independent variable in the regression is the
total sample size within each study [29]; Deeks’ method was originally developed for
meta-analysis of diagnostic tests, and the regression independent variable is the ‘effec-
tive sample size’ (Table 3.1) [31]. If the allocation ratio for the treatment and control
groups is close to 1:1, which is common in randomized controlled trials, then the ‘ef-
fective sample size’ is close to the total sample size. Therefore, it is not surprising to
obtain similar results using Tang’s and Deeks’ tests.
All seven tests considered in this chapter are motivated by the funnel plot; however,
the funnel plot’s asymmetry needs to be interpreted from various perspectives. For
example, since small studies may be biased due to poor quality in design and they are
likely targeted at high-risk groups that can produce positive treatment effects, some
authors often view the funnel plot as an approach to checking for ‘small study effects’ in
general, rather than publication bias in particular [30, 90, 91]. In addition, the P -value
plots in Figures 3.1 and 3.2 indicate that some publication bias tests tend to detect
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more statistically significant publication bias in larger meta-analyses. As the number of
studies increases, a meta-analysis likely collects more heterogeneous or outlying studies,
which can cause a funnel plot’s asymmetry for reasons other than publication bias.
Outliers may be present in meta-analysis due to several reasons. For example, some
study results could be outlying because of errors in the process of recording, analyzing,
or reporting data. Also, if the quality of a systematic review is poor, the populations
in certain studies may not meet strict inclusion and exclusion criteria, so such studies
may be outlying compared with the other collected studies. Outliers may lead to a
heavy tail on one side of the treatment effect’s distribution, so the funnel plot may look
asymmetric.
Between-study heterogeneity also seriously threatens proper interpretation of the
funnel plot’s asymmetry. It arises because the collected studies differ in their patient
selection, baseline disease severity, study location, etc. [78, 92]. The random-effects
meta-analysis is usually applied to deal with heterogeneity; a normal distribution is con-
ventionally specified to model study-specific underlying treatment effects [6, 93]. This
model is appropriate if heterogeneity permeates the entire collection of studies; however,
it is also possible that heterogeneity is mostly limited to several subgroups of studies,
while the studies within each subgroup share a common overall treatment effect. In the
presence of multiple subgroups, even if the funnel plot within each subgroup is fairly
symmetric, the funnel plot based on the entire collection of studies can be asymmetric;
such asymmetry is induced by heterogeneity, but not publication bias [34, 94]. Per-
forming separate analysis within each subgroup is more appropriate for such data than
pooling the results of all studies. As heterogeneity is common in meta-analysis [78,95],
researchers need to carefully assess heterogeneity along with checking for publication
bias. For example, Ioannidis and Trikalinos [89] advised that it may not be appropriate
to use the publication bias tests if the I2 statistic [13, 95] is greater than 50% or the
Q statistic [9, 10] is significant with P -value < 0.1. Although these criteria may not
be rigorous for determining whether the publication bias tests are appropriate, a fairly
large heterogeneity measure alerts researchers to interpret the funnel plot’s asymmetry
with great caution.
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(d) Tang's regression test
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Figure 3.1: The P -values produced by the various publication bias tests for the 6080
Cochrane meta-analyses with continuous outcomes. Plus signs indicate P -values <
10−7.
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Figure 3.2: The P -values produced by the various publication bias tests for the 14,523
Cochrane meta-analyses with binary outcomes. Plus signs indicate P -values < 10−7.
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Figure 3.3: Proportions of the Cochrane meta-analyses having statistically significant publication bias (P -value < 0.1)
based on the various tests and their 95% confidence intervals. ‘Any test’ implies the proportion of having statistically
significant publication bias detected by at least one test. The label ‘All’ on the horizontal axis represents all extracted
meta-analyses with continuous/binary outcomes.
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Table 3.1: Brief descriptions for the various publication bias tests and summary of test results for the Cochrane meta-analyses.
No. of meta-analyses with P -value < 0.1 (Proportion)
Test Designed for Description Based on all Cochrane meta-analyses Based on the restricted dataseta
Continuousb Binaryc Continuousd Binarye
Begg’s rank All Use the rank correlation test to assess 467 (7.7%) 1253 (8.6%) 43 (8.6%) 133 (9.6%)
test outcomes the association between standardized
effect size and its standard error.
Trim and fill All Estimate the number of suppressed 378 (6.2%) 1523 (10.5%) 33 (6.6%) 177 (12.8%)
method outcomes studies, and calculate P -value using
its negative binomial distribution in
the absence of publication bias.
Egger’s All Weighted linear regression of y on s, 843 (13.9%) 2455 (16.9%) 74 (14.8%) 264 (19.1%)
regression test outcomes with weights 1/s2.
Tang’s All Weighted linear regression of y on 727 (12.0%) 1723 (11.9%) 67 (13.4%) 180 (13.0%)
regression test outcomes 1/
√
N , with weights N .
Macaskill’s Binary Weighted linear regression of y on N , N/A 2055 (14.1%) N/A 200 (14.5%)
regression test outcomes with weights Ns ×Nf/N .
Deeks’ Binary Weighted linear regression of y on N/A 1729 (11.9%) N/A 182 (13.2%)
regression test outcomes 1/
√
Ne, with weights Ne.
Peters’ Binary Weighted linear regression of y on N/A 1717 (11.8%) N/A 189 (13.7%)
regression test outcomes 1/N , with weights Ns ×Nf/N .
Notation: y, effect size; s2, within-study variance; N , total no. of patients; Ns and Nf , no. of patients with and without events for binary outcomes
respectively; Ne, effective sample size, defined as 4N0 ×N1/N , where N0 and N1 are sample sizes the control and treatment groups respectively;
N/A, not applicable.
a The restricted dataset consists of the meta-analyses with the largest numbers of studies in the corresponding Cochrane systematic reviews.
b Among 6080 meta-analyses with continuous outcomes.
c Among 14,523 meta-analyses with binary outcomes.
d Among 499 meta-analyses with continuous outcomes in the restricted dataset.
e Among 1380 meta-analyses with binary outcomes in the restricted dataset.
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Table 3.2: Cohen’s κ coefficients for the agreement among the pub-
lication bias tests. Within each sub-table, the results in the upper
and lower triangular are based on the Cochrane meta-analyses with
continuous and binary outcomes, respectively.
Based on all Cochrane meta-analyses with at least five studies:
Begg 0.23 0.48 0.33 N/A N/A N/A
0.25 T & F 0.35 0.20 N/A N/A N/A
0.46 0.43 Egger 0.51 N/A N/A N/A
0.26 0.30 0.43 Tang N/A N/A N/A
0.14 0.24 0.35 0.55 Macaskill N/A N/A
0.27 0.30 0.43 0.93 0.53 Deeks N/A
0.27 0.25 0.40 0.67 0.47 0.66 Peters
Based on the meta-analyses with the largest numbers of studies
in the corresponding Cochrane systematic reviews:
Begg 0.40 0.51 0.33 N/A N/A N/A
0.30 T & F 0.41 0.25 N/A N/A N/A
0.46 0.45 Egger 0.48 N/A N/A N/A
0.29 0.31 0.45 Tang N/A N/A N/A
0.17 0.24 0.38 0.60 Macaskill N/A N/A
0.28 0.31 0.45 0.95 0.59 Deeks N/A
0.27 0.28 0.46 0.69 0.55 0.70 Peters
Begg, the rank test; Egger, Tang, Macaskill, Deeks, and Peters,
the regression tests; T & F, the trim and fill method; N/A, not
applicable. Cohen’s κ coefficients ≥ 0.60 are in bold.
Chapter 4
Quantifying Publication Bias in
Meta-Analysis
This chapter introduces an alternative measure to quantify publication bias, the skew-
ness of the standardized deviates. The new measure not only has an intuitive inter-
pretation as the asymmetry of the collected study results but also can serve as a test
statistic. The large sample properties of the new measure are studied. We also evalu-
ate its performance using simulations and three actual meta-analyses published in the
Cochrane Database of Systematic Reviews.
4.1 Notation and the regression test
Suppose a meta-analysis collects n studies; each study reports an effect size yi (e.g.,
log odds ratio for binary outcomes) and its within-study variance s2i , due to sampling
error (i = 1, . . . , n). If the collected studies are deemed homogeneous, sharing a common
underlying true effect size µ, then the fixed-effect model is customarily used, specified by
yi ∼ N(µ, s2i ). The studies are heterogeneous if they have different underlying effect sizes
µi; the corresponding random-effects model assumes yi ∼ N(µi, s2i ) and µi ∼ N(µ, τ2),
where τ2 is the between-study variance and µ is interpreted as the overall mean effect
size [6]. The random-effects model reduces to the fixed-effect model by setting τ2 = 0.
To detect publication bias, Egger et al. [25] proposed a regression test, regressing
40
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the standardized effect sizes (yi/si) on the corresponding precisions (1/si); that is,
yi/si = α+ µ · 1/si + i, i iid∼ N(0, σ2).
Egger’s regression test transforms the original null hypothesis, H0: no publication bias,
to testing H ′0: the regression intercept is zero. Alternatively, in the presence of no-
ticeable heterogeneity between studies, we may slightly modify Egger’s test by using
the marginal standard deviations to produce the regression predictors and responses
under the random-effects model. Note that the random-effects model can be written
marginally as yi = µ+δi+ξi, where δi
iid∼ N(0, τ2) is the random effect and ξi ∼ N(0, s2i )
is the sampling error in study i. Dividing by the marginal standard deviation (s2i+τ
2)1/2,
we have the following modified regression test:
yi(s
2
i + τ
2)−1/2 = α+ µ(s2i + τ
2)−1/2 + i, i
iid∼ N(0, σ2). (4.1)
Like Egger’s test, the intercept α is zero under the true model; in the presence of
publication bias, it departs from zero. The overall mean effect size µ becomes the
regression slope. Also, σ2 allows potential under- or over-dispersion of the errors. In
practice, heterogeneity is routinely assessed using the Q or I2 statistic [6,10,13,95], and
the between-study variance can be estimated as τ̂2 using the method of moments or the
maximum restricted likelihood method [69,93]. If heterogeneity is not significant, then
setting τ2 = 0 reduces Equation (4.1) to Egger’s original test. Since the heterogeneity
frequently appears in meta-analyses [78], this chapter will introduce publication bias
measures based on the modified regression test.
Let the least squares estimates of the regression coefficients in model (4.1) be α̂ and
µ̂. The estimated regression intercept is essential in the regression test; we denote this
statistic as
TI = α̂.
Under the null hypothesis, TI divided by its standard error follows the t-distribution
with degrees of freedom n−2, which gives the P -value of the regression test, denoted as
PI . Since the standardized effect sizes are unit-free, the estimated regression intercept
TI is also unit-free. Therefore, TI can serve as a measure for quantifying publication
bias [25]. However, the regression intercept TI lacks an intuitive interpretation for the
asymmetry of the collected study results. Meta-analysts usually report only the P -value
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of the regression test, not the magnitude of TI , to describe the severity of publication
bias.
4.2 Skewness and skewness-based test
The regression test does not fully describe the asymmetry of the collected study re-
sults. By linear regression theory, the estimated intercept can be expressed as TI =
n−1
∑n
i=1 d̂i, where
d̂i =
yi − µ̂√
s2i + τ̂
2
is an estimate of the study-specific standardized deviate di = (yi − µ)(s2i + τ2)−1/2.
Therefore, the regression intercept TI only reflects the average of the standardized
deviates. To better test and quantify publication bias, we further consider the shape of
the di’s.
Note that di = α+ i, so the standardized deviates di are distributed with the same
shape as the errors i. To test the original H0, we may alternatively test H
′′
0 : α = 0
and i
iid∼ N(0, σ2) vs. H ′′1 : α 6= 0 or i’s are iid from a skewed distribution with mean
zero. Clearly, H ′′0 is stronger than the null hypothesis H ′0 of Egger’s test, but it is still
a necessary condition if the original null hypothesis H0 holds. Hence, the statistical
power should be enhanced by testing H ′′0 compared to testing H ′0.
In the statistical literature, skewness has long been used as a descriptive quan-
tity for the asymmetry of a distribution [96], but it is fairly novel in the literature of
meta-analysis. To assess publication bias in meta-analysis, we may quantify the asym-
metry of  = (1, . . . , n)
T by the skewness, calculated as Skew() = m3/s
3, where s ={
(n− 1)−1∑ni=1(i − ¯)2}1/2 is the sample standard deviation, m3 = n−1∑ni=1(i− ¯)3
is the sample third central moment, and ¯ = n−1
∑n
i=1 i. In practice, we may replace
the unknown errors  with the regression residuals ̂ = (̂1, . . . , ̂n)
T, where ̂i = d̂i−TI .
Denote the sample skewness of the errors as
TS = Skew(̂),
which we propose as an alternative measure of publication bias. We will show that TS
is a consistent estimate of the true skewness.
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The sample skewness TS can take any real value. A symmetric distribution (i.e.,
publication bias is not present) has zero skewness. A noticeably large positive skewness
indicates that the right tail of standardized deviates’ distribution is longer than its left
tail. Therefore, some studies on the left side in the funnel plot (i.e., those with negative
effect sizes) might be missing due to publication bias. In this situation, the regression
intercept TI is also expected to be positive. On the other hand, a large negative skewness
implies that some studies may be missing on the right side. A common but rough rule of
interpreting skewness is as follows. If the skewness is less than 0.5 in absolute magnitude,
the distribution of the standardized deviates is approximately symmetric; the skewness
is deemed considerable if it is between 0.5 and 1 in absolute magnitude, and it may
be substantial if its absolute value is greater than 1. To interpret the skewness more
rigorously, we study its large sample properties.
Denote βk = E(1 − β)k as the kth central moment of the errors i, where β =
E(1) = 0, and the sample kth central moment is mk = n
−1∑n
i=1(i − ¯)k. Then the
true skewness of the errors is γ = β3/β
3/2
2 . In addition, let m̂k = n
−1∑n
i=1(̂i − ¯̂)k
be the sample kth central moment after plugging in the known residuals ̂i; note that
¯̂ = n−1
∑n
i=1 ̂i = 0. Denote
D−→ as the convergence in distribution. We have the
following proposition regarding the asymptotic distribution of the sample skewness TS .
Proposition 4. Assume that the study-specific errors i have finite sixth central moment
(i.e., β6 <∞) and the marginal precisions (s2i +τ2)−1/2 have finite third moment. Then,√
n(TS − γ)/
√
v̂
D−→ N(0, 1) as n→∞, where
v̂ = 9 +
35
4
m̂−32 m̂
2
3 − 6m̂−22 m̂4 + m̂−32 m̂6 +
9
4
m̂−52 m̂
2
3m̂4 − 3m̂−42 m̂3m̂5.
Proposition 4 provides an approximate 95% confidence interval (CI) of the sample
skewness TS . Consequently, TS not only quantifies publication bias but also serves as a
test statistic. Under H ′′0 , we can simplify the asymptotic distribution of TS as follows.
Corollary 1. Under the null hypothesis H ′′0 ,
√
n/6TS
D−→ N(0, 1) as n→∞.
Appendix B.2 provides the proofs. The P -value of the skewness-based test is calcu-
lated using Corollary 1:
PS = 2
(
1− Φ
(√
n/6|TS |
))
.
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The regression intercept TI quantifies the departure of the average standardized
deviate from zero; the skewness TS quantifies the departure of the standardized deviates’
distribution from symmetry. The regression test and the skewness-based test may differ
in power in different situations. Therefore, we may combine the test results of TI and
TS so that the combined test maintains high power across various settings. Under
H ′′0 , note that TI is the least squares estimate of the intercept and TS depends only
on the residuals ̂i. Because the least squares estimates of regression coefficients are
independent of the residuals if the errors i are normally distributed, we immediately
have the following proposition.
Proposition 5. Under the null hypothesis H ′′0 , TI and TS are independent.
Due to the independence of TI and TS , the adjusted P -value for combining TI and
TS can be calculated as PC = 1 − (1 − Pmin)2, where Pmin = min{PI , PS} [97]. The
performance of the skewness-based test and the combined test will be studied using
simulations and actual meta-analyses.
In practice, many meta-analyses only collect a small number of studies, and the
large sample properties may apply poorly for them. Alternatively, a nonparametric
bootstrap can be used to derive the 95% CI of the skewness: take samples of size n with
replacement from the original data {(yi, s2i )}ni=1 for B (say 1000) iterations and calculate
2.5% and 97.5% quantiles of the skewness over the B bootstrap samples. A parametric
resampling method can also be used to produce a P -value for the skewness-based test.
Specifically, first, estimate the overall mean effect size µ¯ under the null hypothesis that
there is no publication bias. Second, draw n samples under the null hypothesis, i.e.,
y?i ∼ N(µ¯, s2i + τ̂2), and repeat this for B iterations. Third, based on the B sets of
bootstrap samples, calculate the skewness as T
(b)
S for b = 1, . . . , B. Finally, the P -value
of the skewness-based test is PS =
[∑B
b=1 I(|T (b)S | ≥ |TS |) + 1
]
/(B + 1), where I(·) is
the indicator function. Similar procedures can also be used for the regression intercept
TI .
The code to implement the proposed methods will be included in our R package
‘altmeta’, available on the Comprehensive R Archive Network (CRAN).
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4.3 Simulations
We performed simulations to evaluate the type I error rate and power of the modified
regression test TI , the proposed skewness-based test TS , and the combined test based on
the adjusted P -value PC . The commonly-used Egger’s regression test, Begg’s rank test,
and the trim and fill method (T & F) were also considered. In addition, we calculated the
P -values of TI and TS using both their theoretical null distributions and the resampling
methods. As suggested by many other authors (e.g., [32]), the nominal significance
level was set to 10% for publication bias tests because the tests usually have low power.
For each simulated meta-analysis, the true overall effect size was µ = 1, the within-
study standard errors were drawn from si ∼ U(1, 4), and the between-study standard
deviation was set to τ = 0 (I2 = 0%), 1 (6% ≤ I2 ≤ 50%), and 4 (50% ≤ I2 ≤ 94%).
The study-specific effect sizes were then generated as yi ∼ N(µi, s2i ) and µi ∼ N(µ, τ2).
The number of studies collected in each meta-analysis was set to n = 10, 30, and 50.
We considered the following three scenarios to induce publication bias.
I. (Suppressing non-significant findings) We used the above parameters to generate
artificial studies, and suppose that they aimed at testing H0 : µ = 0 vs. H1 :
µ 6= 0. We assumed that studies with significant findings (i.e., P -value < 0.05
for treatment effect size) were published with probability 1. Also, studies with
non-significant findings were published with probability pi; the publication rate
was set to pi = 0, 0.02, 0.05, and 1. Note that pi = 1 implies no publication bias.
Studies were generated iteratively until we obtained n published studies to form
a simulated meta-analysis.
II. (Suppressing small studies with non-significant findings) In many cases, small
studies with non-significant findings are more likely to be suppressed than large
studies; hence, some authors prefer to treat the funnel-plot-based methods as
approaches to checking for ‘small-study effects’ [91]. We also simulated meta-
analyses following this scenario. Studies with significant findings were published
with probability 1. Large studies with non-significant findings and standard errors
si < 1.5 were also published with probability 1; however, small studies with non-
significant findings and standard errors si ≥ 1.5 were published with probability
pi, where pi = 0, 0.1, 0.2, and 1. Again, pi = 1 implies no publication bias. The
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studies were generated iteratively until we obtained n published studies to form a
simulated meta-analysis.
III. (Suppressing negative effect sizes) Publication bias can be also induced on the
basis of study effect size [26, 33, 98]. For each simulated meta-analysis, n + m
studies were generated, and the m studies with the most negative effect sizes were
suppressed. We set m = 0, bn/3c, and b2n/3c, where bxc denotes the largest
integer not greater than x. Note that m = 0 implies no publication bias.
For each setting, 10,000 meta-analyses were simulated. The Monte Carlo standard errors
of all type I error rates and powers reported below were less than 1%.
Table 4.1 presents the type I error rates and powers for Scenario I. Type I error
rates of most tests are controlled well, while that of Egger’s test is a little inflated when
the heterogeneity is substantial (τ = 4). For weak or moderate heterogeneity (τ = 0 or
1), Egger’s regression test and the modified regression test TI have similar power, and
Begg’s rank test seems to be more powerful than the regression test. Also, the trim
and fill method performs poorly. Note that its power drops as pi decreases from 0.05
to 0 when n = 50 and τ = 0 or 1. Indeed, the trim and fill method is based on the
assumption in Scenario III; that is, studies are suppressed if they have most negative
(or positive) effect sizes, not according to their P -values. In Scenario I, the two-sided
hypothesis testing for treatment effects H0 : µ = 0 vs. H1 : µ 6= 0 can produce significant
findings with both negative and positive effect sizes, so the simulated meta-analyses can
seriously violate the assumption of the trim and fill method.
For small meta-analysis with n = 10, using the asymptotic property in Corollary 1,
the skewness-based test TS is less powerful than the regression test and Begg’s rank
test when pi = 0.02 or 0.05, and its type I error rate is much smaller than the nominal
significance level 10%. This is possibly because TS ’s asymptotic property is a poor
approximation for small n. However, using the resampling method, the power of TS is
dramatically higher than the other tests when τ = 0 and 1. Moreover, as the number
of studies n increases to 30 and 50, the skewness-based test using either the asymptotic
property or the resampling method still outperforms the other tests, and its power
remains high as the heterogeneity becomes substantial (τ = 4).
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Table 4.2 shows the results for Scenario II. The regression test and Begg’s rank
test are more powerful than TS when τ = 0 and 1, while they are outperformed by TS
when τ = 4. In this scenario, TS seems to be less powerful than in Scenario I. For
each simulated meta-analysis, because only small studies with non-significant findings
were suppressed, large studies are still symmetric in the funnel plot. Consequently,
the distribution of the n studies may have two modes: the large studies are centered
around the true overall effect size µ, and the small studies have an overestimated mean
due to the suppression. Since the interpretation of skewness is obscure for multi-modal
distributions, TS may lose power in this scenario.
Table 4.3 presents the type I error rates and powers for Scenario III. Since the
trim and fill method’s assumption is perfectly satisfied in this scenario, this method is
generally more powerful than the other tests. In the absence of heterogeneity (τ = 0),
both the regression test and Begg’s rank test are more powerful than the skewness-based
test TS ; as the heterogeneity increases, they are outperformed by TS , especially when n
is large.
In summary, the skewness-based test TS can be much more powerful than the existing
tests in some settings, while no test can uniformly outperform the others. Although TS
suffers from low power when the heterogeneity is weak or moderate in Scenarios II and
III, the combined test of TI and TS maintains high power in most settings by borrowing
strengths from each of the separate test.
4.4 Case studies
We illustrate the performance of the skewness measure and test by three actual meta-
analyses published in the Cochrane Database of Systematic Reviews. The first meta-
analysis was performed by Stead et al. [99] to investigate the effect of nicotine gum
for smoking cessation; it contains 56 studies and the effect size is the log risk ratio.
The second meta-analysis, performed by Hro´bjartsson and Gøtzsche [100], investigates
the effect of placebo interventions for all clinical conditions regarding patient-reported
outcomes; it contains 109 studies and the effect size is standardized mean difference.
The third meta-analysis reported in Liu and Latham [101] compares the effect of the
progressive resistance strength training exercise vs. control; it contains 33 studies and
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the effect size is also standardized mean difference. Figure 4.2 presents their contour-
enhanced funnel plots; the shaded regions represent different significance levels [102].
The proposed methods and the commonly-used tests were applied to the three meta-
analyses, and both the theoretical null distributions and the resampling methods were
used to calculate the 95% CIs and P -values for TI and TS . We also calculated the
P -values for the combined test. Table 4.4 presents the results. Since the size of each ex-
ample n is large (for meta-analyses), the 95% CIs and P -values based on the theoretical
null distributions are similar to those based on the resampling methods.
For the meta-analysis in Stead et al. [99], the three commonly-used tests yield P -
values > 0.10, indicating non-significant publication bias; the P -value of the modified
regression test TI is also large. However, the proposed skewness TS is 0.91 with 95%
CI (0.14, 1.68) and P -value 0.005 using the resampling methods; it implies substantial
publication bias. Since TS is significantly greater than zero, some studies with negative
effect sizes may be missing. Indeed, the funnel plot in Figure 4.2(a) shows that most
studies are massed on the right side, tending to have significant positive results; some
studies are potentially missing on the left side. Moreover, benefiting from the high power
of the skewness-based test, the combined test also indicates significant publication bias.
For the meta-analysis in Hro´bjartsson and Gøtzsche [100], all tests imply significant
publication bias; the P -values of Begg’s rank test, the trim and fill method, and the
skewness-based test are fairly small (< 0.01). Both the regression intercept TI and the
skewness TS are significantly negative, indicating that some studies are missing on the
right side in the funnel plot; Figure 4.2(b) confirms this. For the meta-analyses in Liu
and Latham [101], Figure 4.2(c) shows that its funnel plot is approximately symmetric,
so there appears to be no publication bias. Indeed, all tests yield P -values much greater
than 0.1, and the publication bias measures TI and TS are close to zero.
4.5 Discussion
This chapter proposed a new measure, the skewness of the standardized deviates, for
quantifying potential publication bias in meta-analysis. The intuitive interpretation of
the asymmetry of the collected study results makes this measure appealing; its per-
formance was illustrated by three actual meta-analyses. Also, the skewness can serve
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as a test statistic and its large sample properties have been studied. The simulations
showed that the skewness-based test has high power in many cases. The large-sample
properties of the skewness did not perform well for small n, but this can be remedied by
using resampling methods. In addition, we proposed a combined test that depends on
the P -values of both the regression and skewness-based tests; it is shown to be powerful
in most simulation settings.
The proposed skewness has some limitations. First, for small meta-analyses, the
variation of the sample skewness can be large. Researchers should always use skewness
along with its 95% confidence interval. Second, although a symmetric distribution has
zero skewness, zero skewness does not necessarily imply a symmetric distribution; for
example, an asymmetric distribution may have zero skewness if it has a long but thin
tail on one side and a short but fat tail on the other side. Also, the skewness generally
describes publication bias well when the effect sizes are unimodal, but its interpretation
for multi-modal distributions is obscure. Therefore, the regression intercept is preferred
when the studies appear to have multiple modes, which may be identified by visual
examining the funnel plot. Third, like many other approaches to assessing publication
bias, the skewness is based on checking the funnel plot’s asymmetry. However, such
asymmetry can be caused by sources other than publication bias [90], such as reference
bias [103, 104], studies with poor quality in design [105, 106], the existence of multiple
subgroups [34], etc. When applying the methods in this chapter to detect or quantify
the asymmetry of study results, researchers may need to examine carefully whether the
asymmetry is caused by publication bias or other sources of bias. In addition, in the
simulations and actual meta-analyses, different methods for publication bias can lead
to fairly different conclusions. Therefore, we are allowed to use a wealth of methods to
detect any potential publication bias.
Like the routinely-used I2 statistic for assessing heterogeneity, the skewness may be
a good characteristic of meta-analysis for quantifying publication bias. In the statistical
literature, the skewness is a conventional descriptive quantity for asymmetry, but it
may not be optimal to serve as a test statistic; more sophisticated tests for a continuous
distribution have been extensively discussed (e.g., [107–109]). Exploring more powerful
tests based on the standardized deviates warrants future study.
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Figure 4.1: The funnel plot of a simulated meta-analysis containing 60 studies. The 10
studies with the most negative effect sizes were suppressed due to publication bias, and
the remaining 50 studies were ‘published’.
51
−0.5 0.0 0.5 1.0
0.
5
0.
4
0.
3
0.
2
0.
1
0.
0
(a) Stead et al. (2012)
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(b) Hróbjartsson and Gøtzsche (2010)
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(c) Liu and Latham (2009)
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Figure 4.2: Contour-enhanced funnel plots of the three actual meta-analyses. The
vertical and diagonal dashed lines represent the overall estimated effect size and its
95% confidence limits, respectively, based on the fixed-effect model. The shaded regions
represent different significance levels for the effect size.
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Table 4.1: Type I error rates (pi = 1) and powers (pi < 1) expressed as percentage, for various tests for publication bias due to
suppressing non-significant findings (Scenario I).
Test
τ = 0 (I2 = 0%) τ = 1 (6% ≤ I2 ≤ 50%) τ = 4 (50% ≤ I2 ≤ 94%)
pi = 1 pi = 0.05 pi = 0.02 pi = 0 pi = 1 pi = 0.05 pi = 0.02 pi = 0 pi = 1 pi = 0.05 pi = 0.02 pi = 0
n = 10:
Egger 10 15 23 35 11 14 20 31 13 10 10 11
Begg 7 13 28 57 5 12 23 44 5 4 4 4
T & F 11 8 12 30 11 7 10 21 5 8 9 9
TI 10 17 26 40 10 17 25 39 10 14 15 16
TI
* [9] [21] [29] [41] [11] [19] [27] [39] [9] [15] [17] [17]
TS 1 7 20 37 1 8 18 32 1 3 3 4
TS
* [10] [27] [48] [59] [10] [29] [46] [58] [10] [15] [17] [19]
Combined 6 14 29 61 6 14 27 52 5 9 10 11
Combined* [10] [26] [50] [75] [10] [27] [47] [68] [8] [15] [17] [18]
n = 30:
Egger 10 17 27 45 10 14 23 35 14 11 12 12
Begg 7 28 64 97 7 24 55 89 5 4 5 6
T & F 12 16 18 17 13 19 20 18 9 21 21 20
TI 10 18 27 42 10 17 25 36 10 15 16 18
TI
* [9] [22] [33] [49] [11] [21] [31] [43] [10] [18] [20] [22]
TS 6 50 83 94 6 59 83 92 5 16 20 24
TS
* [10] [61] [88] [96] [10] [70] [88] [94] [10] [26] [30] [34]
Combined 8 42 77 93 8 48 76 90 8 16 19 23
Combined* [10] [53] [85] [96] [11] [61] [84] [94] [9] [23] [28] [32]
n = 50:
Egger 9 20 35 58 11 17 28 46 14 12 13 14
Begg 7 38 83 100 7 33 75 98 5 5 7 9
T & F 12 20 17 10 12 23 19 13 9 18 18 18
TI 9 19 31 49 10 18 28 43 10 16 18 20
TI
* [9] [24] [38] [57] [11] [23] [34] [51] [10] [19] [21] [24]
TS 7 77 96 99 7 84 96 98 7 30 36 41
TS
* [10] [82] [97] [99] [10] [87] [97] [99] [10] [37] [44] [49]
Combined 8 67 94 99 9 75 93 98 8 25 30 35
Combined* [9] [74] [96] [100] [11] [81] [96] [99] [9] [31] [36] [42]
The nominal significance level is 10%.
* The results in square brackets are based on the parametric resampling method.
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Table 4.2: Type I error rates (pi = 1) and powers (pi < 1) expressed as percentage, for various tests for publication bias due to
suppressing small studies with non-significant findings (Scenario II).
Test
τ = 0 (I2 = 0%) τ = 1 (6% ≤ I2 ≤ 50%) τ = 4 (50% ≤ I2 ≤ 94%)
pi = 1 pi = 0.2 pi = 0.1 pi = 0 pi = 1 pi = 0.2 pi = 0.1 pi = 0 pi = 1 pi = 0.2 pi = 0.1 pi = 0
n = 10:
Egger 10 14 22 51 11 13 19 43 13 9 10 12
Begg 7 8 13 30 5 7 12 30 5 4 5 7
T & F 11 10 11 15 11 9 10 13 5 4 5 5
TI 10 15 23 56 10 14 23 54 10 13 16 21
TI
* [9] [19] [29] [61] [11] [19] [28] [59] [9] [15] [18] [25]
TS 1 1 1 5 1 1 1 5 1 1 1 3
TS
* [10] [10] [11] [19] [10] [9] [11] [22] [10] [9] [11] [17]
Combined 6 9 16 48 6 8 15 46 5 7 9 14
Combined* [10] [15] [23] [58] [10] [14] [22] [55] [8] [10] [14] [21]
n = 30:
Egger 10 20 34 69 10 18 30 62 14 10 12 16
Begg 7 16 30 68 7 14 28 66 5 5 7 13
T & F 12 18 23 32 13 15 17 21 9 13 14 13
TI 10 21 36 70 10 20 33 66 10 14 18 25
TI
* [9] [24] [40] [74] [11] [23] [37] [71] [10] [17] [22] [32]
TS 6 5 12 54 6 6 14 58 5 6 10 21
TS
* [10] [10] [18] [59] [10] [10] [21] [64] [10] [11] [17] [31]
Combined 8 16 30 80 8 14 28 75 8 10 14 24
Combined* [10] [20] [36] [83] [11] [18] [33] [81] [9] [13] [20] [33]
n = 50:
Egger 9 26 46 82 11 24 41 78 14 12 14 20
Begg 7 21 43 85 7 19 41 84 5 5 9 19
T & F 12 17 19 21 12 14 15 13 9 12 12 10
TI 9 26 46 82 10 25 42 79 10 15 19 29
TI
* [9] [29] [50] [85] [11] [27] [46] [82] [10] [19] [24] [36]
TS 7 7 20 79 7 9 24 83 7 10 18 36
TS
* [10] [10] [25] [81] [10] [11] [30] [85] [10] [14] [24] [43]
Combined 8 20 41 92 9 19 39 89 8 12 18 34
Combined* [9] [23] [46] [93] [11] [22] [44] [91] [9] [16] [24] [41]
The nominal significance level is 10%.
* The results in square brackets are based on the parametric resampling method.
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Table 4.3: Type I error rates (m = 0) and powers (m > 0) expressed as percentage, for various
tests for publication bias due to suppressing the m most negative effect sizes out of a total of n+m
studies (Scenario III).
Test
τ = 0 (I2 = 0%) τ = 1 (20% ≤ I2 ≤ 50%) τ = 3 (70% ≤ I2 ≤ 90%)
m = 0 bn/3c b2n/3c m = 0 bn/3c b2n/3c m = 0 bn/3c b2n/3c
n = 10:
Egger 10 21 31 10 19 25 13 15 14
Begg 6 12 18 6 10 14 4 5 6
T & F 11 27 38 11 25 33 5 13 18
TI 10 21 31 10 18 25 10 11 13
TI
* [9] [12] [13] [11] [13] [12] [9] [12] [13]
TS 2 2 4 2 2 3 1 2 3
TS
* [10] [13] [17] [10] [13] [16] [10] [14] [16]
Combined 6 14 20 6 12 16 6 7 8
Combined* [9] [13] [15] [11] [13] [15] [8] [13] [16]
n = 30:
Egger 10 57 77 11 44 60 14 18 20
Begg 8 46 67 7 35 54 5 12 17
T & F 13 87 97 13 81 92 9 51 63
TI 10 57 77 10 44 60 10 14 16
TI
* [10] [38] [46] [12] [33] [39] [10] [13] [17]
TS 6 25 40 6 25 39 6 26 40
TS
* [10] [34] [51] [11] [34] [51] [10] [37] [52]
Combined 8 54 76 8 43 64 8 23 35
Combined* [10] [42] [56] [12] [39] [53] [9] [30] [44]
n = 50:
Egger 10 77 93 11 61 80 14 19 22
Begg 8 69 89 8 56 76 5 18 26
T & F 12 98 100 13 95 99 9 69 75
TI 10 77 93 11 61 80 10 16 20
TI
* [10] [59] [74] [12] [52] [61] [10] [15] [19]
TS 8 46 69 7 47 68 7 51 69
TS
* [10] [53] [75] [10] [54] [75] [10] [58] [76]
Combined 9 77 95 10 67 87 8 44 62
Combined* [10] [65] [85] [12] [62] [79] [9] [49] [67]
The nominal significance level is 10%.
* The results in square brackets are based on the parametric resampling method.
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Table 4.4: Results of assessing publication bias for three actual meta-analyses.
Meta-analysis
No. of
I2 (%)
P -value Intercept TI Skewness TS P -value of the
studies Egger Begg T & F Measure 95% CI P -value Measure 95% CI P -value combined test
Stead et al. 56 39 0.173 0.136 0.500 0.47 (−0.47, 1.41) 0.323 0.91 (0.14, 1.68) 0.005 0.011
[−0.43, 1.42] [0.317] [0.06, 1.50] [0.005] [0.010]
Hro´bjartsson and Gøtzsche 109 42 0.049 0.009 <0.001 −0.81 (−1.54, −0.09) 0.028 −0.74 (−1.23, −0.24) 0.002 0.003
[−1.56, −0.10] [0.030] [−1.17, −0.25] [0.002] [0.004]
Liu and Latham 33 11 0.905 0.469 0.500 0.06 (−0.91, 1.02) 0.905 0.01 (−0.63, 0.64) 0.989 0.991
[−1.09, 1.25] [0.894] [−0.73, 0.68] [0.987] [0.989]
The results in square brackets are based on the parametric resampling method.
Chapter 5
Bayesian Multivariate
Meta-Analysis of Multiple
Factors
This chapter proposes multivariate meta-analysis of multiple factors (MVMA-MF) to
jointly synthesize all risk and protective factors in a field-wide systematic review. Us-
ing the information across multiple factors, this method can produce better estimates
of association measures between the factors and the disease condition, compared with
separate meta-analyses. Multivariate meta-analysis methods have gained much atten-
tion in the recent literature [110–113]. They improve effect estimates by borrowing
information on the correlations between multiple endpoints [114]. Multivariate meta-
analysis methods have been applied to several areas, such as meta-analysis of diagnostic
tests [115–117], meta-analysis of multiple outcomes [118,119], and network meta-analysis
of mixed treatment comparisons [51,53,56,67]. Mixed treatment comparisons use both
direct and indirect evidence of treatment contrasts to synthesize the comparisons be-
tween multiple treatments; its focus is different from MVMA-MF, because MVMA-MF
is concerned with estimating the effect of multiple factors, but not the contrasts between
them.
A multivariate random-effects model generally requires estimates of correlations
within each collected study. In some situations, within-study correlations are known
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to be zero. For example, in meta-analysis of diagnostic tests, the study-specific sensi-
tivity and specificity are statistically independent within studies because they are cal-
culated from the true negative and true positive patients, respectively [111]. However,
in MVMA-MF, the factors can be correlated within each study because they may be
measured on the same patients. Such within-study correlations are unknown unless in-
dividual patient data are available. Ignoring within-study correlations in the standard
multivariate random-effects model may have a great impact on the estimated overall
effect sizes [120].
To deal with unknown within-study correlations, this chapter considers an alterna-
tive Bayesian model for MVMA-MF. The conventional multivariate model partitions
the overall covariance matrix into two parts: the within-study level that is due to
sampling error, and the between-study level that is due to heterogeneity between the
collected studies. Instead of partitioning the overall correlations into the two levels, the
alternative model directly specifies one single overall correlation matrix; hence, it may
be viewed as a hybrid approach. This model is the Bayesian version of the model in-
troduced by Riley et al. [121]. Currently, Riley’s model is implemented in a frequentist
way, such as using the restricted maximum likelihood method [122]. However, the data
for a MVMA-MF are usually fairly sparse (e.g., Table 5.1), and our simulation study
in Appendix A.6 shows that the frequentist method generates poor 95% confidence in-
tervals for sparse data; also, the algorithm for maximizing the (restricted) likelihood
does not converge for many simulated data. Instead of using the frequentist method, a
fully Bayesian approach is applied to perform MVMA-MF. Both the simulations and
the case study demonstrate the benefit of joint modeling.
5.1 The motivating pterygium data
Instead of reporting only one risk factor at a time, Serghiou et al. [49] collected the
odds ratios of all putative risk factors for pterygium, an eye disease. Specifically, they
identified 60 eligible studies reporting on a total of 65 risk factors. Since most risk factors
were only reported in less than 3 studies, we focus on the following 8 risk factors, each
of which was reported in at least 4 studies: (1) occupation type (outdoor vs. indoor);
(2) smoking status (yes vs. no); (3) education attainment (low vs. high); (4) use of hat
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(yes vs. no); (5) use of spectacles (yes vs. no); (6) area of residence (rural vs. urban);
(7) use of sunglasses (yes vs. no); and (8) latitude of residence (low vs. high). These
risk factors are sorted from high to low according to their frequencies reported in the
collected studies. Also, we cleaned the data by removing the log odds ratios that were
obtained using a multivariate regression model, because they were adjusted for different
risk factors in different studies. Table 5.1 presents the cleaned data and Figure 5.1 shows
the network plot of the 8 risk factors. The network indicates that most pairs of risk
factors are simultaneously reported in some studies, but several pairs, such as ‘area of
residence’ and ‘use of hat’, are not. From Table 5.1, the risk factor ‘latitude of residence’
was reported in only 4 studies, while 23 studies reported ‘occupation type’. Most studies
reported different subsets of the 8 risk factors, and many entries in Table 5.1 are missing.
The estimated overall effect sizes produced by univariate models may be poor because
some risk factors have data in few studies. Also, many factors (e.g., ‘area of residence’
and ‘education attainment’) are expected to be correlated, so a multivariate model may
be more appropriate for this dataset than univariate models.
5.2 Conventional meta-analysis models
This section reviews some existing models for general multivariate meta-analysis. Sup-
pose that n independent studies are collected; each study reports a p-dimensional vector
of effect sizes, denoted as yi = (yi1, . . . , yip)
T. Denote its within-study covariance ma-
trix as Si (i = 1, . . . , n). The conventional univariate meta-analysis pools the results
for each j = 1, . . . , p separately; a fixed- or random-effects model is applied to the data
{(yij , vij)}ni=1, where vij is the within-study variance, i.e., the jth diagonal element in
Si [6,7]. Since most studies were conducted by different research teams in different places
using different methods, the studies are usually expected to be heterogeneous [78]. Also,
the random-effects model may produce more conservative results than the fixed-effects
model [123,124], so this chapter focuses on the random-effects setting that accounts for
the heterogeneity between studies. We denote the univariate model as Model U, which
ignores both within- and between-study correlations.
Multivariate meta-analysis has recently gained much attention for simultaneously
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synthesizing the p-dimensional effect sizes [110–112]. Given that the within-study co-
variance matrices Si are known, the commonly used random-effects model is specified
as follows to analyze the multivariate data {(yi,Si)}ni=1:
yi ∼ N(µi,Si);
µi ∼ N(µ,T),
(5.1)
where µi represents study i’s underlying true effect sizes, µ = (µ1, . . . , µp)
T contains
the overall effect sizes, and T = (τij) is the p × p between-study covariance matrix.
We denote this multivariate model as Model M . Note that within-study variances
are routinely reported in published articles, but within-study correlations are usually
unavailable. Let Di = diag(Si) be the diagonal matrix consisting of the within-study
variances.
To analyze the data {(yi,Di)}ni=1 when the within-study correlations are unknown,
a na¨ıve multivariate method is to simply ignore these correlations by setting them to 0
but still account for the between-study correlations; we denote this model as Model M0.
Nevertheless, ignoring within-study correlations could lead to poor estimated effect sizes,
especially when the within-study correlations are comparable to or greater than the
between-study correlations [120]. The following section introduces an alternative model
that can incorporate both within- and between-study correlations for MVMA-MF.
5.3 Multivariate meta-analysis of multiple factors
5.3.1 Multivariate hybrid meta-analysis model
Model M may be deemed ideal to perform MVMA-MF: it uses the factors’ within-study
correlations that are usually unknown, and it provides a benchmark for the performance
of other potential models. Note that study i’s marginal covariance matrix in Model M
is Mi = Si + T, which can be written as Mi = (Di + ∆)
1/2Ri(Di + ∆)
1/2, where
∆ = diag(τ21 , . . . , τ
2
p ) contains the between-study variances (i.e., diagonal elements in
T), and Di is a diagonal matrix containing the within-study variances (i.e., diagonal
elements in Si). The marginal correlation matrix of study i, Ri, is determined by both
Si and T, and thus needs to be estimated if the within-study correlations are unknown.
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It may be inefficient to use the data merely from the n studies to simultaneously estimate
all the Ri’s, which involve too many parameters.
Alternatively, extending the bivariate model in Riley et al. [121], we consider a mul-
tivariate model that does not require within-study correlations to perform MVMA-MF:
yi ∼ N
(
µ, (Di + Ψ)
1/2R(Di + Ψ)
1/2
)
,
where Ψ = diag(ψ21, . . . , ψ
2
p) is a diagonal matrix that consists of additional variances
beyond sampling error due to between-study heterogeneity for the p effect sizes. In this
model, all collected studies are assumed to share a common marginal correlation matrix
R. This assumption effectively reduces the number of parameters to be estimated and
accounts for both within- and between-study correlations. The simulation study in
Appendix A.6 generates data with different study-specific correlation matrices; it shows
that the alternative model still performs well even if its assumption that Ri ≡ R does
not hold. Like Model M, the alternative model partitions the marginal variances of yi,
Di + Ψ, into the within- and between-study levels; however, it directly uses the matrix
R to model the overall correlations, instead of partitioning the correlations into the
previous two levels. Therefore, the alternative model may be deemed hybrid, and we
denote it as Model H .
5.3.2 Missing data
So far, only models for complete data have been discussed. In MVMA-MF, each col-
lected study often reports a small subset of the complete set of factors, and many factors
are missing, as in Table 5.1. It is straightforward to extend the four methods (Models U,
M, M0, and H) to deal with missing data; Model H for missing data will be detailed here.
Suppose that y˜i = (y˜i1, . . . , y˜ip)
T contains the complete p factors in study i; however, we
only observe ti factors and their within-study variances (1 ≤ ti ≤ p). Denote the effect
sizes of the ti factors as yi = (yi1, . . . , yiti)
T, which is a ti-dimensional sub-vector of y˜i,
and let Di be the ti × ti diagonal matrix containing the within-study variances. We
write yi = Xiy˜i, where Xi = (ei1, . . . , eiti)
T is a ti × p matrix indicating missingness.
Specifically, for each j = 1, . . . , ti, we define eij = (eij1, . . . , eijp)
T with eijk = 1 if the
observed yij is the effect size of factor k, and eijk = 0 otherwise. For example, for
61
study 3 in the pterygium data (Table 5.1),
X3 =

1 0 0 0 0 0 0 0
0 1 0 0 0 0 0 0
0 0 1 0 0 0 0 0
 .
Recall that µ, Ψ, and R represent the overall mean effect sizes, the between-study
variances, and the marginal correlation matrix for the complete p factors, respectively.
Hence, for the observed ti-dimensional vector yi, its overall mean is Xiµ, its marginal
variances form the diagonal matrix Di + XiΨX
T
i , and its marginal correlation matrix
is XiRX
T
i . Consequently, the hybrid model for missing data can be specified as
yi ∼ N (Xiµ,Φi) ,where Φi = (Di + XiΨXTi )1/2XiRXTi (Di + XiΨXTi )1/2.
The simulation study in Appendix A.6 compares the performance of Model H with
Models M, M0, and U when some factors are missing under various mechanisms. The
performance of Model H is shown to be close to the ideal Model M that requires unknown
within-study correlations. When factors are missing not at random (e.g., in the presence
of publication bias), Model H produces estimated overall effect sizes with smaller biases
and mean squared errors and larger 95% credible interval (CrI) coverage probabilities,
compared with Models M0 and U.
5.3.3 Bayesian hybrid model
Currently existing statistical software, such as the Stata command ‘mvmeta’, can only
implement Model H in a frequentist way [121,122]. However, when the dimension of fac-
tors p is large compared with the number of collected studies, the estimated covariance
matrix using the frequentist method may be quite inconsistent [125], leading to poor
interval estimates. Indeed, the simulation study in Appendix A.6 shows that the fre-
quentist method produces poor 95% confidence intervals when the data for MVMA-MF
are sparse, and the algorithm for maximizing the (restricted) likelihood does not con-
verge for many simulated datasets. Therefore, we use a fully Bayesian approach to
estimating the overall multivariate effect size µ and its covariance matrix, which are
of interest in Model H. Vague priors are assigned to both the mean and variance-
covariance structures. Appendix A.5 provides the details of the implementation. The
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R code for the Bayesian MVMA-MF will be provided in our package ‘altmeta’, freely
available at http://cran.r-project.org/package=altmeta. The simulation study in
Appendix A.6 indicates that the 95% CrIs obtained using the Bayesian method gener-
ally have higher coverage probabilities than those obtained using the frequentist method
for sparse data, which are common in MVMA-MF.
5.4 Real data analysis
Section 5.1 introduced the pterygium dataset in detail. Since the within-study cor-
relations are unknown, we used Models H, M0, and U but not Model M to estimate
the overall log odds ratios of the 8 risk factors. Due to the sparsity of the dataset, the
Bayesian method may be preferred. The Markov chain Monte Carlo (MCMC) algorithm
was used to implement the Bayesian analysis with three chains; each chain contained
a run of 100,000 updates after a 100,000-run burn-in period. The convergence of each
chain was checked using trace plots. Table 5.2 presents the median overall log odds
ratios with 95% CrIs. Figure 5.2 shows the posterior density plots of the 8 risk factors;
each plot contains three density curves corresponding to the three models.
For risk factors that are reported in a relatively large number of studies (e.g., occu-
pation type, smoking status, and education attainment), the three models yield similar
estimated overall log odds ratios; their density curves are also fairly similar. For risk
factors that are only reported in a few studies (e.g., use of spectacles, area of residence,
and latitude of residence), the peaks of the posterior densities produced by Model H are
narrower and higher compared with those produced by Models M0 and U, indicating
that Model H produces narrower 95% CrIs. Also, for the risk factor use of sunglasses,
the location of its posterior density produced by Model H is noticeably different from
those produced by the other two modes. Figure 5.3 depicts the estimated overall corre-
lations between the 8 risk factors produced by Model H. It shows that many factors are
correlated and some correlations are fairly high. Hence, ignoring the within-study corre-
lations could lead to fairly different estimated log odds ratios; the unknown within-study
correlations need to be carefully considered in MVMA-MF.
Furthermore, we performed a sensitivity analysis to investigate the impact of risk
factor selection on the estimated overall log odds ratios. We considered two scenarios
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for the set of risk factors to be included in MVMA-MF: (i) the sub-dataset consists of
the k most frequently reported risk factors; and (ii) the sub-dataset consists of the k
least frequently reported risk factors (k = 2, . . . , 8). For example, when k = 2, the sub-
dataset under scenario (i) contains the risk factors (1) occupation type and (2) smoking
status; the sub-dataset under scenario (ii) contains the risk factors (7) use of sunglasses
and (8) latitude of residence. The proposed hybrid model was implemented using the
Bayesian method to analyze these sub-datasets.
Figure 5.4 shows the 95% CrIs of the overall log odds ratios under both scenarios;
the labels of risk factors used in the figure can be found in Table 5.2’s first column. In
scenario (i), starting from the two most frequently reported risk factors, infrequently re-
ported risk factors are iteratively added to the multivariate meta-analysis. Figure 5.4(i)
shows that the estimated overall log odds ratios of risk factors 4 and 5 have some
changes as new factors were added to the sub-datasets. The 95% CrIs of the three
most frequently reported risk factors 1–3 change little. This might be explained by two
reasons. First, the correlations between these three factors are weak (Figure 5.3), so
the addition of risk factor 3 has little impact on estimating the effect sizes of factors 1
and 2. Also, the later added factors 4–8 have much smaller sample sizes (less than six
studies) compared with factors 1–3, which are reported in more than ten studies, so the
correlations may contribute little to the estimated effect sizes of factors 1–3.
Compared with scenario (i), Figure 5.4(ii) shows larger changes of estimated overall
log odds ratios in scenario (ii). Under this scenario, starting from the two least frequently
reported risk factors, more frequently reported risks are iteratively added to the mul-
tivariate meta-analysis. The 95% CrIs of infrequently reported risk factors, such as 5
and 6, become narrower as more reported risk factors are included in the MVMA-MF.
This illustrates the benefit of jointly modeling multiple risk factors: the inference on
infrequently reported risk factors can be strengthened by borrowing information from
frequently reported risk factors through the correlations between them.
5.5 Discussion
This chapter proposed MVMA-MF with application to the pterygium data. In contrast
to the tradition of meta-analyzing each single factor separately, we encourage researchers
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to collect all possible factors and analyze them jointly to enhance the estimation of over-
all effect sizes. A multivariate hybrid model was introduced to implement MVMA-MF
in which within-study correlations are usually unknown. The simulation study in Ap-
pendix A.6 shows that the proposed method performs better than the univariate model
and the model that ignores within-study correlations, especially when some factors are
missing not at random.
An important issue of MVMA-MF is to incorporate the effect size of a certain factor
that has been adjusted for other factors. For example, in the original pterygium data
presented in Serghiou et al. [49], many collected studies report only log odds ratios that
are obtained using multivariate regression after adjusting for different factors (e.g., age
and gender), while log odds ratios without any adjustments are unavailable from these
studies. We do not include such data in Table 5.1 due to the inconsistent adjustments.
How to incorporate such data with different adjustments is of great interest to enrich
the data for MVMA-MF and enhance the robustness and precision of MVMA-MF. We
leave this to future studies.
Another interesting but challenging problem is to robustly impute the missing factors
when the missingness is not at random; this missingness mechanism is closely related
to publication bias [28]. Although the simulation study in Appendix A.6 shows that
the proposed hybrid model performs better than Models M0 and U, its performance
(assessed by bias and 95% CrI coverage probability) is expected to be further improved
in the presence of publication bias. Approaches to correcting publication bias have been
introduced and widely used in univariate meta-analysis [26]; similar methods are highly
needed for multivariate meta-analysis.
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Figure 5.1: Network plot of the pterygium data. The nodes represent the risk factors,
and the edge between two nodes indicate that these nodes are simultaneously reported
in common studies. The node size is proportional to the number of studies that report
the corresponding risk factor, and the edge thickness is proportional to the number of
studies that simultaneously report the corresponding two risk factors.
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Figure 5.2: Posterior density plots produced by Models H (accounting for both between-
and within-study correlations), Model M0 (only accounting for between-study correla-
tions), and Model U (ignoring both between- and within-study correlations) for the log
odds ratios of the 8 risk factors in the pterygium data.
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by Model H in the pterygium data. Darker color implies higher correlation.
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Figure 5.4: Bayesian estimates of log odds ratios produced by Model H based on subsets
of the pterygium data. Each horizontal solid line represents 95% CrI of log odds ratio.
The number placed at the median log odds ratio within each 95% CrI represents the
corresponding risk factor’s label. The results of the sub-datasets that contain k =
2, . . . , 8 risk factors are accordingly listed from upper to lower, separated by the dotted
lines.
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Table 5.1: The pterygium data containing 29 studies with 8 risk factors. The effect size is log odds ratio with within-study standard
error in parentheses. The blank entries indicate that the risk factors are unavailable from the corresponding studies.
Study
Risk factor
(1) Occupation (2) Smoking (3) Education (4) Hat (5) Spectacles (6) Area (7) Sunglasses (8) Latitude
1 −0.08 (0.34)
2 1.54 (0.10)
3 0.28 (0.17) 0.53 (0.10) 0.53 (0.13)
4 0.45 (0.11) 0.41 (0.10) 0.97 (0.23)
5 0.30 (0.40)
6 0.12 (0.40) 0.48 (0.70)
7 1.40 (0.23)
8 0.39 (0.13) 0.05 (0.13)
9 0.55 (0.22) −0.04 (0.26)
10 3.04 (1.03)
11 1.95 (0.40) 1.21 (0.42) 0.67 (0.36) −1.34 (0.34) 0.12 (0.31)
12 1.10 (0.30)
13 2.03 (0.39) −0.69 (0.21) −1.14 (0.38) −1.64 (0.21) 2.99 (0.74)
14 0.83 (0.09) 0.11 (0.09) 0.91 (0.09) −0.58 (0.12) 1.14 (0.13)
15 0.41 (0.22)
16 −0.20 (0.24) 1.73 (0.18)
17 0.42 (0.15) −0.11 (0.25) 0.38 (0.21) 0.22 (0.15) −0.64 (0.15) −0.52 (0.37)
18 0.63 (0.12) 0.03 (0.05) 1.24 (0.24)
19 0.89 (0.08) −0.08 (0.07) 1.70 (0.08) −0.17 (0.08) −0.06 (0.14)
20 0.39 (0.22) −0.13 (0.30)
21 0.90 (0.30) 0.85 (0.49)
22 −0.48 (0.25) 0.31 (0.25) 0.87 (0.20)
23 0.66 (0.26)
24 −0.46 (0.72) −0.73 (0.52)
25 0.76 (0.34) −0.48 (0.55) 1.05 (0.33)
26 0.03 (0.11) 0.19 (0.09)
27 1.16 (0.36) 0.53 (0.23) 0.83 (0.25)
28 0.12 (0.03) 0.14 (0.20) 1.43 (0.28) 1.43 (0.22)
29 0.41 (0.09) −0.26 (0.10) 0.46 (0.09)
Risk factors: (1) occupation type; (2) smoking status; (3) education attainment; (4) use of hat; (5) use of spectacles; (6) area of
residence; (7) use of sunglasses; and (8) latitude of residence.
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Table 5.2: The estimated overall log odds ratios (95% CrI) of the 8 risk factors in
the pterygium data obtained by Models H (accounting for both between- and within-
study correlations), Model M0 (only accounting for between-study correlations), and
Model U (univariate model ignoring both between- and within-study correlations) using
the Bayesian method.
Risk factor No. of Studies
Estimated overall log odds ratio
Model H Model M0 Model U
(1) Occupation type 23 0.65 (0.40, 0.92) 0.65 (0.41, 0.93) 0.66 (0.42, 0.91)
(2) Smoking status 16 0.10 (−0.07, 0.29) 0.10 (−0.07, 0.29) 0.08 (−0.07, 0.25)
(3) Education attainment 10 0.74 (0.40, 1.11) 0.74 (0.42, 1.07) 0.74 (0.46, 1.06)
(4) Use of hat 6 0.49 (−0.84, 1.61) 0.44 (−0.77, 1.55) 0.32 (−0.84, 1.41)
(5) Use of spectacles 6 −0.59 (−1.00, −0.11) −0.58 (−1.06, −0.06) −0.60 (−1.26, 0.05)
(6) Area of residence 5 1.05 (0.30, 1.78) 1.10 (0.22, 1.97) 1.24 (0.39, 2.11)
(7) Use of sunglasses 5 −0.34 (−1.55, 0.75) −0.51 (−1.64, 0.62) −0.57 (−1.76, 0.63)
(8) Latitude of residence 4 0.91 (−0.73, 2.68) 1.04 (−0.98, 3.10) 1.14 (−0.70,3.37)
Chapter 6
Sensitivity to Excluding
Treatments in Network
Meta-Analysis
This chapter examines the sensitivity to treatment exclusion of an alternative approach
to network meta-analysis, namely the arm-based approach, recently developed from
the perspective of missing data analysis [67]. The detailed model is briefly reviewed
in Appendix A.8. This model assumes: 1) each study is independently chosen from a
conceptual urn containing a large number of studies, and thus we can assign a joint dis-
tribution on the arm parameters independently across different studies; 2) each study
hypothetically compares all treatments, many of which are missing at random. The
arm-based model does not estimate the population-averaged absolute risk of each arm
independently; instead, it respects the study randomization by accounting for the corre-
lations between treatments within each study, which allows for ‘borrowing information’
across treatment arms. This point is illustrated by an example in Appendix A.7, in
which absolute risk estimates from the arm-based model differ from estimates from a
simple logit random effects model using only studies with a specific treatment arm. In
addition, simulation results and real data analyses have shown that in some cases the
effect size estimates given by this arm-based method are less biased than those given
by the contrast-based model [67].
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Besides reporting changes due to treatment exclusion in the population-averaged
absolute risk estimates from the arm-based model, we compare changes in relative ef-
fects (i.e., log odds ratio change) with those obtained from the contrast-based model.
In this regard, the arm-based and contrast-based methods have a key difference: If a
study only has two treatment arms and one of these arms is omitted from the network
meta-analysis, a contrast-based analysis must omit the entire study, while an arm-
based analysis can retain the single remaining arm. Note that single-arm studies do
contribute information to estimation of relative effects from the perspective of missing
data analysis, which is somewhat counter-intuitive. To give a simple illustration, con-
sider paired bivariate normally distributed random variables X and Y with parameters
(µx, µy, σ
2
x, σ
2
y , ρ), e.g., the probit-transformed absolute risks in the arm-based model.
The expected value of Y given X is µy + ρ
σy
σx
(X − µx). Once we observe a value X = x
in a particular pair (with Y unobserved), the expected difference between Y and X for
this pair becomes µy−x+ρσyσx (x−µx), which does not equal µy−µx. Also, the variance
of Y given X is (1 − ρ2)σ2y ≤ σ2y . Therefore, even if Y is unobserved, modeling X and
Y jointly, as in the arm-based model, helps reduce the standard error of a comparison.
This point is illustrated by an example in Appendix A.7.
This chapter is organized as follows. Section 6.1 describes the specific network meta-
analysis models being compared and the datasets to which we applied them. Section 6.2
presents results describing sensitivity of the network meta-analysis models to treatment
exclusion. Section 6.3 closes with some suggestions on network meta-analysis and several
limitations in our study.
6.1 Statistical analysis methods
6.1.1 Dataset selection
We reviewed forty network meta-analyses studied by Veroniki et al. [126] and selected
fourteen networks containing 567 randomized controlled trials with a total of 389,361
participants. Our selection criteria were that every treatment in the network should be
evaluated in at least three studies; otherwise, the networks are poorly connected at that
treatment node. We denote the fourteen networks as Ara 2009 [127], Ballesteros 2005
[128], Bucher 1997 [129], Cipriani 2009 [61], Eisenberg 2008 [130], Elliott 2007 [131],
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Lu 2006 [52,132], Lu 2009 [54,133,134], Middleton 2010 [135], Mills 2009 [136], Picard
2000 [137], Puhan 2009 [138], Thijs 2008 [139], and Trikalinos 2009 [140]. Tables 6.1
and 6.2 lists their characteristics including the outcomes, the investigated treatments
with their weighted node degrees, and the total number of studies, participants, and
events. For each node (treatment) in a network, the weighted degree is defined as
the sum of weights on all edges incident to that node. In a network meta-analysis,
the edge weight equals the number of pairwise comparisons between two treatments,
so the weighted degree represents the frequency with which a particular treatment is
investigated in all of the network’s studies. The node with the greatest weighted degree
can be considered the most well-connected. Figure 6.1 shows network plots for the 14
datasets.
6.1.2 Performing network meta-analysis and removing treatments
We fit the arm-based and contrast-based network meta-analysis Bayesian hierarchical
models separately to each of the 14 network datasets. Appendix A.8 gives details about
these models. We used Markov chain Monte Carlo (MCMC) to compute posteriors for
the effect sizes of interest, implemented using JAGS via the R package ‘rjags’.
Analyses with a treatment removed were performed as follows. Suppose a network
includes K treatments. We first applied both the arm-based and contrast-based models
to the complete network dataset (the full network) to estimate log odds ratios comparing
each pair from the K treatments; we also estimated the population-averaged treatment-
specific absolute risks using the arm-based model. Next, for each treatment, we excluded
it from the network and applied the analyses to the remaining dataset (the reduced
network) consisting of K − 1 treatments. The key difference between the arm-based
and contrast-based models becomes pertinent at this point. If a treatment was removed
from a network, then for any two-arm studies that included that treatment, only one
treatment arm remained. For an analysis using the arm-based model, we could keep the
single-arm studies as they still contribute to the likelihood function from the perspective
of an analysis with missing data. However, for an analysis using the contrast-based
model, because it uses information about contrasts, the single remaining arm no longer
provides any information for estimation in the reduced network, so the whole two-
arm study must be deleted if one of the treatments is excluded. Multi-arm studies
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– those comparing more than two treatments – that included the removed treatment
were retained for analyses under both the arm-based and contrast-based models. For
the present study, we did not consider any exclusion that creates a disconnected or
poorly connected network, i.e., that resulted in at least one treatment in a network
being evaluated in fewer than three studies. Table 6.2’s ‘ineligible trt removal’ column
shows treatment exclusions that produce such ineligible reduced networks under analyses
with the arm-based and contrast-based models. When comparing the arm-based and
contrast-based models, we only considered treatment removals that were eligible under
both models. Appendix A.9 gives an example of which treatments were considered for
exclusion.
6.1.3 Fold changes of estimated absolute risks in the arm-based model
For analysis using the arm-based model, we used fold changes of estimated population-
averaged treatment-specific absolute risks to assess the impact of the treatment exclu-
sion. Assume that the population-averaged absolute risk for a particular treatment is
estimated as pif using the full network and pir using the reduced network. Then, the
fold change for this treatment-specific absolute risk is defined as the maximum of pif/pir
and pir/pif . Thus, the fold change is never less than 1. Mills et al. [66] judged that a
relative change not exceeding 1.03-fold is minor while a change greater than 1.10-fold
is large, and over 1.20-fold is substantial, though such categorization is subjective and
may need to be adapted to specific situations.
6.1.4 Comparison between arm-based and contrast-based methods
Without either external data or a separate model to estimate a reference treatment’s
absolute risk, the contrast-based method can only estimate odds ratios or their loga-
rithms [58,65,67]. We focused on the changes of log odds ratio (LOR) when comparing
the arm-based and contrast-based methods according to their sensitivity to treatment
exclusion in the fourteen networks. For each network and treatment exclusion, we ap-
plied both models to the full and reduced networks. Then we calculated the LOR
change (LORC) as the difference between the LOR estimates using the full and reduced
networks: LORC
(−k)
ij = L̂OR
(−k)
ij − L̂ORij , where i, j index the treatments compared
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by this LOR and k indexes the treatment removed in the reduced network, i 6= j 6= k.
L̂ORij and L̂OR
(−k)
ij are point estimates from the Bayesian analysis, which can be either
the posterior means or medians; this chapter presents results for the posterior means.
Because of LORC
(−k)
ij + LORC
(−k)
ji = 0 by the symmetry of LOR, when we used
statistical tests to compare the arm-based and contrast-based models according to sensi-
tivity to treatment exclusion, we considered the absolute LOR change, i.e., |LORC(−k)ij |.
Further, the average absolute LOR change is calculated for each model by averaging
every |LORC(−k)ij | comparing all possible pairs of treatments based on all eligible treat-
ment exclusions across all networks; a smaller average absolute change indicates a more
robust network meta-analysis model with respect to treatment exclusion. To demon-
strate that LOR changes resulting from an individual treatment exclusion in a network
may be in opposite directions for the arm-based and contrast-based models, we present
LORC
(−k)
ij with their directions in Figure 6.2, rather than their absolute values. To
preserve any correlation structure between treatments in a network, when testing the
difference between the arm-based and contrast-based methods, we used bootstrap re-
sampling [141] at the network level (using 10,000 bootstrap samples); that is, each boot-
strap sample consisted of fourteen resampled networks, drawn with replacement from
the original fourteen networks. Based on the bootstrap samples, we calculated 95%
confidence intervals (CIs) and P -values for each model’s mean absolute LOR change
and their difference.
6.2 Results
6.2.1 Fold changes of estimated population-averaged absolute risks by
the arm-based model
For the arm-based model, Table 6.3 reports the average and maximal fold changes of
estimated population-averaged absolute risks and connectivity information about nodes
associated with the maximal change for each network. The average fold changes in all
networks are 1.05 or less; in 13 of 14 networks, the maximal change is below 1.10-fold.
These small changes indicate the arm-based model’s robustness to treatment exclusion.
Although the arm-based model is robust in most cases, treatment exclusion can still
produce significant changes (larger than 1.20-fold) for certain networks. For example,
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in the network Trikalinos 2009, excluding the treatment PTCA results in a 1.39-fold
change in the absolute risk estimate of the treatment MT. Referring to Tables 6.1–6.3,
several potential factors affecting the fold changes are listed below.
1. Removing treatments with larger weighted degree tends to cause larger fold changes,
while the most affected treatment tends to have small weighted degree. In 6/14
networks, the maximal fold change is caused by the removal of treatment with the
largest weighted degree; in 7/14 networks, the most affected treatment has the
smallest weighted degree.
2. Including more studies and increasing network connectivity may help to reduce
the impact of treatment exclusion. For example, Cipriani 2009 examined 111
studies on 12 treatments, and each treatment is connected to at least three other
treatments. All changes are smaller than 1.04-fold, and the average change is less
than 1.01-fold. On the other hand, Ara 2009 summarized only 11 studies on 5
treatments, and treatment exclusion caused changes as large as 1.09-fold.
3. Network meta-analyses with low event rates may produce large fold changes. For
example, the na¨ıve absolute risk in Trikalinos 2009 is only 3.1%, and 22/124
treatment groups reported zero events (Table 6.2). Although this network includes
62 studies, the maximal fold change is 1.39.
We should note that the factors above are not sufficient or necessary conditions when
judging whether a network is robust to treatment exclusion. For example, Ballesteros
2005 has only 9 studies, but its average and maximal fold changes are smallest among
the fourteen networks. The changes may be small in this network because it has a high
na¨ıve absolute risk.
6.2.2 Comparing the arm-based and contrast-based models
Figure 6.2 presents all LOR changes (LORC
(−k)
ij ) due to treatment exclusions in the
fourteen networks under the arm-based and contrast-based models. In Figure 6.2’s
upper panels, the LOR changes under the arm-based model are estimated including
single-arm studies. The scatter plot indicates that LOR changes for the arm-based
model tend to be smaller in magnitude than those for the contrast-based model. The
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empirical cumulative distribution function (ECDF) in top right panel of Figure 6.2
supports this observation. Because LORC
(−k)
ij + LORC
(−k)
ji = 0, the LOR changes
between treatments i and j appear symmetrically in both the scatter plot and the
ECDF graph. In addition, as each symmetric pair has the same absolute LOR change,
we may only keep one value when we statistically test the difference between the arm-
based and contrast-based models. (The resulting P -value remains the same if we include
both values, as we use a nonparametric bootstrap resampling technique at the network
level.)
Let µAB and µCB denote the true mean absolute LOR change (i.e., the expected
value of |LORC(−k)ij | across all treatment exclusions in all networks) under the arm-
based and contrast-based models, respectively. Based on 10,000 bootstrap samples, µAB
is estimated as 0.020 with 95% CI (0.015, 0.031), and µCB is estimated as 0.047 with 95%
CI (0.029, 0.100); µCB − µAB is estimated as 0.028 with 95% CI (0.011, 0.071) and two-
sided P -value 0.005 for testing H0 : µAB = µCB vs. HA : µAB 6= µCB. Therefore, at 0.05
significance level, the absolute change under the contrast-based model is significantly
larger than the change under the arm-based model, which suggests that the arm-based
model is more robust than the contrast-based model to treatment exclusion.
To see whether the smaller average absolute LOR change caused by the arm-based
model is due to the additional information it uses (that is, the retained single-arm
studies), we applied the arm-based model to the same reduced networks that were used
by the contrast-based model, in which single-arm studies were excluded. Figure 6.2’s
lower panels show the resulting LOR changes: the scatter plot and ECDF graph suggest
that the arm-based and contrast-based models perform nearly the same when they use
the same information. Let µ˜AB denote the true mean absolute LOR change when
applying the arm-based model to the data used by the contrast-based model. Using
the same bootstrap approach as above, the 95% CI for µ˜AB is (0.044, 0.089) with point
estimate 0.054. The point estimate is comparable to that of the contrast-based model,
but the 95% CI is slightly narrower; µCB − µ˜AB is estimated as −0.006 with 95% CI
(−0.049, 0.027), with two-sided P -value 0.59 for testing H0 : µ˜AB = µCB vs. HA : µ˜AB 6=
µCB. These findings indicate that single-arm studies – which the arm-based model can
use – provide valuable information.
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The above conclusions are based on using posterior means as Bayesian point esti-
mates. We also considered posterior medians as point estimates, with results similar to
those presented here.
6.3 Discussion
This chapter examined the sensitivity of arm-based network meta-analysis to treatment
exclusion, and compared that to the sensitivity of the contrast-based approach. For the
arm-based model, we investigated the fold changes of estimated population-averaged
absolute risks and found that the arm-based model is fairly robust for most networks.
Because the changes of estimated population-averaged absolute risks were mostly less
than 1.05-fold, relative effect sizes based on the marginal absolute risks, such as the
odds ratio or relative risk, would also have small changes. Although in general the
changes were minor, removing specific treatments can be influential, as in, e.g., Trikali-
nos 2009. An influential treatment is typically investigated in many studies [66], while
infrequently studied treatments are most likely to be affected by exclusion of other treat-
ments to which they were compared. This suggests that when performing a network
meta-analysis, researchers should be cautious if they only want to assess new treatments
or if they want to exclude placebo arms or well-established treatments [66].
When comparing log odds ratio changes, the arm-based model generally outper-
formed the contrast-based model. Using bootstrap resampling, the difference between
the arm-based and contrast-based models was statistically significant when single-arm
studies were included in analyses using the arm-based model. However, when we
dropped single-arm studies from reduced networks, the arm-based model performed
almost the same as the contrast-based model. This implies that the arm-based model’s
greater robustness arises mainly from retaining single-arm studies. Some traditional
pairwise meta-analyses have considered incorporating single-arm studies [142–145]; when
single-arm studies are available for network meta-analysis, the arm-based model can be
an attractive alternative approach.
One might wonder why the arm-based and contrast-based models did not give iden-
tical results when the arm-based model was restricted by excluding single-arm studies
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in Section 6.2.2. The reason is that the two models involve different random-effect as-
sumptions. Specifically, Shuster et al. [146] described two types of assumptions about
random effects in meta-analysis. The first type of random effects, called ‘studies at
random’ (SR), assumes that the studies are independently chosen from a conceptual
urn containing a large number of studies. The second type assumes that the relative
effects in each study are randomly drawn from a conceptual urn while the studies are
fixed; this is called ‘effects at random’ (ER), which makes assumptions over and above
SR, namely that the distribution of the random relative effects is independent of the
study design. Arguably, the arm-based model requires the SR assumption, while the
contrast-based model requires ER.
Our study has several limitations. First, we did not check evidence consistency in
the investigated networks; detecting inconsistency in network meta-analysis is still an
open question, which is partly discussed by Lu and Ades [52]. For the contrast-based
model, this study assumes that the pairwise comparisons among any trio of treatments,
say A, B, and C, are inter-related as θBC = θAC−θAB. If this consistency does not hold,
we could use approaches based on an inconsistency model such as θBC = θAC−θAB +φ,
which is discussed in Salanti et al. [53]. Here, φ represents the inconsistency between
the direct evidence for treatment B vs. C and the indirect evidence from pairwise com-
parisons of A vs. B and A vs. C. For the arm-based model, one may consider detecting
inconsistency between two treatments by comparing their absolute risk differences in
direct comparisons vs. indirect comparisons [147]. A large discrepancy implies poten-
tial inconsistency between these two treatments. The second limitation of our study
is that we used a selection criterion requiring each treatment to be studied in at least
three studies, mainly due to the need for an adequate number of studies to estimate
parameters for the distribution of random effects. The literature has no well-established
criterion serving this purpose.
In conclusion, arm-based methods can be an attractive alternative when data from
some single-arm studies are available. For example, if we are interested in comparing
treatments A, B, and C in a network meta-analysis, ‘single-arm’ study data on A can
come from two-arm studies comparing A vs. D or other treatments. Furthermore,
although the arm-based model is generally more robust than the contrast-based model,
for some network meta-analyses, the contrast-based methods seem to be more robust
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to some treatment exclusions. For example, the LOR changes under the arm-based
model can be fairly large, while the corresponding changes under the contrast-based
model can be nearly zero (Figure 6.2). Therefore, analysts are advised to consider both
the arm-based and contrast-based models for network meta-analysis, especially when
making inference for a small or poorly connected network.
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Figure 6.1: Network plots of the fourteen networks. A thicker edge indicates more
comparisons between the treatments (nodes) of the edge.
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Figure 6.2: Comparing the arm-based and contrast-based models according to log odds
ratio changes. In the upper two panels, single-arm studies are kept in the reduced
networks for the arm-based model; in the lower panels, the arm-based model is applied
only to studies that can also be used by the contrast-based model, i.e., single-arm
studies are excluded. Left panels are scatter plots of log odds ratio changes under the
contrast-based model (vertical axis) vs. those under the arm-based model (horizontal
axis). Right panels show the empirical cumulative distribution function of log odds ratio
changes under the two models.
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Table 6.1: Characteristics of the fourteen network meta-analyses.
Network Outcome
No. of No. of Treatment names (abbreviations) [weighted degree], sorted by weighted degree (largest to
studies treatments smallest)
Ara 2009 Adverse event leading to 11 5 Atorvastatin 80 mg/day (ATO 80) [9]; Simvastatin 40 mg/day (SIM 40) [8]; Simvastatin 80
drug discontinuation mg/day (SIM 80) [7]; Rosuvastatin 40 mg/day (ROS 40) [5]; Placebo [3].
Ballesteros 2005 Efficacy of antidepressants in 9 4 Placebo [12]; Tricyclic antidepressant (TCA) [8]; Monoamine oxidase inhibitor (MAOI) [5];
dysthymia Selective serotonin reuptake inhibitor (SSRI) [5].
Bucher 1997 Number of Pneumocystis 18 4 Aerosolized pentamidine (AP) [14]; Trimethoprim-sulphamethoxazole (TMP-SMX) [13];
carinii pneumonia Dapsone/pyrimethamine (D/P) [5]; Dapsone (D) [4].
Cipriani 2009 Unipolar major depression 111 12 Fluoxetine (FLU) [54]; Paroxetine (PAR) [32]; Sertraline (SER) [28]; Venlafaxine (VEN)
[27]; Escitalopram (ESC) [17]; Citalopram (CIT) [14]; Mirtazapine (MIR) [13]; Bupropion
(BUP) [12]; Fluvoxamine (FVX) [11]; Duloxetine (DUL) [8]; Reboxetine (REB) [8];
Milnacipran (MIL) [6].
Eisenberg 2008 Smoking abstinence 61 5 Placebo [64]; Transdermal nicotine (TN) [23]; Nicotine gum (NG) [20]; Bupropion (BUP)
[18]; Varenicline (VAR) [9].
Elliott 2007 The proportion of patients 22 6 β blocker (BB) [12]; Calcium-channel blocker (CCB) [12]; Angiotensin-converting enzyme
who developed diabetes 22 6 inhibitor (ACEI) [11]; Placebo [10]; Thiazide diuretic (TD) [10]; Angiotensin-receptor
blocker (ARB) [5].
Lu 2006 Smoking cessation 24 4 Individual counselling (IC) [21]; No contact [20]; Group counselling (GC) [8]; Self-help [7].
Lu 2009 Gastroesophageal reflux 40 6 H2 receptor antagonist (H2RA) [34]; Proton pump inhibitor (PPI) [17]; Placebo [14]; PPI
disease double dose (PPI-D) [13]; Prokinetic agent (PA) [6]; H2RA double dose (H2RA-D) [4].
Middleton 2010 Patients’ dissatisfaction 20 4 ‘First generation’ endometrial destruction techniques (FG) [17]; ‘Second generation’
endometrial destruction techniques (SG) [14]; Hysterectomy (HYST) [5]; Mirena (MIR) [4].
Mills 2009 Smoking abstinence at at-least 89 4 Control [92]; Nicotine replacement therapy (NRT) [49]; Bupropion (BUP) [39]; Varenicline
4 weeks post-target quit data (VAR) [10].
Picard 2000 Pain on injection with 43 8 Placebo [48]; Lidocaine (mg) mixed with propofol 200 mg (LIDm) [26]; Lidocaine (mg)
propofol given before the injection of propofol (LIDb) [19]; No treatment (No Trt) [19]; Opioids
(OPI) [19]; Lidocaine (mg) with tourniquet (LID+TOU) [13]; Temperature (TEM) [13];
Metoclopramide (MET) [7].
Puhan 2009 Exacerbation in patients with 34 5 Placebo [44]; Long-acting beta-agonists (BA) [33]; Inhaled corticosteroids (IC) [24];
chronic obstructive pulmonary Combined treatment with a long-acting beta-agonist and an inhaled corticosteroid (CT) [20];
disease Long-acting anticholinergics (AC) [11].
Thijs 2008 Efficacy of antiplatelet 23 5 Aspirin (ASA) [22]; Placebo [16]; Aspirin and dipyridamole (ASA+DP) [10];
Thienopyridines (ticlopidin or clopidogrel, THI) [7]; THI+ASA [3].
Trikalinos 2009 Non-acute coronary artery 62 4 Bare-metal stents (BMS) [52]; Percutaneous transluminal balloon coronary angioplasty
disease (PTCA) [43]; Drug-eluting stents (DES) [16]; Medical therapy (MT) [13].
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Table 6.2: (Continued) Characteristics of the fourteen network meta-analyses.
Network
Total Total no. of Na¨ıve Total no. of Total no. of Ineligible treatment removal Smallest Largest
no. of no. of absolute treatment treatment groups Arm-based Contrast-based weighted weighted
participants events risk† groups with zero events model model degree‡ degree
Ara 2009 24,793 1155 0.047 24 2
SIM 40; ATO 80;
3 9
SIM 80
Ballesteros 2005 1386 663 0.478 21 0 Placebo 5 12
Bucher 1997 3416 248 0.073 36 4 AP; TMP-SMX 4 14
Cipriani 2009 24,595 13,951 0.567 224 0 6 54
Eisenberg 2008 26,750 3908 0.146 125 0 Placebo Placebo 9(9)* 64(23)*
Elliott 2007 154,176 10,962 0.071 48 0 5 12
Lu 2006 16,737 2072 0.124 50 2 7 21
Lu 2009 4626 2273 0.491 82 4 H2RA 4 34
Middleton 2010 2886 342 0.119 40 0 FG FG; SG 4(4)* 17(14)*
Mills 2009 29,525 10,847 0.367 181 1 Control 10 92
Picard 2000 4495 2400 0.534 104 2 7 48
Puhan 2009 26,789 7200 0.269 81 1 11 44
Thijs 2008 42,666 6830 0.160 49 0 ASA; THI 3 22
Trikalinos 2009 26,521 821 0.031 124 22 BMS BMS 13(13)* 52(43)*
† Na¨ıve absolute risk is calculated as the ratio of the total no. of Events compared to the total no. of Participants.
‡ Weighted degree of a node (treatment) is the sum of weights (the number of pairwise comparisons between two treatments) on all edges incident
to that node.
* In each of these three networks, one particular treatment is not removed to remain network connectivity; the numbers in parentheses are given
without accounting for these treatments.
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Table 6.3: Summary of fold changes of estimated population-averaged absolute risks using the
arm-based model.
Network
Fold change Removed treatment Maximally affected
Average Maximal
(weighted degree§) causing treatment (weighted
maximal fold change degree§) by the removal
[Rank†/No. of eligible [Rank‡/No. of treatments]
treatment removals]
Ara 2009 1.030 1.087 ATO 80 (9) [1/5] ROS 40 (5) [2/5]
Ballesteros 2005 1.003 1.007 MAOI (5) [3/4] Placebo (12) [4/4]
Bucher 1997 1.019 1.058 TMP-SMX (13) [2/4] D (4) [1/4]
Cipriani 2009 1.005 1.033 SER (28) [3/12] MIL (6) [1/12]
Eisenberg 2008 1.003 1.008 VAR (9) [4/4*] BUP (18) [2/5]
Elliott 2007 1.015 1.056 Placebo (10) [4/6] ACEI (11) [4/6]
Lu 2006 1.012 1.028 No contact (20) [2/4] Self-help (7) [1/4]
Lu 2009 1.006 1.036 H2RA (34) [1/6] Placebo (14) [4/6]
Middleton 2010 1.013 1.037 SG (14) [1/3*] FG (17) [4/4]
Mills 2009 1.011 1.045 Control (92) [1/4] VAR (10) [1/4]
Picard 2000 1.009 1.050 LIDb (19) [3/8] MET (7) [1/8]
Puhan 2009 1.017 1.055 Placebo (44) [1/5] BA (33) [4/5]
Thijs 2008 1.019 1.084 ASA+DP (10) [3/5] THI+ASA (3) [1/5]
Trikalinos 2009 1.055 1.390 PTCA (43) [1/3*] MT (13) [1/4]
† Rank from largest to smallest according to the weighted degrees within the corresponding net-
work.
‡ Rank from smallest to largest according to the weighted degrees within the corresponding net-
work.
§ The weighted degrees refer to the corresponding full network.
* In each of these three networks, one particular treatment is not removed to remain network
connectivity (See Table 6.2).
Chapter 7
On Network Meta-Analysis
Without Evidence Cycles
Although a variety of methods are available for performing network meta-analysis [67,
148–151], currently the most widely used approach is the Bayesian hierarchical model
proposed by Lu and Ades [51], which this chapter calls the Lu–Ades model. In a recent
survey by Nikolakopoulou et al. [152], 111 out of 186 network meta-analyses used the
Lu–Ades model.
By combining information from both direct and indirect comparisons, network meta-
analysis is generally considered more powerful than conventional pairwise meta-analysis,
which compares each pair of treatments separately and thus can only use direct compar-
isons [50]. In network meta-analysis, treatments A and B can be compared via a common
comparator, say treatment C, and the information from A vs. C and B vs. C provides
indirect evidence, while a trial including both A and C provides direct evidence. Hence,
provided that the studies are consistent with each other, network meta-analysis may be
expected to produce more accurate effect estimates with narrower confidence/credible
intervals, compared to pairwise meta-analysis; also, it can provide a coherent ranking
of treatments and thus guide decision making [153]. Because of these attractive fea-
tures, many researchers focus on collecting as many treatments as possible in a network
meta-analysis, but pay little attention to the network’s geometry, taking for granted the
benefit from synthesizing direct and indirect evidence.
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If each pair of treatments A, B, and C is directly compared in at least one study,
then the three treatments form a so-called evidence cycle [52]. This chapter shows
that evidence cycles in the treatment network play a critical role in the improvement
of effect estimates produced by Lu–Ades network meta-analysis compared to separate
pairwise meta-analyses. Specifically, Lu–Ades network meta-analysis yields posterior
distributions identical to separate pairwise meta-analyses for all treatment comparisons
when a treatment network does not contain any evidence cycles. Networks without
evidence cycles frequently appear in systematic reviews. A special case is the star-
shaped network, that is, all collected studies share a common treatment, which is usually
placebo or a well-established standard treatment. For example, among the 186 network
meta-analyses investigated by Nikolakopoulou et al. [152], 35 networks are star-shaped.
We also extend our conclusion to networks with general shapes, which are common in
real applications: treatment comparisons that are not in any evidence cycles cannot
benefit from Lu–Ades network meta-analysis. Instead of discouraging researchers from
performing network meta-analysis, we seek to raise awareness of the power of network
meta-analysis compared to pairwise meta-analysis when using the Lu–Ades model in
certain situations.
The remaining of this chapter is organized as follows. After reviewing the develop-
ment of the Lu–Ades model in Section 7.1, Section 7.2 shows theoretically that the joint
posterior distributions of effect estimates produced by Lu–Ades and by separate pair-
wise meta-analyses are identical for networks without evidence cycles. The proofs are in
Appendix B.3 unless given in the main text. Simulations and a case study to illustrate
the equivalence relationship are presented in Section 7.3, and Section 7.4 concludes with
some discussion.
7.1 Methods for general network meta-analysis: a review
7.1.1 Smith model for pairwise meta-analysis
First, we introduce the Bayesian hierarchical model for the conventional pairwise meta-
analysis proposed by Smith et al. [154], which lays the foundation for Lu–Ades network
meta-analysis of multiple treatment comparisons. Suppose that a pairwise meta-analysis
collects N studies and each study compares the same two treatments, such as an active
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treatment and a control. Let yi1 and yi2 be the observed aggregated outcome measures in
study i’s treatment groups 1 and 2, respectively. The overall relative effect comparing
the two treatments is usually of interest. The Smith random-effects model can be
generalized as follows to estimate the overall relative effect [154]:
yik ∼ f(y | ∆ik, ξik), i = 1, . . . , N, k = 1, 2;
g(∆i1) = µi, g(∆i2) = µi + δi;
δi ∼ N(d, σ2).
(7.1)
Here, µi is commonly called the baseline effect of study i, and the study-specific rel-
ative effects δi are assumed to be exchangeable across studies with mean d, which is
interpreted as the overall relative effect. The variance parameter σ2 reflects heterogene-
ity between studies. The link function is g(·), and f(· | ·, ·) is the outcome measure’s
density function, depending on an unknown location parameter ∆ik and a nuisance pa-
rameter ξik, which is assumed to be known. For example, if the outcome is continuous,
yik is usually assumed to be normally distributed with unknown mean ∆ik and known
standard error ξik, and g(·) is the identity link. If the outcome is binary, such as the
condition of having a certain event, then yik is the number of events, which follows a
binomial density with unknown event rate ∆ik and known sample size ξik. When the
logit link function logit(t) = log{t/(1− t)} is used for binary outcomes, the fixed effect
d represents the overall log odds ratio of treatment 2 compared to treatment 1.
7.1.2 Lu–Ades model for network meta-analysis
Lu and Ades [51, 54] extended the Smith model to multiple treatment comparisons.
Instead of comparing merely two treatments, N studies are included comparing a total
of K treatments in a network meta-analysis (K > 2). Specifically, each study compares
a subset of the K treatments; denote the treatment subset of study i as Ti. A study is
called a two-arm study if it compares two treatments, while a multi-arm study investi-
gates more than two treatments. Again, assume that the observed aggregated outcome
measure yik in study i’s treatment group k follows the distribution f(· | ∆ik, ξik). To
use the Lu–Ades model, a baseline treatment bi needs to be specified for each study i.
Different studies can have different baseline treatments in the Lu–Ades model because
the treatment subsets Ti need not intersect. We denote bi simply as b when it does
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not lead to confusion. The Lu–Ades random-effects model for network meta-analysis is
specified as follows:
yik ∼ f(y | ∆ik, ξik), i = 1, . . . , N, k ∈ Ti;
g(∆ik) = µi +Xikδibk;
δibk ∼ N(dbk, σ2bk), Corr(δibh, δibk) = γbhk, h, k ∈ Ti.
(7.2)
Here, Xik is a dummy variable; Xik = 0 if k = b and Xik = 1 if k ∈ Ti\{b}. Within a
multi-arm study, the correlation between the treatment contrasts δibh and δibk is assumed
to be γbhk. Again, µi represents the baseline effect of study i, the study-specific relative
effects are assumed to be exchangeable, and we focus on estimating the relative effects
of all treatment contrasts dhk (1 ≤ h 6= k ≤ K).
A critical assumption in Lu–Ades network meta-analysis is the consistency equation
for an evidence cycle, which relates the contrasts for a trio of treatments as
dhk = d`k − d`h, for all 1 ≤ h 6= k 6= ` ≤ K. (7.3)
If a treatment network contains evidence cycles, this equation synthesizes both direct
and indirect evidence for the treatment comparisons in the cycles, so that the network
meta-analysis uses more information than a conventional pairwise meta-analysis, which
uses only direct evidence.
The consistency assumption may not hold even approximately in many cases, and
alternative approaches have been proposed to deal with evidence inconsistency; see,
e.g., [52, 53,58,155–157]. A popular method is to add inconsistency factors w to Equa-
tion (7.3), that is, dhk = d`k − d`h +whk`. This method is closely related to the number
of independent cycles in the network, which is quantified by the inconsistency degrees
of freedom dfIC [52]. If all studies are two-armed, then dfIC = T −K + 1, where T is
the number of all treatment comparisons, i.e., the edges in the network. However, when
multi-arm studies are present, the definition of inconsistency degrees of freedom is fairly
complex and needs to be considered case by case.
Besides random-effects models, fixed-effects models are also frequently used in meta-
analysis. These models assume that the collected studies are homogeneous, that is, that
the relative effects for each treatment comparison share a common mean across studies,
and their variation is entirely due to sampling error within studies. To be specific, the
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Smith fixed-effects model for pairwise meta-analysis is
yik ∼ f(y | ∆ik, ξik), i = 1, . . . , N, k = 1, 2;
g(∆i1) = µi, g(∆i2) = µi + d,
(7.4)
while the Lu–Ades fixed-effects model for network meta-analysis is
yik ∼ f(y | ∆ik, ξik), i = 1, . . . , N, k ∈ Ti;
g(∆ik) = µi +Xikdbk.
(7.5)
Implementation is easier for the fixed-effects model than the random-effects model be-
cause the latter involves complex specification of heterogeneity variances, which will
be detailed in Section 7.2.3. However, the homogeneity assumption may be unrealistic
in many cases [78], and the credible intervals produced by the fixed-effects model may
have low coverage probabilities if heterogeneity is present in some treatment compar-
isons [158].
7.2 Network meta-analysis without evidence cycles
7.2.1 Direct and indirect evidence
The treatment network is assumed to be connected throughout this chapter; if the
network consists of several disjoint sub-networks, then a separate analysis can be applied
to each sub-network. For a treatment network without cycles, all collected studies must
be two-armed because multi-arm studies create evidence cycles. Consequently, we no
longer need to account for the correlations between treatment contrasts within studies
in the Lu–Ades random-effects model (7.2).
To investigate the performance of the Lu–Ades model for a network without cycles,
we explore the posterior distributions of all treatment contrasts. The (K − 1)K/2
treatment contrasts are denoted as a vector e = (dhk; 1 ≤ h < k ≤ K)T. In graph
theory, a connected network without cycles is a spanning tree and contains exactly
K − 1 edges; denote the set of these edges as a (K − 1)-dimensional vector eb =
(e1, . . . , eK−1)T, where ej = dhk for some h < k and each ej provides direct evidence.
Thus, the set of all treatment contrasts e can be split into two subsets: eb, each contrast
in which is directly compared in the network, and a (K − 2)(K − 1)/2-dimensional
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vector ef = (dhk; dhk /∈ eb)T that can only be imputed from indirect evidence. By the
definition of Lu and Ades [52], the treatment contrasts in eb are basic parameters, which
involve all K treatments but do not form cycles; those in ef are referred to as functional
parameters because they can be represented as functions of the basic parameters. The
evidence consistency equation (7.3) necessarily holds for networks without cycles because
evidence inconsistency only occurs within evidence cycles; indeed, these networks have
zero inconsistency degrees of freedom. Therefore, ef is entirely determined by eb; that is,
we may write ef = Aeb, where A is a known (K−2)(K−1)/2× (K−1) transformation
matrix. We have the following proposition regarding the transformation matrix A.
Proposition 6. The transformation matrix A is unique for each set of basic parameters,
and each entry of A is 0 or ±1.
Proposition 6 holds for any type of connected network, including those containing
cycles, under the assumption of evidence consistency. In networks without cycles, there
is only one set of basic parameters eb, so the transformation matrix A is uniquely
defined.
7.2.2 Equivalence of the Lu–Ades model and separate Smith models
In a network without cycles, suppose that study i, which must be two-armed, compares
treatments ki vs. hi (hi < ki); that is, the corresponding treatment contrast is dhiki .
For j = 1, . . . ,K − 1, let Sj = {i : dhiki = ej} be the set of studies that give the
direct treatment comparison ej . Consequently, the N studies S = {1, . . . , N} in the
network can be partitioned into K − 1 subsets according to their treatment contrasts:
S = ⋃K−1j=1 Sj . Moreover, let Dj = {(yik, ξik); i ∈ Sj , k ∈ Ti} be the data (aggregated
outcome measures and nuisance parameters) provided by the studies in Sj , and let
D = ⋃K−1j=1 Dj be the full data in the whole network. The Smith model for pairwise
meta-analysis uses the data Dj for each j separately to estimate the corresponding
treatment contrast ej , and we denote the resulting posterior distribution as p(ej | Dj).
The Lu–Ades model for network meta-analysis uses the full data D to simultaneously
compare all treatments, and we denote the joint posterior distribution of the direct
treatment contrasts as p(eb | D). We have the following theorem.
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Theorem 1. For a treatment network without evidence cycles, given the same set of
priors, the Lu–Ades fixed-effects model (7.5) gives posterior distributions of direct treat-
ment contrasts identical to those from separate Smith fixed-effects model (7.4), that is,
p(eb | D) =
K−1∏
j=1
p(ej | Dj). (7.6)
This equation also holds for the Smith and Lu–Ades random-effects models (7.1) and
(7.2), if the Lu–Ades model uses different heterogeneity variances for different treatment
contrasts.
Equation (7.6) implies that the posterior estimate of ej produced by the Lu–Ades
model is only informed by the data in studies Sj ; thus, the posterior distributions of
the ej ’s are mutually independent.
Proof of Theorem 1. In the Smith and Lu–Ades fixed-effects models, we denote µ =
(µ1, . . . , µN )
T as the vector of all studies’ baseline effects, and let µ˜j = (µi; i ∈ Sj)T be
the vector of those baseline effects in studies Sj . For j = 1, . . . ,K − 1, denote yj =
(yik; i ∈ Sj , k ∈ Ti)T and ξj = (ξik; i ∈ Sj , k ∈ Ti)T. Also, let y = (yik; i ∈ S, k ∈ Ti)T
and ξ = (ξik; i ∈ S, k ∈ Ti)T; thus, D = {(y, ξ)} and Dj = {(yj , ξj)}. By the properties
of conditional probability, the joint posterior of the direct treatment contrasts produced
by the Lu–Ades fixed-effects model is
p(eb | D) =
∫
p(eb,µ | D) dµ ∝
∫
f(y | eb,µ, ξ)p(eb)p(µ) dµ.
Here, f(· | ·) is the probability density function of the observed outcome measures con-
ditional on the pertinent parameters, and p(eb) =
∏K−1
j=1 p(ej) and p(µ) =
∏K−1
j=1 p(µ˜j)
are priors for the treatment contrasts and baseline effects, respectively. Since condi-
tional on µ and eb, the outcome measure yj in studies Sj depends on µ˜j and ej but
not the other basic parameters in eb, we have f(y | eb,µ, ξ) =
∏K−1
j=1 f(yj | ej , µ˜j , ξj).
Consequently,
p(eb | D) ∝
K−1∏
j=1
∫
f(yj | ej , µ˜j , ξj)p(ej)p(µ˜j) dµ˜j ∝
K−1∏
j=1
p(ej | Dj).
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In the random-effects models, we further denote σj as the heterogeneity standard
deviation of the treatment contrast ej . Let σ = (σ1, . . . , σK−1)T. Similarly, we have
p(eb | D) =
∫∫
p(eb,σ,µ | D) dσ dµ ∝
∫∫
f(y | eb,σ,µ, ξ)p(eb)p(σ)p(µ) dσ dµ,
where p(σ) =
∏K−1
j=1 p(σj) is the prior for the heterogeneity standard deviations. Again,
because f(y | eb,σ,µ, ξ) =
∏K−1
j=1 f(yj | ej , σj , µ˜j , ξj), the joint posterior distribution
of direct treatment contrasts produced by the Lu–Ades random-effects model is
p(eb | D) =
K−1∏
j=1
∫∫
f(yj | ej , σj , µ˜j , ξj)p(ej)p(σj)p(µ˜j) dσj dµ˜j ∝
K−1∏
j=1
p(ej | Dj).
This completes the proof.
Unlike the ej ’s in eb that are directly compared in the network, the estimates of ef
are entirely informed by indirect evidence. The network meta-analysis seems to be an
efficient approach to simultaneously estimating all treatment contrasts, including the
indirect ones. However, the following theorem shows that separate Smith models also
produce posterior distributions of indirect treatment contrasts identical to those given
by the Lu–Ades model.
Theorem 2. Under the model settings in Theorem 1 and using the evidence consis-
tency equation (7.3), the joint posterior distributions of the indirect treatment contrasts
ef produced by the Lu–Ades model and by separate Smith models are identical for a net-
work without evidence cycles. Specifically, under some regularity assumptions given in
Appendix B.3, the joint posterior distribution of ef is
p(ef | D) = 1
(2pi)P
∫
RP
e−it
Tefϕf(t) dt,
where P = (K − 2)(K − 1)/2 and i2 = −1. The characteristic function of ef is ϕf(t) =
ϕb(A
Tt) for t ∈ RP , where ϕb(s) =
∏K−1
j=1
∫
R e
isjejp(ej | Dj) dej is the characteristic
function of the direct treatment contrasts eb for s = (s1, . . . , sK−1)T ∈ RK−1.
Theorems 1 and 2 imply that for a network without cycles Lu–Ades network meta-
analysis does not change the posterior distributions (thus, point estimates and credi-
ble intervals) of any treatment contrasts produced by separate Smith pairwise meta-
analyses.
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7.2.3 Lu–Ades random-effects model with equal heterogeneity vari-
ances
Besides potential evidence inconsistency, modeling the heterogeneity variances and co-
variances is another important issue in the Lu–Ades random-effects model (7.2). The
difficulty arises from the fundamental relationship of the relative effects, δihk = δi`k−δi`h,
so the heterogeneity standard deviations are constrained by the triangular inequality
|σ`h − σ`k| ≤ σhk ≤ |σ`h + σ`k|. (7.7)
Lu and Ades [54] introduced a reparameterization of the σhk’s that permits specifica-
tion of unstructured variance and correlation components for network meta-analysis.
However, for conceptual and technical simplicity, the heterogeneity variances σ2bk are
often assumed to be equal to a common variance σ2 and the between-contrast cor-
relations γbkl are set to 1/2 [50, 51]. This assumption is widely used in applications
(e.g., [61, 159, 160]), though it imposes a possibly quite strong constraint on the treat-
ment comparisons, which may be unrealistic for many cases [54].
Under the assumption of equal heterogeneity variances, we have the following theo-
rem.
Theorem 3. For a treatment network without evidence cycles, the Lu–Ades random-
effects model (7.2) with equal heterogeneity variances σ2bk = σ
2 is equivalent to simulta-
neously using the Smith random-effects models (7.1) for studies Sj, conditional on the
common heterogeneity variance σ2.
The Smith models in Theorem 3 may not be deemed separate, because each model
uses the common heterogeneity variance σ2, which is informed by all studies S instead
of the study set Sj for a specific treatment contrast. Although the Lu–Ades random-
effects model can therefore produce different results from separate Smith random-effects
models that have no constraints on the heterogeneity variances σ2bk, Theorem 3 implies
that these differences are caused entirely by the specification of heterogeneity variances
if the treatment network does not contain evidence cycles. Thus, under this model
setting, the Lu–Ades model still provides no gain from synthesizing direct and indirect
evidence apart from the strong assumption that σ2bk = σ
2.
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7.2.4 Acyclic treatment comparisons in general networks
In a general treatment network that may contain evidence cycles, it commonly occurs
that some treatment comparisons are not in any cycles [161]; we refer to such treat-
ment comparisons as acyclic comparisons. Theorem 1 can be extended to the posterior
distributions of acyclic comparisons in networks with general shapes. Specifically, sup-
pose that a network with K treatments contains J acyclic comparisons, denoted as
ea = (e1, . . . , eJ)
T.
Proposition 7. For a network with K treatments, the number of acyclic comparisons
J does not exceed K − 1.
Studies that report the acyclic comparison ej (j = 1, . . . , J) must be two-armed;
otherwise, multi-arm studies create evidence cycles containing ej , contradicting the
definition of an acyclic comparison. As in Section 7.2.2, let Sj be the set of studies
that report the acyclic comparison ej , and S? = S\
⋃J
j=1 Sj be the remaining studies
in the network. The studies in S? produce a sub-network that does not have any
acyclic comparisons and thus must contain evidence cycles if the set S? is not empty.
Suppose that e?b is a set of basic parameters in the sub-network consisting of S?; then
eb = (e
T
a , e
?T
b )
T is a set of basic parameters for the full network S. Also, denote the data
provided by Sj as Dj and the data provided by S? as D?. Then we have the following
theorem.
Theorem 4. For acyclic treatment comparisons in a general network, the Lu–Ades
model does not improve their posterior distributions compared to separate Smith models
under the model settings in Theorem 1. Specifically, using the same set of priors in
the two models, the joint posterior distribution of the basic parameters produced by the
Lu–Ades model is
p(eb | D) = p(e?b | D?)
J∏
j=1
p(ej | Dj). (7.8)
Here, p(eb | D) is produced by the Lu–Ades network meta-analysis on the full
network S, while p(e?b | D?) is the posterior based on the sub-network consisting of S?.
The study set S? does not exist in a network without cycles so that p(e?b | D?) drops out
of Equation (7.8), which is thus reduced to Equation (7.6). Theorem 4 can therefore be
viewed as a generalization of Theorem 1.
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Since the acyclic comparisons ea are not contained in any evidence cycles, they are
not subject to the risk of evidence inconsistency. The sub-network consisting of S?
contains evidence cycles, so the evidence may be inconsistent; however, Theorem 4 still
applies for this situation.
7.3 Numerical studies
7.3.1 Simulations
We conducted simulations to illustrate the equivalence of the Lu–Ades and Smith mod-
els’ performance when the treatment network does not contain any cycles. The outcome
was assumed to be continuous and normally distributed, and each treatment’s outcome
measure yik and its within-study standard error ξik were observed. The situation of a
binary outcome will be explored in the real data analysis in Section 7.3.2. We simu-
lated data containing five treatments with three network shapes, shown in Figure 7.1.
Each network does not contain cycles: Shape 1 is a star-shaped network with its cen-
ter at treatment 1; Shape 2 is a chain-shaped network with treatment contrasts from
2 vs. 1 to 5 vs. 4; and Shape 3 is more general than the star and chain shapes. Also, in
each network four treatment contrasts are observed and form a set of basic parameters
eb. These treatment contrasts are reported in 5, 10, 15, or 20 studies, as described in
Figure 7.1. Thus, each simulated network contained a total of 50 studies.
To simulate the outcome measures, we first generated samples for all five treat-
ments in each study, and then omitted certain treatment arms to create networks with
the shapes in Figure 7.1; the omitted data were assumed to be missing completely
at random. Specifically, the five treatments’ within-study standard errors were drawn
from ξik ∼ U(0.1, 1) (i = 1, . . . , 50, k = 1, . . . , 5). The observed treatment-specific
outcome measure was generated from yik ∼ N(µik, ξ2ik), where µik represents the un-
derlying true measure of treatment k in study i. The study-specific true measures
were drawn from (µi1, . . . , µi5)
T ∼ N((µ1, . . . , µ5)T,Ψ), where µk represents the over-
all mean of treatment k (k = 1, . . . , 5), and Ψ represents the between-study covari-
ance matrix. We set µk = k; hence, the true relative effect of treatments k vs. h was
dhk = µk−µh = k−h. Also, Ψ = DRD, where R = (ρhk) is the correlation matrix with
ρkk = 1 and ρhk = 0.4 (1 ≤ h 6= k ≤ 5), and the between-study standard deviations
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D = diag(τ1, . . . , τ5) were sampled for three cases: (i) all studies were homogeneous
with τk = 0; (ii) all treatments had a common heterogeneity standard deviation τk = τ
with τ ∼ U(1, 1.5); and (iii) the five treatments had different heterogeneity standard
deviations with τk ∼ U(0.4k − 0.4, 0.4k) for k = 1, . . . , 5. Finally, certain treatments
in certain studies were randomly omitted to produce networks with Shapes 1–3. For
example, in the network with Shape 1, treatments 3–5 were omitted in five studies, so
these five studies compared treatments 2 vs. 1. For each network shape, 1000 repli-
cates of network data were generated; for each replicate, the Markov chain Monte Carlo
algorithm was applied to implement the Smith and Lu–Ades models using one chain,
which contained a run of 50,000 updates after a 20,000-run burn-in period. For both
the Smith and Lu–Ades models, three model settings were considered: a fixed-effects
model, a random-effects model with different heterogeneity variances, and a random-
effects model with a common heterogeneity variance. Vague priors were used for the
study-specific baseline effects and the basic parameters; U(0, 10) priors were used for
the heterogeneity standard deviations in the random-effects models. The functional
parameters, such as d23 in network with Shape 1, were estimated using the evidence
consistency equation (7.3). The models’ performance was evaluated according to bias
and mean squared error of the estimated relative effects and coverage probability of the
95% credible intervals.
Table 7.1 presents the results of some treatment contrasts for Case (iii) of the
between-study standard deviation; the simulation results for Cases (i) and (ii) are in
Appendix A.10. Since the treatments were missing completely at random in all cases,
each model produced nearly unbiased point estimates for each treatment contrast. In
Case (i), where the treatment effects were homogeneous across studies, using either pair-
wise or network meta-analysis for all three networks in Figure 7.1, both the fixed- and
random-effects models produced estimated relative effects with similar mean squared
errors. Also, the fixed-effects model led to credible interval coverage probabilities that
are fairly close to the nominal level 95%, while the two random-effects models produced
slightly inflated coverage probabilities, indicating that their 95% credible intervals were
wider than the fixed-effects model. However, in Cases (ii) and (iii), due to the high
heterogeneity, the fixed-effects model led to very poor credible interval coverage proba-
bilities, while those produced by the random-effects models were generally satisfactory;
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the mean squared errors produced by the fixed-effects model were also much larger than
those of the random-effects models. Moreover, in Case (iii), the true heterogeneity vari-
ances τ2k differed across treatments, while the second random-effects model incorrectly
assumed the τ2k ’s were equal. Interestingly, the results produced by this random-effects
model were fairly similar to those produced by the correct random-effects model as-
suming different heterogeneity variances, although the incorrect model had slightly low
credible interval coverage for the treatment contrast d15 in network with Shape 1 and
d45 in networks with Shapes 2 and 3. Most importantly, for all three network shapes,
the Smith model for pairwise meta-analysis produced effect estimates with biases, mean
squared errors, and credible interval coverage probabilities almost identical to those
produced by the Lu–Ades model for network meta-analysis; some slight differences are
due to Monte Carlo error. Therefore, the Lu–Ades network meta-analysis did not im-
prove the effect estimates compared to Smith pairwise meta-analysis, as suggested in
Theorems 1–3.
7.3.2 Real data analysis
We applied the Smith and Lu–Ades models to the data collected by Trikalinos et al. [140],
consisting of 63 studies of four treatments for non-acute coronary artery disease. All
studies are two-armed. We indexed the treatments as (1) medical therapy; (2) per-
cutaneous transluminal balloon coronary angioplasty; (3) bare-metal stents; and (4)
drug-eluting stents. The outcome is the number of deaths due to the disease in each
treatment group, which follows a binomial distribution. The complete data are available
in Appendix A.11. We used the logit link function for the Smith and Lu–Ades models,
so the overall relative effects produced by these models are log odds ratios comparing
pairs among the four treatments. Also, in the Lu–Ades model, the treatment with the
smallest index was used as the baseline in each study.
Figure 7.2 presents the treatment network; we refer to this as the full network.
The full network has one evidence cycle, while the treatment comparison 4 vs. 3 is
acyclic as it is not contained in any cycles. To illustrate the performance of the Lu–
Ades model in a network without evidence cycles, we removed the four studies that
directly compare treatments 3 vs. 1 from the complete data; the remaining studies lead
to a chain-shaped network without cycles, which we call the reduced network. The
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Smith and Lu–Ades models were applied to both the full and reduced networks. In the
Lu–Ades model, eb = (d12, d23, d34)
T was chosen as the set of basic parameters; thus,
ef = (d13, d14, d24)
T was the set of functional parameters. The three model settings in
Section 7.3.1’s simulations were considered, and vague priors were assigned to the study-
specific baseline effects and the basic parameters. In the random-effects models, U(0, 10)
priors were used for the heterogeneity standard deviations σ12, σ23, and σ34. When the
Lu–Ades random-effects model with different heterogeneity variances was applied to the
full network, due to the triangle inequality constraint (7.7) in the evidence cycle, the
prior of σ13 was set to U(|σ12−σ23|, σ12 +σ23) as suggested by Lu and Ades [52]. Three
chains were used to implement the Smith and Lu–Ades models via Markov chain Monte
Carlo; each chain contained a run of 100,000 updates after a 100,000-run burn-in period.
Table 7.2 presents the median overall log odds ratios of all treatment contrasts
with their 95% credible intervals. When pairwise meta-analysis was applied to the full
network, the estimation of the indirect comparisons d14 and d24 was not applicable due
to unknown correlations between the separate estimated effects of d12, d13, d23, and d34;
however, this difficulty does not exist in the reduced network without cycles, as shown
in Theorem 1. The potential scale reduction factors [162] of all traced parameters were
much smaller than 1.05, indicating that the Markov chains sampled from the posterior
distributions have stabilized; also, the convergence of the chains was visually checked
using trace plots. In addition, we assessed the Monte Carlo standard errors of the point
and interval estimates using the R package ‘mcmcse’. Most results have Monte Carlo
standard errors much less than 0.01; those with standard errors greater than 0.01 are
noted in Table 7.2.
For the reduced chain-shaped network, under each model setting, the Smith and Lu–
Ades models produced nearly the same estimates of log odds ratios for all six treatment
contrasts. Most differences between the two models are no more than 0.01 in absolute
magnitude for point estimates and lower/upper bounds of 95% credible intervals, and
are due entirely to Monte Carlo error. These results are consistent with Theorems 1–3.
When the Lu–Ades model was applied to the full network, Table 7.2 shows that the
estimated overall log odds ratios of the basic parameters d12 and d23 differ from those
using the reduced network; thus, d13, d14, and d24, which are based on the basic pa-
rameters d12 and d23, also differ from their results using the reduced network. Recall
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that the reduced network only removed four studies that compare treatments 3 vs. 1.
However, two of the four studies enrolled more than 1000 patients in each of their treat-
ment groups, and they are the largest two among all 63 studies in the full network;
see Table A.10 in Appendix A.11. Thus, the removal of these large studies caused the
large differences noted above. Nevertheless, since the treatment contrast 4 vs. 3 is not
contained in any evidence cycles, the estimated overall log odds ratio of d34 differs by no
more than Monte Carlo error when the Lu–Ades model was used for the full and reduced
networks under both the fixed-effects setting and the random-effects setting with differ-
ent heterogeneity variances. This is consistent with Theorem 4. Furthermore, when all
treatment contrasts were assumed to have a common heterogeneity variance, the 95%
credible interval of the log odds ratio for d34 using the reduced network noticeably differs
from that using the full network. This change arises because the estimate of d34 partly
depends on the estimated heterogeneity variance, which is influenced by the removal of
the four studies that compare treatments 3 vs. 1 from the full network.
7.4 Discussion
In applications, the equivalence of Lu–Ades network meta-analysis and Smith pairwise
meta-analysis for acyclic comparisons is rarely noticed, even if the results from both
types of meta-analyses are reported. This may be due to two reasons: inconsistent
model assumptions and model specifications. First, most articles implement the Lu–
Ades model using a common heterogeneity variance for all treatment comparisons, while
performing separate pairwise meta-analyses using different heterogeneity variances for
each treatment comparison. Due to these inconsistent model assumptions, the effect
estimates produced by network and pairwise meta-analyses for acyclic comparisons are
different, as suggested by Theorem 3. As noted, the assumption of a common hetero-
geneity variance was used in Lu and Ades [51] for conceptual and technical simplicity,
and it may not be realistic in many cases [54]. Second, compared to the Smith Bayesian
hierarchical model, the frequentist inverse-variance fixed-effects model or DerSimonian–
Laird random-effects model [69] currently dominates pairwise meta-analysis, possibly
because the frequentist models can be easily implemented by various statistical software
packages (e.g., [163, 164]). These frequentist methods usually produce effect estimates
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noticeably different from the Smith Bayesian model. Hence, when reporting results from
both pairwise and network meta-analyses, researchers are encouraged to use consistent
model specifications, such as the Lu–Ades model combined with the Smith model, so
that the benefit of network meta-analysis can be accurately reflected by the differences
between the results from pairwise and network meta-analyses.
This chapter showed that evidence cycles are necessary to improve effect estimates
when using Lu–Ades network meta-analysis. Such improvement depends highly on
the evidence consistency assumption (7.3) for each cycle, which effectively reduces the
degrees of freedom of the total of (K − 1)K/2 treatment comparisons dhk (1 ≤ h < k ≤
K). However, each cycle potentially suffers from evidence inconsistency [52, 58], which
is caused by a discrepancy among the trio of treatment comparisons within evidence
cycles. By allowing inconsistency factors w for evidence cycles to deal with this problem,
the degrees of freedom of the treatment contrasts increases, and the power of Lu–Ades
network meta-analysis is accordingly reduced. In other words, when using the Lu–Ades
model to gain more power from network meta-analysis, researchers must accept a greater
risk of evidence inconsistency.
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Figure 7.1: Simulated treatment networks with three shapes. Vertices represent treat-
ments; edges represent direct comparisons. Edge width is proportional to the number
of studies that report the corresponding direct comparison; vertex size is proportional
to the number studies that include the corresponding treatment.
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Figure 7.2: Network of four treatments on non-acute coronary artery disease. Treatment
IDs: (1) medical therapy; (2) percutaneous transluminal balloon coronary angioplasty;
(3) bare-metal stents; and (4) drug-eluting stents.
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Table 7.1: Biases (outside brackets), mean squared errors (inside parentheses), and
95% credible interval coverage probabilities (%, inside square brackets) of the esti-
mated relative effects produced by the Smith model (pairwise meta-analysis) and the
Lu–Ades model (network meta-analysis) in simulations. The data were simulated
using different heterogeneity standard deviations for different treatments.
Network Treatment Network meta-analysis Pairwise meta-analysis
shape contrast FE RE1 RE2 FE RE1 RE2
Shape 1 d12 −0.03 −0.03 −0.03 −0.03 −0.03 −0.02
(0.21) (0.20) (0.20) (0.21) (0.20) (0.20)
[81] [99] [100] [81] [99] [100]
d15 0.03 0.03 0.03 0.03 0.03 0.03
(0.35) (0.18) (0.18) (0.35) (0.18) (0.18)
[41] [96] [92] [40] [95] [92]
d23 0.02
a 0.02 0.02 0.02a 0.02 0.02
(0.43) (0.35) (0.35) (0.43) (0.35) (0.35)
[73] [99] [100] [73] [99] [100]
d45 0.04
a 0.03 0.03 0.04a 0.03 0.03
(0.59c) (0.31) (0.31) (0.59c) (0.31) (0.31)
[44] [97] [95] [44] [97] [95]
Shape 2 d12 −0.02 −0.03 −0.02 −0.03 −0.03 −0.02
(0.21) (0.20) (0.21) (0.21) (0.20) (0.21)
[82] [99] [100] [81] [99] [100]
d13 −0.01a −0.02 −0.02 −0.03a −0.02 −0.02
(0.42) (0.35) (0.37) (0.42) (0.35) (0.36)
[76] [99] [99] [75] [99] [100]
d15 −0.01b −0.03a −0.02a −0.03b −0.02a −0.02a
(1.09d) (0.73d) (0.74d) (1.09d) (0.73d) (0.74d)
[63] [99] [98] [62] [99] [98]
d45 0.02 0.02 0.02 0.02 0.02 0.02
(0.37) (0.18) (0.18) (0.37) (0.18) (0.18)
[37] [96] [92] [36] [96] [92]
Shape 3 d12 −0.02 −0.03 −0.02 −0.03 −0.03 −0.02
(0.21) (0.20) (0.21) (0.21) (0.20) (0.21)
[82] [99] [100] [81] [99] [100]
d13 −0.02a −0.02 −0.02 −0.03a −0.02 −0.02
(0.42) (0.35) (0.37) (0.42) (0.35) (0.37)
[75] [99] [100] [75] [99] [100]
d15 −0.01a −0.02a −0.02a −0.02a −0.02a −0.02a
(0.63c) (0.44) (0.44) (0.63c) (0.43) (0.44)
[62] [99] [99] [61] [99] [99]
d45 0.02 0.02 0.02 0.02 0.02 0.02
(0.37) (0.18) (0.18) (0.37) (0.18) (0.18)
[37] [96] [92] [36] [96] [92]
FE: fixed-effects model; RE1: random-effects model with different heterogeneity
variances for different treatment contrasts; RE2: random-effects model with a
common heterogeneity variance.
dhk: treatment k compared to h.
Monte Carlo standard error of bias: a, 0.02–0.03; b, 0.03–0.04; otherwise, less
than 0.02. Monte Carlo standard error of mean squared error: c, 0.02–0.03; d,
0.03–0.05; otherwise, less than 0.02. Monte Carlo standard errors of all coverage
probabilities are less than 2%.
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Table 7.2: Log odds ratios (95% credible intervals) between the four treatments on non-acute coronary artery
disease.
Network meta-analysis Pairwise meta-analysis
LOR FE RE1 RE2 FE RE1 RE2
Full network:
d12 −0.07 −0.16 −0.12 −0.21 −0.29 −0.29
(−0.31, 0.17) (−0.65, 0.32) (−0.58, 0.28) (−0.52, 0.09) (−1.06, 0.30) (−0.84, 0.20)
d13 −0.11 −0.24 −0.22 −0.04 0.00 −0.01
(−0.31, 0.08) (−0.91a, 0.25) (−0.73, 0.20) (−0.26, 0.18) (−2.06c, 2.64c) (−0.65, 0.73)
d14 −0.03 −0.22 −0.19 N/A N/A N/A
(−0.49, 0.42) (−1.10a, 0.50a) (−0.98, 0.46)
d23 −0.05 −0.10 −0.10 −0.21 −0.22 −0.21
(−0.29, 0.20) (−0.58, 0.34) (−0.47, 0.25) (−0.53, 0.11) (−0.81, 0.34) (−0.62, 0.19)
d24 0.03 −0.07 −0.07 N/A N/A N/A
(−0.45, 0.52) (−0.83a, 0.60) (−0.75, 0.54)
d34 0.08 0.04 0.03 0.08 0.04 0.03
(−0.33, 0.49) (−0.56a, 0.53) (−0.52, 0.54) (−0.33, 0.50) (−0.55, 0.53) (−0.53, 0.55)
Reduced chain-shaped network:
d12 −0.21 −0.29 −0.31 −0.21 −0.29 −0.30
(−0.51, 0.09) (−1.03b, 0.31a) (−0.91, 0.24) (−0.52, 0.09) (−1.06, 0.30) (−0.91, 0.24)
d13 −0.42 −0.52 −0.52 −0.42 −0.53 −0.51
(−0.86, 0.03) (−1.41b, 0.31a) (−1.26, 0.17) (−0.86, 0.02) (−1.47, 0.30) (−1.26, 0.17)
d14 −0.34 −0.49a −0.51 −0.34 −0.49 −0.50
(−0.95, 0.27) (−1.55b, 0.46a) (−1.48a, 0.36) (−0.95, 0.27) (−1.60, 0.48) (−1.48, 0.35)
d23 −0.21 −0.22 −0.21 −0.21 −0.22 −0.21
(−0.53, 0.11) (−0.80, 0.34) (−0.64, 0.21) (−0.53, 0.11) (−0.81, 0.34) (−0.65, 0.21)
d24 −0.13 −0.19 −0.20 −0.13 −0.18 −0.20
(−0.66, 0.40) (−1.00a, 0.56) (−0.94, 0.49) (−0.66, 0.40) (−1.02, 0.56) (−0.94, 0.48)
d34 0.08 0.04 0.01 0.08 0.04 0.01
(−0.34, 0.50) (−0.55a, 0.53) (−0.58, 0.55) (−0.33, 0.50) (−0.55, 0.53) (−0.58, 0.55)
LOR: log odds ratio; FE: fixed-effects model; RE1: random-effects model with different heterogeneity
variances for different treatment contrasts; RE2: random-effects model with a common heterogeneity
variance; N/A: not applicable.
dhk: treatment k compared to h.
Monte Carlo standard error: a, 0.01–0.02; b, 0.02–0.03; c, 0.06–0.07; otherwise, less than 0.01.
Chapter 8
Conclusion
8.1 Summary of major findings
This thesis introduced several innovative statistical methods and ideas for both univari-
ate and multivariate meta-analyses. Outlying studies are common in meta-analyses and
have great impact on conventional heterogeneity measures; however, no widely accepted
guidelines exist for handling outliers. Chapter 2 proposed new heterogeneity measures
that are less affected by outliers than the conventional ones. Assessing publication
bias is another critical problem in meta-analysis. Chapter 3 empirically compared the
performance of seven popular methods for publication bias using a large collection of
real meta-analyses from the Cochrane Library. We found that Egger’s regression test
detected publication bias in more meta-analyses than the other methods, while the
agreement among the seven tests was generally low or moderate, indicating potential
limitations of current methods. Chapter 4 proposed an intuitive measure to quantify
publication bias so that the severity of publication bias can be compared across meta-
analyses. Specifically, the intercept from Egger’s regression test can serve as a measure
of publication bias, though it does not fully reflect the collected studies’ asymmetry
due to publication bias. We introduced a new measure, the skewness of the regression
residuals, which has a more intuitive interpretation than the regression intercept. It
can be also used as a test statistic for publication bias; simulations showed that it is
powerful in many settings.
The data available for meta-analysis have been greatly enriched due to recent trends
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of data sharing, and methods for multivariate meta-analysis are being increasingly devel-
oped to synthesize the effects of multiple outcomes, multiple treatments, etc. A disease
condition is typically associated with multiple risk and protective factors in medical
sciences. Many studies report associations for multiple factors, but so far nearly all
published meta-analyses separately synthesize the association between each factor and
the disease condition. As the collected studies usually report different subsets of fac-
tors and use different subpopulations, results from separate meta-analyses may not be
comparable. Chapter 5 introduced an innovative concept, multivariate meta-analysis of
multiple factors, which synthesizes the factors simultaneously and thus improves sta-
tistical efficiency and reduces potential biases compared with separate analyses. The
difficulty in multivariate meta-analysis of multiple factors is that the factors are likely
correlated within studies but such correlations are usually unavailable from published
articles. We used a Bayesian hierarchical model to handle this problem.
Network meta-analysis has also become very popular in the last decade. We have
released a user-friendly R package ‘pcnetmeta’ to implement an arm-based network
meta-analysis model, which focuses on estimating treatment-specific effects and is based
on a missing data perspective. For binary outcomes, the arm-based method reports
comprehensive summary results, including event rates, risk ratios, risk differences, and
odds ratios; thus, it is more flexible than the contrast-based network meta-analysis
method, which focuses only on estimating relative effects (e.g., odds ratios). The arm-
based method can use single-arm studies, while the contrast-based method cannot.
Chapter 6 showed that single-arm studies provide valuable information for treatment
comparisons and enhance the robustness of a network meta-analysis.
Although network meta-analysis is generally considered more powerful than conven-
tional pairwise meta-analyses of pairs of treatments, the improvement of effect estimates
produced by network meta-analysis has never been studied theoretically. Chapter 7
proved that a pairwise comparison that is not part of an evidence cycle in a contrast-
based network meta-analysis has posterior distribution identical to that produced by a
simple pairwise meta-analysis. Many network meta-analyses do not contain evidence
cycles, such as star-shaped treatment networks, in which several active treatments are
compared with the control but the active treatments are not mutually compared. In
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such settings, the results of Lu–Ades network meta-analysis model are therefore equiva-
lent to performing separate pairwise meta-analyses on each treatment comparison. We
also illustrated this equivalence using simulation studies and a real data analysis. We
hope that the findings in this thesis will provide other researchers with valuable insights
into future systematic reviews and meta-analyses.
8.2 Future research
Data sharing will necessarily lead to fast development of multivariate meta-analysis so
that all available information can be used effectively. In this connection, we have several
aims for future research on meta-analysis.
(i) Methods for assessing publication bias in multivariate meta-analysis. Although
many methods are available for univariate meta-analysis, assessing publication
bias in multivariate meta-analysis (including network meta-analysis) is largely un-
touched. As the dimension increases, assessing publication bias becomes challeng-
ing because some studies may be completely suppressed while some may selectively
report subsets of their outcomes. Approaches to adjusting for publication bias will
greatly improve the precision of conclusions from multivariate meta-analyses. We
plan to extend the work of quantifying publication bias in univariate meta-analysis
to multivariate settings. Based on the multivariate version of Egger’s regression
test, the skewness of study-specific multivariate residuals can be used as an overall
publication bias measure for all endpoints. We will derive test statistics and their
theoretical properties based on this overall measure.
(ii) Meta-analysis methods based on penalized likelihood. As discussed in Chapter 2,
conventionally, heterogeneity between studies needs to be assessed separately for
each endpoint, and either fixed or random effects are accordingly used to estimate
the effect of that endpoint. This process is inefficient when the meta-analysis
dataset contains many endpoints. Also, it is generally recognized that both the
fixed- and random-effects models have several limitations. In addition, hetero-
geneity is overestimated in the presence of outliers, which are common in meta-
analyses. The new penalized-likelihood-based method will use a set of tuning
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parameters to control the strength of penalties on the likelihood of the random-
effects model. If the tuning parameters are set to zero, the resulting effect esti-
mates are identical to those produced by the conventional random-effects model.
If the tuning parameters are large enough, the new method leads to the fixed-
effects estimates. Therefore, this method can be viewed as trading off between
the fixed- and random-effects models.
(iii) Meta-analysis that combines patient-level data from existing databases with ag-
gregated summary data from a literature search. This combination can overcome
many drawbacks of using only aggregated data. For example, aggregated data
are often poorly reported and presented differently across studies, such as report-
ing odds ratio vs. relative risk. The trend toward data sharing lays a promising
foundation for meta-analysis of individual patient data. Taking advantage of the
increasing attention from governmental organizations and medical journals, we
plan to request individual patient data from data-sharing resources and use them
to help evaluate the performance of the new methods.
(iv) Meta-analysis accounting for post-randomization variables. Non-compliance with
assigned treatments is common in randomized controlled trials and may induce
bias in estimated treatment effects. The main existing method, meta-regression,
adjusts for study-level baseline covariates, not for arm-level post-randomization
variables. We will develop an arm-based approach to jointly modeling both out-
come measures and post-randomization variables in both univariate and multi-
variate meta-analyses, so that the estimated effects of different endpoints can be
comparable at the same level of non-compliance.
Additionally, an important step in promoting new statistical methods is to provide
open-source user-friendly software. We will continue to develop R packages and SAS
macros so that researchers who do not specialize in (bio)statistics can implement the new
methods easily. For example, many frequentist and Bayesian methods for publication
bias are based on so-called selection models that not only detect but also adjust for
publication bias. These methods are usually complicated and require careful coding,
limiting their applications. We plan to release a sophisticated R package that includes
a comprehensive set of selection-model-based methods for assessing publication bias.
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Appendix A
Supplementary Materials
A.1 Sensitivity analysis for the weighted-median-based ro-
bust heterogeneity measure
Since the weighted median in Qm is discontinuous due to the indicator function [165] in
Equation (2.2), the approach by Horowitz [72] is applied to approximate the indicator
function I(t > 0) by a smooth function J(t) in the following simulations and case studies.
For example, J(t) can be the scaled expit function J(t) = 1/[1 + exp(−t/)], where 
is a pre-specified small constant, say 10−4. This section presents sensitivity analysis on
the choice of . We use the data of the case study in Section 2.5.1. Table A.1 presents
the results based on B = 10, 000 resampling iterations.
A.2 Performance of heterogeneity measures in three arti-
ficial meta-analyses
This section illustrates that I2r and I
2
m can be larger than I
2 and provide useful in-
formation on assessing heterogeneity. Three artificial meta-analyses were created; each
contains ten studies with the same within-study variance 1. The observed effect sizes
in half of the studies are yi = b, and those in another half are yi = −b, where b was
set to 0.5, 1, and 2. Figure A.1 presents the corresponding forest plots. Note that
in these meta-analyses, the condition wi(yi − µ¯)2 = C is satisfied, so the equality in
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I2r ≤ I2 + (1− 2/pi)(1− I2) holds.
Figure A.1(a) shows the meta-analysis with b = 0.5. Since the observed effect size
of each study is contained in the 95% CIs of all other studies, the collected studies
are considered homogeneous; all of I2, I2r , and I
2
m are calculated as 0. For the meta-
analysis with b = 1.0 shown in Figure A.1(b), five studies report the effect size −1,
lying outside the 95% CIs (−0.96, 2.96) of the other five studies. Despite this, the 95%
CIs of the total ten studies overlap in a large region, i.e., (−0.96, 0.96). Therefore,
the between-study heterogeneity is moderate, but may not be substantial. The three
heterogeneity measures are calculated as I2 = 0.10, I2r = 0.43, and I
2
m = 0.36; I
2 may
indicate homogeneity but both I2r and I
2
m imply moderate heterogeneity. Figure A.1(c)
shows the meta-analysis with b = 2. The 95% CIs of five studies do not overlap with
those in the other five studies; therefore, these studies are clearly heterogeneous. The
heterogeneity measures are calculated as I2 = 0.78, I2r = 0.86, and I
2
m = 0.84; all
suggest considerable heterogeneity.
A.3 Complete simulation results for heterogeneity mea-
sures
The simulation settings have been detailed in Section 2.4. Tables A.2–A.4 present the
complete results.
A.4 Performance of various publication bias tests based
on the restricted dataset
Figures A.2–A.4 present the results based on the restricted Cochrane dataset, which
consists of the largest meta-analysis from each systematic review. They correspond to
Figures 3.1–3.3 in Section 3.2.
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A.5 Implementation of multivariate hybrid model
A.5.1 Restricted maximum likelihood method
Since the hybrid model for complete data is a special case of that for missing data by
setting Xi to the p× p identity matrix Ip, we only discuss the situation of missing data.
For the frequentist approach, we consider the restricted maximum likelihood (REML)
method, which is commonly used to estimate variance/covariance components [166].
The restricted log-likelihood of the hybrid model is [167]
λREML = Const.− 1
2
n∑
i=1
log |Φi| − 1
2
log
∣∣∣∣∣
n∑
i=1
XTi Φ
−1
i Xi
∣∣∣∣∣− 12
n∑
i=1
rTi Φ
−1
i ri,
where ri = yi −Xiµ˜ represents the residuals and
µ˜ = (
n∑
i=1
XTi Φ
−1
i Xi)
−1(
n∑
i=1
XTi Φ
−1
i yi).
We may treat λREML as the log-likelihood of the residuals ri, and the REML estimates
are obtained by maximizing λREML. Denote the estimates of Ψ and R as Ψ̂ and R̂,
respectively. Hence, the overall effect size µ is estimated as
µ̂ = (
n∑
i=1
XTi Φ̂
−1
i Xi)
−1(
n∑
i=1
XTi Φ̂
−1
i yi),
where Φ̂i = (Di + XiΨ̂X
T
i )
1/2XiR̂X
T
i (Di + XiΨ̂X
T
i )
1/2. The covariance matrix of µ̂ is
estimated as V̂ar[µ̂] = (
∑n
i=1 X
T
i Φ̂
−1
i Xi)
−1.
The optimization problem is subject to that the marginal correlation matrix R is
positive definite and its diagonal elements are 1. To ensure these constraints, we consider
the spherical decomposition of R [168]. This technique is basically a reparameterization
of the Cholesky decomposition. Specifically, write R = LLT, where L = (Lij) is a lower
triangular matrix with nonnegative diagonal elements. Let L11 = 1 and for i = 2, . . . , p,
Lij =

cos θi2 if j = 1;(∏j
k=2 sin θik
)
cos θi,j+1 if j = 2, . . . , i− 1;∏i
k=2 sin θik if j = i.
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Here, θij ’s are angle parameters for 2 ≤ j ≤ i ≤ p. Note that using this parameter-
ization, the diagonal elements of R, rjj =
∑j
i=1 L
2
ij , are guaranteed to be 1 by the
properties of sine and cosine functions. Moreover, to ensure the uniqueness of Lij ’s,
the angle parameters are constrained to be θij ∈ (0, pi). Since the boundaries of the
parameters are linear, and the optimization problem for the REML estimates can be
solved by many statistical software, such as the R function optim().
A.5.2 Bayesian method
In high-dimensional data analysis, it is well-known that the sample covariance is not
consistent if the dimension is close to or greater than the sample size [125, 169]. For
the proposed hybrid model, the estimated overall correlation matrix using the REML
method may also suffer from the ‘curse of dimensionality’, especially when the number
of factors is large and the data are sparse. The covariance matrix of the overall effect
sizes could be poorly estimated, so the 95% confidence intervals (CIs) of the overall
effect sizes may have inappropriate coverage probabilities. Alternatively, the Bayesian
method may provide better estimates by assigning vague priors to variance/covariance
parameters; it has been used in mixed treatment comparisons in which the data are also
sparse [54, 67]. The performance of the Bayesian and REML methods will be studied
using simulations in Appendix A.6.
In Bayesian analysis, the inverse-Wishart prior is frequently specified for unstruc-
tured positive definite matrix [170]; however, the posterior estimates may be sensitive
to the selection of hyperparameters for the inverse-Wishart prior [171, 172]. Instead,
we consider the separation strategy to specify vague priors for the variance and cor-
relation components separately [54, 173]. Again, the aforementioned spherical decom-
position of the marginal correlation matrix R is applied to guarantee its positive def-
initeness. Specifically, for each j = 1, . . . , p, we use vague priors N(0, 103) for the
fixed effects µj and uniform priors U(0, 10) for the between-study standard deviations
ψj [174]. For the correlation matrix that is parameterized using the angle parameters
θij (2 ≤ j ≤ i ≤ p), we specify uniform priors θij ∼ U(0, pi). We implement the
Bayesian method using the MCMC algorithm through the software JAGS version 4.2.0
(http://mcmc-jags.sourceforge.net/). The medians of posterior samples are used
as the point estimate, and the 2.5% and 97.5% quantiles are used as the lower and upper
133
bounds of the 95% credible interval, respectively.
Practitioners need to be cautious for the convergence of the hybrid model. The
REML method may fail to converge when the dimension of factors is high and the
sample size is small. An estimated overall correlation close to ±1 may lead to poor
convergence and unstable estimated covariance of the overall effect sizes [121]. We
may check the sensitivity of the REML estimates by specifying several different initial
values for maximizing restricted log-likelihood; large changes of the results may indicate
that the estimates are unstable, possibly due to high dimension. The Bayesian method
may be preferred in such situations; this method has been popular in the literature of
mixed treatment comparisons which also deal with sparse data [54,67]. When using the
Bayesian method, researchers still need to pay attention on checking the stabilization
and convergence of MCMC algorithm by various criteria [162,175].
A.6 Simulations for multivariate meta-analysis of multiple
factors
We conducted simulations in various settings to compare the performance of the pro-
posed hybrid model (Model H) with the ideal model that uses within-study correlations
(Model M), the model that ignores within-study correlations but accounts for between-
study correlations (Model M0), and the univariate model that ignores both types of
correlations (Model U). Bias and root mean squared error (RMSE) of point estimate
and 95% CI/CrI coverage probability are used to evaluate the models’ performance.
We set the number of studies in each simulated MVMA-MF dataset to 30 and con-
sidered 5 factors in total. Without loss of generality, the true overall effect sizes of
the 5 factors were set to 0, i.e., µ = (0, 0, 0, 0, 0)T. Also, the between-study standard
deviation τ was fixed as 1 for each factor; the within-study standard deviation σ of
each factor was set to 0.5, 1, or 2. These choices for σ represent different extents of
heterogeneity between studies; since the between-study variance τ2 was fixed, the stud-
ies tend to be more homogeneous as the within-study variance σ2 increases. Moreover,
we considered the exchangeable correlation structure for both the between- and within-
study correlation matrices, RB = (rBij) and RW = (rWij), which are determined by the
correlation parameters ρB and ρW respectively; that is, rBij = ρB and rWij = ρW for
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1 ≤ i 6= j ≤ 5. The between-study correlation was fixed as ρB = 0.5, and ρW was drawn
from U(0, 0.3), U(0.3, 0.6), or U(0.6, 0.9) to represent different extents of within-study
correlations. Hence, the simulated studies have different marginal correlation matri-
ces, and the settings do not favor the assumption in the proposed hybrid model. For
each setting, 1000 MVMA-MF datasets were simulated using the ideal Model M, i.e.,
Equation (5.1), with Si = σ
2RW and T = τ
2RB. Finally, three scenarios of missing-
ness were considered: (I) all 5 factors were observed in all studies, i.e., the data were
complete; (II) the data of factors 1, 3, and 5 in 10 studies were missing completely at
random; and (III) the smallest 10 effect sizes of factors 1, 3, and 5 were missing. The
missingness that is not at random in scenario (III) can be considered as the effect of
publication bias. Moreover, we also considered a missingness scenario that is similar to
(III) but contains more missing values: (III′) the smallest 25 effect sizes of factors 1, 3,
and 5 were missing; in this case, the three factors were only available from 5 studies, so
the simulated MVMA-MF dataset was much sparser than the previous settings. Both
the REML and Bayesian methods were applied to implement the four models. For the
Bayesian method, the results of each simulated MVMA-MF dataset was based on one
chain with a run of 10,000 updates after a 10,000-run burn-in period.
To save space, here we present the results of factors 1, 2, and 3 in some settings
in Table A.5; the results of factors 4 and 5 are fairly similar to those of factors 2 and
1, respectively. First, recall that the data of factors 2 and 4 were complete under
each scenario; their corresponding results produced by the four models are almost the
same. All models lead to nearly unbiased estimated effect sizes and proper 95% CI/CrI
coverage probabilities for these two factors under each scenario. Second, the results of
factors 1, 3, and 5 produced by the four models differ little when the data are complete
under scenario (I) or missing completely at random under scenario (II); this is expected
from the perspective of missing data analysis [176]. Third, if the missingness is not at
random under scenario (III), the results produced by the four models are noticeably
different. The univariate model leads to the largest bias and RMSE and the lowest
95% CI/CrI coverage probability. Since Model M0 still accounts for the between-study
correlations, its performance is similar to the proposed Model H when ρW is small
compared to ρB. However, the proposed Model H outperforms Model M0 when ρW is
larger than ρB. This is due to that the within-study level dominates the estimation of
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the overall effect sizes in such a situation, but Model M0 ignores correlations at this
level. Finally, note that Model M is ideal as it uses the within-study correlations that
are usually unavailable in real data. Although Model H does not use the within-study
correlations, Table A.5 shows that the biases and RMSEs produced by Model H are
fairly close to the ideal Model M across various settings. Also, the 95% CI/CrI coverage
probability produced by Model H is generally higher than those produced by Models M0
and U.
In most situations, the biases and RMSEs of point estimates obtained using the
REML method are close to those obtained using the Bayesian method. However, under
the missingness scenarios (III) and (III′), the 95% CrI coverage probabilities for factors 1,
3, and 5 obtained using the Bayesian method are generally higher than those obtained
using the REML method. As noted in Section 5.3.3, this may be due to that the
estimated covariance matrix is inconsistent when many observations are missing and
the dimension is close to the sample size. In addition, when using the hybrid model
to analyze the data under scenario (III′), the optimization algorithm for the REML
estimates did not converge for many simulated replicates, likely due to the sparsity of
the data (only five samples observed for each of factors 1, 3, and 5). We ran around
2500 iterations to obtain 1000 datasets that produced converged REML estimates, and
these 1000 datasets were used to produce the results in Table A.5 for scenario (III′).
Also, under this scenario, the biases and RMSEs produced by the hybrid model using
the REML method are noticeably different from those using the Bayesian method for
factors 1, 3, and 5; again, the differences may be caused by the poor estimates of the
REML method for sparse data. Hence, the Bayesian method is possibly preferred to
implement the multivariate hybrid model when the dimension of factors is high but the
number of observations is limited.
A.7 Estimating population-averaged absolute risks for the
smoking cessation data
Consider using both the arm-based and contrast-based models to estimate absolute risks
for the smoking cessation data presented by Hasselblad [132] and Lu and Ades [52]. This
network meta-analysis dataset consists of 24 studies on a total of 16,737 participants,
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comparing the effects of self-help (B), individual counseling (C), and group counseling
(D) vs. no contact (A). It is straightforward to estimate the population-averaged ab-
solute risks using the arm-based model.2 To illustrate that the arm-based model does
not simply estimate the population-averaged absolute risks for each treatment arm in-
dependently, we also consider separate logit and probit random effects models on each
treatment to estimate the corresponding population-averaged absolute risks. Specif-
ically, the random effects model for a treatment is yi ∼ bin(ni, pi), g(pi) = u + vi,
vi ∼ N(0, σ2), where i indexes different studies, and yi and ni represent the number
of events and participants on a given treatment arm. We used a vague prior for the
fixed effect u and an inverse gamma prior for the variance σ2. The link function g(·)
is either the logit or probit link. The treatment’s population-averaged absolute risk
can be estimated for the logit link as 1
1+exp(−u/√1+C2σ2) where C =
16
√
3
15pi , and for the
probit link as Φ(u/
√
1 + σ2), where Φ(·) is the standard normal cumulative distribution
function [177].
To estimate absolute risks using contrast-based NMA, we first selected a reference
treatment group and used the above logit random effects model to estimate absolute risk
distribution for the reference group, which was further used to estimate the population-
averaged absolute risks of other treatment groups. The related WinBUGS code for the
‘random effect models for multiple arm trials’ is available at http://www.bristol.ac.
uk/social-community-medicine/projects/mpes/mtc/. Specifically, based on sep-
arate logit random effects models on each treatment, we used N(−2.62, 2.68−1) as
the prior of logit absolute risks for treatment A, N(−1.94, 1.23−1) for treatment B,
N(−1.69, 1.69−1) for treatment C, and N(−1.44, 1.51−1) for treatment D, when each is
chosen as the reference group, respectively. The results were based on 500,000 MCMC
iterations with 500,000 additional burn-in iterations, and are listed in Table A.6.
Table A.6 illustrates differences between the population-averaged absolute risks es-
timated by the arm-based model and by separate logit or probit models. In particular,
because the arm-based approach models the absolute risks of treatment arms jointly
to account for correlations among them within a study, the posterior of population-
averaged absolute risks from the arm-based model generally have narrower 95% cred-
ible intervals than those from separate models. In addition, the contrast-based model
leads to much wider 95% credible intervals. This may arise because the contrast-based
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model only uses the point estimates of u and σ2 from the separate logit/probit random
effects models as a ‘fixed’ prior distribution for the reference group, and the absolute
risk estimates of other treatments greatly depend on this prior information.
A.8 The arm-based and contrast-based models
Assume that a network meta-analysis reviews I studies on K treatments, where each
study investigates a subset of the K treatments. Label the studies i = 1 to I and the
treatments k = 1 to K. Let Ti be the subset of the K treatments that is compared
in ith study. Further, in the ith study, let nik be the number of participants allocated
to treatment k (k ∈ Ti), and let yik be the number of events. For binary outcome,
both types of NMA models are based on the binomial likelihood yik ∼ bin(nik, pik) for
k ∈ Ti; they differ in the way they model the underlying absolute risks pik in each
study’s treatment group.
The arm-based model [67] is specified as follows:
g(pik) = µk + νik;
(νi1, νi2, . . . , νiK)
T ∼ N(0,ΣK),
where g(·) is a link function and ΣK is the variance-covariance matrix of the vector of
random effects (νi1, νi2, . . . , νiK)
T. Let σ2k, k = 1, 2, . . . ,K denote the diagonal elements
of ΣK . The µk’s are fixed effects for the treatments. Notice that the νik’s are correlated
within each study via the multivariate normal distribution; thus the arm-based model
respects within-study randomization. When the link function g(·) is the probit link (i.e.,
Φ−1(·)), the population-averaged absolute risk of treatment k is pik = E[pikµk, σk] =
Φ
(
µk/
√
1 + σ2k
)
[177]. With this estimate for absolute risks, we can calculate odds
ratios, relative risks, and risk differences. This study uses an inverse-Wishart prior for
ΣK , Σ
−1
K ∼ W (VK ,K), where VK is a K × K matrix with diagonal elements 1 and
off-diagonal elements 0.005. The inverse-Wishart prior is commonly used for variance-
covariance matrices and is considered vague [171, 173]. Also, since it is conjugate,
this prior allows some mathematical simplicity [178]. Zhang et al. [67] give practical
computer code implementing MCMC for this model, and the R package ‘pcnetmeta’
(http://cran.r-project.org/package=pcnetmeta) provides user-friendly functions.
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A popular contrast-based model proposed by Lu and Ades [51,54] specifies a baseline
treatment b(i) in the ith study. For convenience, we simply denote b(i) as b. The
Bayesian hierarchical model for this approach is
g(pik) = µi +Xikδibk;
δibk ∼ N(dbk, σ2bk).
In this model, Xik is a dummy variable taking the value 1 if k 6= b and 0 if k = b. Also,
µi is the baseline effect for treatment b in the ith study, and δibk is the relative effect of
treatment k compared to the baseline b on the logit scale. This model treats the µi’s as
nuisances and uses non-informative priors for them. This model focuses on the treatment
contrasts δibk and the parameter of interest is the overall relative effect dhk = dbk − dbh;
therefore, this model is described as contrast-based. Practical computer code is available
at http://www.bristol.ac.uk/social-community-medicine/projects/mpes/mtc/.
This study uses the two models as described above. Since the contrast-based model
cannot estimate absolute effects, some authors have proposed the so-called ‘contrast-
based + baseline’ model [58], which is specified as
g(pik) = µi +Xikδi1k;
δi1k ∼ N(d1k, σ21k);
µi ∼ N(m,σ2m).
Here, instead of being treated as a nuisance, µi is modeled as the absolute effect of the
‘reference’ treatment 1. The absolute effect of treatment k is estimated by ak = m+d1k.
This model not only assumes that the relative effects δi1k are exchangeable between
studies, but also requires exchangeability between studies of the absolute effect µi for
the ‘reference’ treatment. Also, this model can be reduced to the arm-based model: we
may rewrite g(pik) = (m+d1k)+(µ˜i1 + δ˜i,1k) for k 6= 1, where µ˜i1 = µi1−m ∼ N(0, τ2m)
and δ˜i,1k = δi,1k − d1k ∼ N(0, σ21k). Therefore, m + d1k and µ˜i1 + δ˜i,1k correspond to
the treatment-specific fixed effect µk and the random effect νik in the arm-based model,
respectively. More details of NMA models can be found in the work by Hong et al. [150]
with discussion [179, 180]. Due to its similarity to the arm-based model and its strong
assumptions, this study does not consider the ‘contrast-based + baseline’ model.
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A.9 An example of excluding a treatment to form a re-
duced network
Table A.7 gives an example to illustrate the data available for arm-based and contrast-
based models after excluding each treatment being considered. This network consists
of six studies labeled A to F, which evaluate the efficacy of three treatments, labeled 1
to 3. Studies A to E are two-armed, while Study F is three-armed. The six rightmost
columns show data that can be used by the arm-based and contrast-based methods if
each of the three treatments is excluded. For the arm-based model, in the complete
network and reduced networks each retained treatment is investigated in at least 3
studies. However, for the contrast-based model only exclusion of treatment 3 is eligible
for consideration under our criteria (i.e., that each retained treatment is investigated in
at least 3 studies).
The foregoing criterion would imply that no treatment exclusions need to be ruled
out for the arm-based method. However, certain treatment exclusions, such as the
removal of treatment placebo in Eisenberg 2008, would create a disconnected network.
Therefore, we ruled out such treatment exclusions in the present study.
A.10 Additional simulations comparing pairwise and net-
work meta-analyses in the absence of evidence cycles
Tables A.8 and A.9 present the simulation results for Cases (i) and (ii) of the five
treatments’ heterogeneity standard deviations, respectively.
A.11 Complete data for the network meta-analysis of non-
acute coronary artery disease
Table A.10 presents the dataset of the network meta-analysis performed by Trikalinos
et al. [140]. It investigates the effects of four treatments for non-acute coronary artery
disease.
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Figure A.1: Forest plots of the three artificial meta-analyses. The column ‘Est’ contains the observed effect size in each
study; the columns ‘Lower’ and ‘Upper’ contain the lower and upper bounds of the corresponding 95% CI.
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Figure A.2: The P -values produced by the various publication bias tests for the 499
Cochrane meta-analyses with continuous outcomes in the restricted dataset. Plus signs
indicate P -values < 10−7.
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(d) Tang's regression test
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(e) Macaskill's regression test
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(f) Deeks' regression test
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(g) Peters' regression test
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Figure A.3: The P -values produced by the various publication bias tests for the 1380
Cochrane meta-analyses with binary outcomes in the restricted dataset. Plus signs
indicate P -values < 10−7.
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P
r
o
p
o
r
t
i
o
n
 
(
%
)
l
l l
l
l
l l
l
l
l
l
l
l
l
l
l l
l
0
10
20
30
40
50
60
70
80
5
(280)
6
(205)
7
(161)
8
(98)
9
(90)
10
(90)
11
(61)
12
(42)
13
(34)
14
(33)
15
(30)
16
(33)
17
(30)
18
(27)
19
(23)
20
(16)
> 20
(127)
All
(1380)
l
Begg's rank test
Trim and fill method
Egger's regression test
Tang's regression test
Macaskill's regression test
Deeks' regression test
Peters' regression test
Any test
Figure A.4: Proportions of the Cochrane meta-analyses having statistically significant publication bias (P -value < 0.1)
based on the various tests in the restricted dataset and their 95% confidence intervals. ‘Any test’ implies the proportion
of having statistically significant publication bias detected by at least one test. The label ‘All’ on the horizontal axis
represents all extracted meta-analyses with continuous/binary outcomes.
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Table A.1: Sensitivity analysis on the choice of  for the weighted-median-based hetero-
geneity measures.
 Qm P -value τ̂m (95% CI) Hm (95% CI) I
2
m (95% CI)
10−2 31.340 0.006 0.298 (0, 0.561) 1.354 (1, 1.884) 0.455 (0, 0.718)
10−3 31.273 0.006 0.296 (0, 0.563) 1.352 (1, 1.886) 0.453 (0, 0.719)
10−4 31.259 0.006 0.296 (0, 0.563) 1.351 (1, 1.886) 0.452 (0, 0.719)
10−5 31.259 0.006 0.296 (0, 0.563) 1.351 (1, 1.886) 0.452 (0, 0.719)
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Table A.2: Type I error rates and powers of three heterogeneity tests for the simulated
meta-analyses containing 10 studies with outliers in Scenario I.
Outlier pattern
Size/power† RMSE CP (%)
Q‡ Qr Qm τ̂2DL τ̂
2
r τ̂
2
m τ̂
2
DL τ̂
2
r τ̂
2
m
Scenario I (contamination) with τ2 = 0 (homogeneity) and si ∼ U(0.5, 1):
No outliers 0.04 (0.05) 0.04 0.04 0.18 0.22 0.16 100 100 100
C 0.74 (0.74) 0.53 0.47 1.04 0.80 0.56 99 98 100
(C,C) 0.97 (0.97) 0.93 0.91 1.70 1.68 1.16 92 92 98
(C,−C) 0.98 (0.98) 0.93 0.92 2.14 1.55 1.24 91 91 97
(C,C,C) 0.99 (0.99) 0.99 0.99 2.21 2.66 1.91 48 55 78
(C,C,−C) 1.00 (1.00) 0.99 1.00 3.01 2.57 2.07 48 57 79
Scenario I (contamination) with τ2 = 1 (heterogeneity) and si ∼ U(0.5, 1):
No outliers 0.75 (0.74) 0.72 0.70 0.72 0.82 0.71 76 88 82
C 0.99 (0.98) 0.97 0.97 2.24 1.89 1.37 98 98 99
(C,C) 1.00 (1.00) 1.00 1.00 3.57 3.58 2.59 92 93 98
(C,−C) 1.00 (1.00) 1.00 1.00 4.44 3.49 2.77 92 92 98
(C,C,C) 1.00 (1.00) 1.00 1.00 4.47 5.29 3.94 67 71 88
(C,C,−C) 1.00 (1.00) 1.00 1.00 6.35 5.60 4.54 63 70 86
Scenario I (contamination) with τ2 = 1 (heterogeneity) and si ∼ U(1, 2):
No outliers 0.26 (0.26) 0.22 0.22 1.27 1.52 1.21 76 88 81
C 0.88 (0.89) 0.78 0.75 5.34 4.28 3.06 98 98 99
(C,C) 0.99 (0.99) 0.98 0.98 8.73 8.68 6.15 92 92 98
(C,−C) 1.00 (1.00) 0.99 0.99 10.81 8.09 6.48 91 92 97
(C,C,C) 1.00 (1.00) 1.00 1.00 11.02 13.15 9.66 56 61 83
(C,C,−C) 1.00 (1.00) 1.00 1.00 15.66 13.46 10.97 56 62 82
Scenario I (contamination) with τ2 = 1 (heterogeneity) and si ∼ U(2, 5):
No outliers 0.08 (0.08) 0.08 0.07 4.23 5.28 3.77 77 87 82
C 0.81 (0.81) 0.64 0.60 27.07 20.71 14.06 98 98 100
(C,C) 0.98 (0.98) 0.96 0.95 44.75 44.94 30.35 90 90 97
(C,−C) 1.00 (1.00) 0.96 0.96 55.85 39.94 31.44 90 91 97
(C,C,C) 1.00 (1.00) 1.00 1.00 56.81 69.04 49.87 44 53 75
(C,C,−C) 1.00 (1.00) 1.00 1.00 81.37 68.52 55.13 45 54 74
RMSE: root mean squared error; CP: coverage probability of 95% confidence interval.
† Size (type I error rate) for homogeneous studies (τ2 = 0) and power for heterogeneous
studies (τ2 > 0) at the significance level α = 0.05.
‡ The sizes/powers outside the parentheses are produced by the resampling method; those
inside the parentheses are obtained using Q’s theoretical distribution under the null
hypothesis.
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Table A.3: Type I error rates and powers of three heterogeneity tests for the simulated
meta-analyses containing 30 studies with outliers in Scenario I.
Outlier pattern
Size/power† RMSE CP (%)
Q‡ Qr Qm τ̂2DL τ̂
2
r τ̂
2
m τ̂
2
DL τ̂
2
r τ̂
2
m
Scenario I (contamination) with τ2 = 0 (homogeneity) and si ∼ U(0.5, 1):
No outliers 0.05 (0.06) 0.05 0.05 0.10 0.12 0.10 98 99 99
C 0.55 (0.55) 0.27 0.25 0.37 0.24 0.20 97 97 98
(C,C) 0.89 (0.89) 0.66 0.60 0.63 0.42 0.35 88 90 94
(C,−C) 0.92 (0.92) 0.61 0.61 0.68 0.40 0.36 89 90 94
(C,C,C) 0.98 (0.98) 0.90 0.87 0.88 0.64 0.53 65 74 83
(C,C,−C) 0.99 (0.98) 0.89 0.88 0.99 0.61 0.55 64 73 83
Scenario I (contamination) with τ2 = 1 (heterogeneity) and si ∼ U(0.5, 1):
No outliers 0.98 (0.99) 0.98 0.98 0.40 0.43 0.41 88 93 91
C 1.00 (1.00) 1.00 1.00 0.84 0.63 0.55 97 97 98
(C,C) 1.00 (1.00) 1.00 1.00 1.37 1.00 0.85 93 94 96
(C,−C) 1.00 (1.00) 1.00 1.00 1.45 0.97 0.85 93 94 96
(C,C,C) 1.00 (1.00) 1.00 1.00 1.86 1.44 1.22 76 83 90
(C,C,−C) 1.00 (1.00) 1.00 1.00 2.05 1.40 1.25 77 84 91
Scenario I (contamination) with τ2 = 1 (heterogeneity) and si ∼ U(1, 2):
No outliers 0.48 (0.49) 0.42 0.43 0.74 0.81 0.75 89 93 91
C 0.89 (0.89) 0.78 0.77 1.97 1.36 1.17 98 97 98
(C,C) 0.99 (0.99) 0.94 0.94 3.33 2.29 1.93 91 92 96
(C,−C) 0.99 (0.99) 0.94 0.94 3.50 2.17 1.93 91 92 96
(C,C,C) 1.00 (1.00) 0.99 0.99 4.60 3.41 2.85 70 80 88
(C,C,−C) 1.00 (1.00) 0.99 0.99 5.03 3.24 2.90 71 81 88
Scenario I (contamination) with τ2 = 1 (heterogeneity) and si ∼ U(2, 5):
No outliers 0.11 (0.11) 0.09 0.09 2.32 2.64 2.25 88 92 91
C 0.70 (0.70) 0.43 0.41 9.89 5.96 5.02 97 97 99
(C,C) 0.96 (0.96) 0.81 0.78 17.19 10.92 8.97 90 91 94
(C,−C) 0.96 (0.96) 0.76 0.77 18.10 10.02 8.94 90 91 95
(C,C,C) 1.00 (1.00) 0.95 0.94 23.87 16.90 13.59 65 74 82
(C,C,−C) 1.00 (1.00) 0.95 0.95 26.10 15.49 13.78 64 74 83
RMSE: root mean squared error; CP: coverage probability of 95% confidence interval.
† Size (type I error rate) for homogeneous studies (τ2 = 0) and power for heterogeneous
studies (τ2 > 0) at the significance level α = 0.05.
‡ The sizes/powers outside the parentheses are produced by the resampling method;
those inside the parentheses are obtained using Q’s theoretical distribution under the
null hypothesis.
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Table A.4: Powers of three heterogeneity tests for the simulated meta-analyses con-
taining 30 studies with outliers in Scenario II.
Outlier pattern
Power RMSE CP (%)
Q‡ Qr Qm τ̂2DL τ̂
2
r τ̂
2
m τ̂
2
DL τ̂
2
r τ̂
2
m
Scenario II (heavy tail) with τ2 = 1 (heterogeneity) and si ∼ U(0.5, 1):
df = 3 0.92 (0.92) 0.89 0.88 1.45 0.59 0.56 72 79 73
df = 5 0.98 (0.98) 0.95 0.95 0.55 0.45 0.45 84 90 86
df = 10 0.98 (0.98) 0.97 0.97 0.43 0.43 0.42 88 93 90
Scenario II (heavy tail) with τ2 = 1 (heterogeneity) and si ∼ U(1, 2):
df = 3 0.41 (0.40) 0.35 0.35 1.53 0.88 0.82 83 90 87
df = 5 0.46 (0.46) 0.40 0.40 0.82 0.82 0.77 88 93 90
df = 10 0.48 (0.49) 0.42 0.42 0.76 0.82 0.77 88 94 90
Scenario II (heavy tail) with τ2 = 1 (heterogeneity) and si ∼ U(2, 5):
df = 3 0.10 (0.10) 0.10 0.10 2.66 2.71 2.33 88 92 91
df = 5 0.09 (0.09) 0.09 0.08 2.18 2.54 2.17 88 93 92
df = 10 0.10 (0.10) 0.08 0.09 2.18 2.48 2.12 88 93 91
RMSE: root mean squared error; CP: coverage probability of 95% confidence in-
terval.
‡ The sizes/powers outside the parentheses are produced by the resampling method;
those inside the parentheses are obtained using Q’s theoretical distribution under
the null hypothesis.
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Table A.5: The simulation results produced by Models M, H, M0, and U in various settings of within-study variances and
correlations under different missingness scenarios.
Model
Factor 1 Factor 2 Factor 3
Bias RMSE CP (%) Bias RMSE CP (%) Bias RMSE CP (%)
τ = 1, σ = 1, ρB = 0.5, ρW ∼ U(0.6, 0.9):
No missing data (I)
M 0.00 (0.00) 0.26 (0.26) 94 (94) 0.00 (0.00) 0.26 (0.26) 93 (92) 0.00 (0.00) 0.25 (0.25) 95 (94)
H 0.00 (0.00) 0.26 (0.26) 94 (95) 0.00 (0.00) 0.26 (0.26) 93 (95) 0.00 (0.00) 0.25 (0.25) 95 (96)
M0 0.00 (0.00) 0.26 (0.26) 95 (97) 0.00 (0.00) 0.26 (0.26) 94 (96) 0.00 (0.00) 0.25 (0.25) 96 (97)
U 0.00 (0.00) 0.26 (0.26) 94 (95) 0.00 (0.00) 0.26 (0.26) 94 (94) 0.00 (0.00) 0.25 (0.25) 95 (96)
Factors 1, 3, and 5 in 10 studies are missing completely at random (II)
M 0.00 (0.00) 0.30 (0.29) 93 (95) 0.00 (0.00) 0.26 (0.26) 94 (93) 0.00 (0.01) 0.30 (0.28) 93 (95)
H 0.00 (0.00) 0.31 (0.29) 92 (96) 0.00 (0.00) 0.26 (0.26) 93 (95) 0.00 (0.01) 0.30 (0.29) 92 (96)
M0 0.00 (0.00) 0.30 (0.29) 96 (97) 0.00 (0.00) 0.26 (0.26) 94 (95) 0.00 (0.01) 0.29 (0.28) 95 (98)
U −0.01 (0.00) 0.32 (0.32) 94 (95) 0.00 (0.00) 0.26 (0.26) 94 (94) −0.01 (0.02) 0.32 (0.31) 94 (96)
Factors 1, 3, and 5 in 10 studies are missing not at random (III)
M 0.46 (0.48) 0.54 (0.56) 51 (54) 0.00 (0.00) 0.26 (0.26) 94 (94) 0.46 (0.48) 0.54 (0.55) 48 (52)
H 0.49 (0.51) 0.57 (0.58) 43 (54) 0.00 (0.00) 0.26 (0.26) 94 (96) 0.48 (0.52) 0.56 (0.59) 41 (49)
M0 0.56 (0.58) 0.62 (0.64) 44 (53) 0.00 (0.00) 0.26 (0.26) 94 (95) 0.55 (0.61) 0.62 (0.67) 41 (46)
U 0.75 (0.75) 0.80 (0.80) 16 (19) 0.00 (0.00) 0.26 (0.26) 94 (94) 0.75 (0.75) 0.80 (0.80) 14 (18)
τ = 1, σ = 1, ρB = 0.5, ρW ∼ U(0, 0.3):
Factors 1, 3, and 5 in 10 studies are missing not at random (III)
M 0.68 (0.69) 0.74 (0.74) 23 (26) 0.01 (0.01) 0.26 (0.26) 94 (95) 0.68 (0.70) 0.73 (0.75) 22 (23)
H 0.67 (0.68) 0.73 (0.74) 21 (30) 0.01 (0.01) 0.26 (0.26) 94 (96) 0.67 (0.69) 0.73 (0.74) 21 (27)
M0 0.69 (0.71) 0.75 (0.76) 23 (26) 0.01 (0.01) 0.26 (0.26) 94 (95) 0.70 (0.72) 0.75 (0.77) 21 (24)
U 0.75 (0.75) 0.80 (0.80) 16 (19) 0.01 (0.01) 0.26 (0.26) 94 (95) 0.75 (0.75) 0.80 (0.80) 13 (16)
τ = 1, σ = 2, ρB = 0.5, ρW ∼ U(0.6, 0.9):
Factors 1, 3, and 5 in 10 studies are missing not at random (III)
M 0.58 (0.57) 0.74 (0.73) 70 (74) 0.01 (0.01) 0.42 (0.41) 96 (96) 0.59 (0.59) 0.74 (0.74) 71 (73)
H 0.60 (0.63) 0.76 (0.78) 66 (74) 0.01 (0.01) 0.42 (0.42) 96 (97) 0.61 (0.65) 0.76 (0.80) 65 (73)
M0 0.90 (0.96) 1.00 (1.05) 56 (62) 0.01 (0.01) 0.42 (0.42) 97 (97) 0.90 (1.01) 1.00 (1.10) 55 (57)
U 1.18 (1.18) 1.26 (1.26) 25 (29) 0.01 (0.01) 0.42 (0.42) 94 (96) 1.19 (1.19) 1.27 (1.27) 24 (28)
Factors 1, 3, and 5 in 25 studies are missing not at random (III′)
M 1.60 (1.57) 1.76 (1.72) 32 (76) −0.01 (0.01) 0.41 (0.42) 95 (95) 1.60 (1.58) 1.77 (1.73) 31 (75)
H 1.46 (2.36) 1.64 (2.75) 26 (65) −0.02 (0.01) 0.43 (0.42) 93 (96) 1.47 (2.45) 1.67 (2.73) 27 (65)
M0 2.92 (3.05) 2.99 (3.11) 4 (73) −0.01 (0.01) 0.41 (0.42) 96 (96) 2.95 (3.14) 3.02 (3.20) 3 (62)
U 3.19 (3.21) 3.26 (3.28) 1 (11) −0.01 (0.01) 0.41 (0.42) 94 (95) 3.21 (3.23) 3.27 (3.30) 1 (9)
The results outside parentheses are obtained using the REML method; those inside parentheses are obtained using the Bayesian
method. RMSE: root mean square error; CP: 95% CI/CrI coverage probability.
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Table A.6: Population-averaged absolute risks of the four treatments in the smoking
cessation network meta-analysis. They are obtained by the arm-based model, contrast-
based model using different reference treatments, and separate logit/probit random
effects models on each treatment.
Treatment
Population-averaged absolute risks (posterior mean with 95% credible intervals)
Contrast-based model Separate logit Separate probit Arm-based
Reference treatment (# of studies including this treatment) random effects random effects model (using
A (19) B (6) C (19) D (6) models models probit link)
A
0.078 0.110 0.093 0.098 0.075 0.072 0.083
(0.021, 0.194) (0.012, 0.378) (0.016, 0.280) (0.013, 0.325) (0.055, 0.104) (0.045, 0.108) (0.058, 0.117)
B
0.126 0.156 0.144 0.147 0.174 0.182 0.170
(0.027, 0.334) (0.024, 0.456) (0.023, 0.422) (0.020, 0.454) (0.084, 0.352) (0.069, 0.384) (0.086, 0.304)
C
0.162 0.207 0.180 0.188 0.175 0.173 0.185
(0.044, 0.379) (0.028, 0.587) (0.039, 0.455) (0.029, 0.525) (0.128, 0.241) (0.118, 0.245) (0.135, 0.248)
D
0.203 0.248 0.225 0.220 0.231 0.244 0.233
(0.048, 0.491) (0.034, 0.665) (0.042, 0.574) (0.046, 0.540) (0.125, 0.403) (0.106, 0.450) (0.127, 0.382)
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Table A.7: An example for treatment exclusion in network meta-analysis.
Full network Usable data
Study Treatment (no. of events / Remove Treatment 1 Remove Treatment 2 Remove Treatment 3
ID ID no. of Arm- Contrast- Arm- Contrast- Arm- Contrast-
participants) based based based based based based
A 1 yA1/nA1 – – yA1/nA1 – yA1/nA1 yA1/nA1
A 2 yA2/nA2 yA2/nA2 – – – yA2/nA2 yA2/nA2
B 1 yB1/nB1 – – yB1/nB1 – yB1/nB1 yB1/nB1
B 2 yB2/nB2 yB2/nB2 – – – yB2/nB2 yB2/nB2
C 1 yC1/nC1 – – yC1/nC1 – yC1/nC1 yC1/nC1
C 2 yC2/nC2 yC2/nC2 – – – yC2/nC2 yC2/nC2
D 2 yD2/nD2 yD2/nD2 yD2/nD2 – – yD2/nD2 –
D 3 yD3/nD3 yD3/nD3 yD3/nD3 yD3/nD3 – – –
E 1 yE1/nE1 – – yE1/nE1 yE1/nE1 yE1/nE1 –
E 3 yE3/nE3 yE3/nE3 – yE3/nE3 yE3/nE3 – –
F 1 yF1/nF1 – – yF1/nF1 yF1/nF1 yF1/nF1 yF1/nF1
F 2 yF2/nF2 yF2/nF2 yF2/nF2 – – yF2/nF2 yF2/nF2
F 3 yF3/nF3 yF3/nF3 yF3/nF3 yF3/nF3 yF3/nF3 – –
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Table A.8: Biases (outside brackets), mean squared errors (inside parenthe-
ses), and 95% credible interval coverage probabilities (%, inside square brack-
ets) of the estimated relative effects produced by the Smith model (pairwise
meta-analysis) and the Lu–Ades model (network meta-analysis) in simula-
tions. The data were simulated assuming that treatment effects were homo-
geneous across studies.
Network Treatment Network meta-analysis Pairwise meta-analysis
shape contrast FE RE1 RE2 FE RE1 RE2
Shape 1 d12 −0.01 −0.01 0.00 0.00 −0.01 0.00
(0.10) (0.11) (0.10) (0.10) (0.11) (0.10)
[96] [100] [98] [96] [100] [98]
d15 0.00 0.00 0.00 0.00 0.00 0.00
(0.02) (0.02) (0.02) (0.02) (0.02) (0.02)
[95] [98] [97] [95] [98] [97]
d23 0.01 0.01 0.00 0.00 0.01 0.00
(0.15) (0.16) (0.15) (0.15) (0.16) (0.15)
[96] [100] [97] [96] [100] [97]
d45 −0.01 −0.01 −0.01 −0.01 −0.01 −0.01
(0.06) (0.06) (0.06) (0.06) (0.06) (0.06)
[94] [98] [97] [94] [98] [97]
Shape 2 d12 0.01 0.00 0.00 0.00 −0.01 0.00
(0.10) (0.11) (0.10) (0.10) (0.11) (0.10)
[97] [100] [98] [96] [100] [98]
d13 0.02 0.00 0.00 0.00 −0.01 0.00
(0.14) (0.15) (0.14) (0.14) (0.15) (0.14)
[96] [100] [97] [96] [100] [97]
d15 0.02 0.00 0.01 0.00 0.00 0.01
(0.19) (0.20) (0.19) (0.19) (0.20) (0.19)
[97] [100] [97] [96] [100] [98]
d45 0.00 0.00 0.00 0.00 0.00 0.00
(0.02) (0.02) (0.02) (0.02) (0.02) (0.02)
[94] [98] [96] [94] [98] [97]
Shape 3 d12 0.00 0.00 0.01 0.00 −0.01 0.00
(0.10) (0.11) (0.10) (0.10) (0.11) (0.10)
[97] [100] [98] [96] [100] [98]
d13 0.01 0.00 0.01 0.00 −0.01 0.00
(0.14) (0.15) (0.14) (0.14) (0.15) (0.14)
[96] [100] [97] [96] [100] [98]
d15 0.01 0.00 0.01 0.00 0.00 0.01
(0.13) (0.15) (0.14) (0.13) (0.14) (0.14)
[96] [99] [96] [96] [100] [97]
d45 0.00 0.00 0.00 0.00 0.00 0.00
(0.02) (0.02) (0.02) (0.02) (0.02) (0.02)
[94] [98] [97] [94] [98] [96]
FE: fixed-effects model; RE1: random-effects model with different hetero-
geneity variances for different treatment contrasts; RE2: random-effects
model with a common heterogeneity variance.
dhk: treatment k compared to h.
Monte Carlo standard errors of all biases, mean squared errors, and cov-
erage probabilities are less than 0.02, 0.01, and 2%, respectively.
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Table A.9: Biases (outside brackets), mean squared errors (inside parentheses),
and 95% credible interval coverage probabilities (%, inside square brackets) of the
estimated relative effects produced by the Smith model (pairwise meta-analysis)
and the Lu–Ades model (network meta-analysis) in simulations. The data were
simulated using a common heterogeneity standard deviation for all treatments.
Network Treatment Network meta-analysis Pairwise meta-analysis
shape contrast FE RE1 RE2 FE RE1 RE2
Shape 1 d12 −0.01a 0.01a 0.01a 0.00a 0.01a 0.01a
(0.76e) (0.55d) (0.54d) (0.76e) (0.55d) (0.54d)
[54] [98] [95] [54] [98] [95]
d15 0.02 0.01 0.01 0.02 0.01 0.01
(0.24) (0.12) (0.12) (0.24) (0.12) (0.12)
[48] [96] [96] [48] [96] [96]
d23 −0.02b −0.02a −0.02a −0.02b −0.02a −0.02a
(1.18f) (0.80e) (0.79e) (1.18f) (0.80e) (0.79e)
[53] [99] [95] [53] [98] [95]
d45 0.01
a 0.00 0.00 0.01a 0.00 0.00
(0.52d) (0.27) (0.27) (0.52d) (0.27) (0.27)
[50] [97] [96] [50] [97] [96]
Shape 2 d12 0.01
a 0.00a 0.01a 0.00a 0.01a 0.01a
(0.76e) (0.55d) (0.54d) (0.76e) (0.55d) (0.54d)
[55] [98] [95] [54] [98] [95]
d13 0.02
b 0.00a 0.02a −0.01b 0.01a 0.01a
(1.15f) (0.83e) (0.82e) (1.15f) (0.83e) (0.82e)
[52] [98] [95] [50] [98] [95]
d15 0.02
c −0.01b 0.00b −0.01c 0.00b 0.00b
(1.66f) (1.17f) (1.17f) (1.66f) (1.17f) (1.16f)
[50] [98] [95] [49] [98] [95]
d45 −0.01 −0.03 −0.03 −0.01 −0.03 −0.03
(0.23) (0.12) (0.12) (0.23) (0.12) (0.12)
[47] [95] [95] [46] [95] [95]
Shape 3 d12 0.00
a 0.00a 0.01a 0.00a 0.01a 0.01a
(0.76e) (0.55d) (0.54d) (0.76e) (0.55d) (0.54d)
[55] [98] [95] [54] [98] [95]
d13 0.00
b 0.01a 0.02a −0.01b 0.01a 0.01a
(1.15f) (0.83e) (0.82e) (1.15f) (0.83e) (0.82e)
[51] [98] [94] [50] [98] [94]
d15 0.03
b 0.02a 0.03a 0.02b 0.02a 0.03a
(1.02e) (0.69e) (0.69e) (1.02e) (0.69e) (0.68e)
[54] [98] [95] [54] [98] [94]
d45 −0.01 −0.03 −0.03 −0.01 −0.03 −0.03
(0.23) (0.12) (0.12) (0.23) (0.12) (0.12)
[47] [95] [95] [46] [95] [95]
FE: fixed-effects model; RE1: random-effects model with different heterogeneity
variances for different treatment contrasts; RE2: random-effects model with a
common heterogeneity variance.
dhk: treatment k compared to h.
Monte Carlo standard error of bias: a, 0.02–0.03; b, 0.03–0.04; c, 0.04–0.05;
otherwise, less than 0.02. Monte Carlo standard error of mean squared error:
d, 0.02–0.03; e, 0.03–0.05; f, 0.05–0.08; otherwise, less than 0.02. Monte Carlo
standard errors of all coverage probabilities are less than 2%.
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Table A.10: The effects of four treatments for non-acute coronary artery disease.
Study Treatment ID Study Treatment ID
ID 1 2 3 4 ID 1 2 3 4
1 7/107 5/105 33 0/60 0/60
2 1/44 0/44 34 0/66 0/31
3 6/72 6/72 35 0/48 0/48
4 10/50 9/51 36 4/189 1/192
5 15/112 16/115 37 1/182 1/169
6 43/514 43/504 38 1/71 1/74
7 22/105 6/96 39 0/143 0/145
8 1/34 2/32 40 0/195 4/393
9 84/1084 87/1082 41 0/106 1/96
10 0/51 0/50 42 10/111 0/110
11 95/1138 85/1148 43 1/100 1/100
12 8/257 15/259 44 1/22 0/23
13 3/202 3/205 45 1/122 0/124
14 0/59 0/58 46 1/26 0/24
15 0/42 0/42 47 0/58 1/117
16 10/60 4/60 48 0/38 1/152
17 4/410 4/413 49 5/519 5/522
18 2/176 2/178 50 0/30 0/31
19 1/59 0/57 51 0/134 0/135
20 3/54 6/56 52 2/136 0/131
21 1/30 0/30 53 8/652 9/662
22 14/796 4/794 54 8/576 7/569
23 5/223 6/229 55 2/227 0/219
24 1/208 3/202 56 1/10 0/20
25 0/55 0/55 57 4/525 7/533
26 0/43 1/42 58 5/118 9/120
27 3/365 3/370 59 1/177 2/175
28 4/322 5/286 60 0/50 0/50
29 3/200 2/204 61 5/250 7/250
30 0/196 0/192 62 1/159 1/163
31 3/146 0/154 63 1/100 0/100
32 0/126 3/125
The outcome is death due to non-acute coronary artery disease.
Each entry shows (number of deaths)/(total number of patients).
Blank entries represent treatments that were not investigated in the correspond-
ing studies.
Treatment IDs: (1) medical therapy; (2) percutaneous transluminal balloon coro-
nary angioplasty; (3) bare-metal stents; and (4) drug-eluting stents.
Appendix B
Proofs of Propositions and
Theorems
B.1 Asymptotic values of heterogeneity measures
The proofs will frequently use the property about the mean of folded normal distribution:
if X ∼ N(µ, σ2), then E|X| = σ
√
2
pie
−µ2/(2σ2) + µ(1 − 2Φ(−µ/σ)), where Φ(·) is the
cumulative density function of standard normal distribution. Let bxc be the largest
integer less than or equal to x.
Proof of Proposition 1. Note that µ¯ =
∑n
i=1 wiyi/n∑n
i=1 wi/n
P−→ E[w1y1]E[w1] = µ, we have
Q/n =
1
n
n∑
i=1
wi[(yi − µ)− (µ¯− µ)]2
=
1
n
n∑
i=1
wi(yi − µ)2 − 2(µ¯− µ) · 1
n
n∑
i=1
wi(yi − µ) + (µ¯− µ)2 · 1
n
n∑
i=1
wi
P−→ E[w1(y1 − µ)2] = 1.
Therefore, I2 = 1− 1Q/(n−1)
P−→ 0.
For Qr, applying the triangle inequality |x| − |y| ≤ |x− y|, we have
√
wi|yi − µ¯| − √wi|yi − µ| ≤ √wi|µ¯− µ|;
√
wi|yi − µ| − √wi|yi − µ¯| ≤ √wi|µ¯− µ|.
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Averaging each of the above two inequalities for i = 1, . . . , n, we have∣∣∣∣∣Qr/n− 1n
n∑
i=1
√
wi|yi − µ|
∣∣∣∣∣ ≤ |µ¯− µ| · 1n
n∑
i=1
√
wi
P−→ 0.
Furthermore,
1
n
n∑
i=1
√
wi|yi − µ| P−→ E[|√w1(y1 − µ)|] =
√
2/pi.
Therefore, Qr/n
P−→√2/pi, and I2r = 1− n−1n · 2/pi(Qr/n)2 P−→ 0.
For Qm, by the theory of M-estimation [73], the weighted median µ̂m
P−→ µ. Simi-
larly applying the triangle inequality, we have∣∣∣∣∣Qm/n− 1n
n∑
i=1
√
wi|yi − µ|
∣∣∣∣∣ ≤ |µ̂m − µ| · 1n
n∑
i=1
√
wi
P−→ 0.
Hence, Qm/n
P−→ E[|√w1(y1 − µ)|] =
√
2/pi and I2m = 1− 2/pi(Qm/n)2
P−→ 0.
Proof of Proposition 2. Now, the weights wi have a common value w = 1/σ
2. Under
the random-effects setting, the weighted average and weighted median still converge to
the true overall effect size µ in probability. Similarly to the derivations in Proposition 1,
Q/n
P−→ E[w(y1 − µ)2] = (σ2 + τ2)/σ2; both Qr/n and Qm/n converge to E[|
√
w(y1 −
µ)|] =
√
2
pi
√
(σ2 + τ2)/σ2. Hence, I2 = 1− 1Q/(n−1)
P−→ I20 , I2r = 1− n−1n · 2/pi(Qr/n)2
P−→ I20 ,
and I2m = 1− 2/pi(Q2m/n)2
P
P−→ I20 , where I20 = τ2/(σ2 + τ2).
Proof of Proposition 3. Without loss of generality, let yi = zi + C for i = 1, . . . , bnηc
and yi = zi for i = bnηc + 1, . . . , n, where zi iid∼ N(µ, σ2 + τ2). Denote the weights
wi = w = 1/σ
2.
Note that µ¯ =
∑n
i=1 yi
n =
bnηc
n ·
∑bnηc
i=1 (zi+C)
bnηc +
n−bnηc
n ·
∑n
i=n−bnηc+1 zi
n−bnηc
P−→ η(µ + C) +
(1− η)µ = µ+ ηC. Therefore,
Q/n =
w
n
n∑
i=1
[(yi − µ− ηC)− (µ¯− µ− ηC)]2
=
w
n
n∑
i=1
(yi − µ− ηC)2 − 2w(µ¯− µ− ηC) · 1
n
n∑
i=1
(yi − µ− ηC) + w(µ¯− µ− ηC)2.
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The last two terms on the right hand side converge to 0 in probability. For the first
term, note that
w
n
n∑
i=1
(yi − µ− ηC)2
= w
bnηc
n
·
∑bnηc
i=1 (zi − µ+ (1− η)C)2
bnηc + w
n− bnηc
n
·
∑n
i=n−bnηc+1(zi − µ− ηC)2
n− bnηc .
It converges in probability to wηE[(z1 − µ+ (1− η)C)2] +w(1− η)E[(z1 − µ− ηC)2] =
η[σ2+τ2+(1−η)2C2]/σ2+(1−η)(σ2+τ2+η2C2)/σ2 = (σ2+τ2)/σ2+η(1−η)C2/σ2 =
(1− I20 )−1 +r1r2, where I20 = τ2/(σ2 + τ2), r1 = (1−η)C/σ, and r2 = ηC/σ. Therefore,
Q/n
P−→ (1− I20 )−1 + r1r2,
and
I2 = 1− 1
Q/(n− 1)
P−→ 1− [(1− I20 )−1 + r1r2]−1.
To derive the asymptotic value of I2r , we apply the triangle inequality again as in
the proof of Proposition 1, and obtain∣∣∣∣∣Qr/n−
√
w
n
n∑
i=1
|yi − µ− ηC|
∣∣∣∣∣ ≤ √w|µ¯− µ− ηC| P−→ 0.
Note that
√
w
n
n∑
i=1
|yi − µ− ηC|
=
√
w
bnηc
n
·
∑bnηc
i=1 |zi − µ+ (1− η)C|
bnηc +
√
w
n− bnηc
n
·
∑n
i=n−bnηc+1 |zi − µ− ηC|
n− bnηc
P−→ √wηE[|z1 − µ+ (1− η)C|] +
√
w(1− η)E[|z1 − µ− ηC|]
=
η
σ
[√
σ2 + τ2
√
2
pi
exp
(
−(1− η)
2C2
2(σ2 + τ2)
)
+ (1− η)C
(
1− 2Φ
(
− (1− η)C√
σ2 + τ2
))]
+
1− η
σ
[√
σ2 + τ2
√
2
pi
exp
(
− η
2C2
2(σ2 + τ2)
)
− ηC
(
1− 2Φ
(
ηC√
σ2 + τ2
))]
= η
[√
2
pi
(1− I20 )−1/2 exp
(
−1
2
r21(1− I20 )
)
+ r1
(
1− 2Φ
(
−r1(1− I20 )1/2
))]
+ (1− η)
[√
2
pi
(1− I20 )−1/2 exp
(
−1
2
r22(1− I20 )
)
− r2
(
1− 2Φ
(
r2(1− I20 )1/2
))]
.
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Therefore, Qr/n also converges to the value above in probability, and
I2r = 1−
n− 1
n
· 2/pi
(Qr/n)2
P−→ 1−
{
η
[
(1− I20 )−1/2 exp
(
−1
2
r21(1− I20 )
)
+
√
pi
2
r1
(
1− 2Φ
(
−r1(1− I20 )1/2
))]
+ (1− η)
[
(1− I20 )−1/2 exp
(
−1
2
r22(1− I20 )
)
−
√
pi
2
r2
(
1− 2Φ
(
r2(1− I20 )1/2
))]}−2
.
Finally, we derive the asymptotic value of I2m. The weighted median µ̂m is defined as
the solution to
∑n
i=1 ψ(θ) = 0, where ψ(θ) = w[I(θ ≥ yi)− 0.5]. Equivalently, µ̂m is the
solution to
∑n
i=1 ψ˜(θ) = 0, where ψ˜(θ) = I(θ ≥ yi)− 0.5 as we assume that the weights
are equal. By the theory of M-estimation [73], µ̂m
P−→ µ0, where µ0 is the solution to
E[ψ˜(θ)] = 0. Specifically,
E[ψ˜(θ)] = Pr(θ ≥ yi)− 0.5
= Pr(θ ≥ yi, 1 ≤ i ≤ bnηc) + Pr(θ ≥ yi, bnηc+ 1 ≤ i ≤ n)− 0.5
= ηPr(zi ≤ θ − C) + (1− η) Pr(zi ≤ θ)− 0.5
= ηΦ
(
θ − µ− C√
σ2 + τ2
)
+ (1− η)Φ
(
θ − µ√
σ2 + τ2
)
− 0.5.
Therefore, µ0 satisfied the following equation:
ηΦ
(
−µ+ C − µ0√
σ2 + τ2
)
+ (1− η)Φ
(
µ0 − µ√
σ2 + τ2
)
= 0.5. (B.1)
Applying the triangle inequality as in the proof of Proposition 1, we have∣∣∣∣∣Qm/n−
√
w
n
n∑
i=1
|yi − µ0|
∣∣∣∣∣ ≤ √w|µ̂m − µ0| P−→ 0.
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Note that
√
w
n
n∑
i=1
|yi − µ0|
=
√
w
bnηc
n
·
∑bnηc
i=1 |zi − µ0 + C|
bnηc +
√
w
n− bnηc
n
·
∑n
i=n−bnηc+1 |zi − µ0|
n− bnηc
P−→ √wηE[|z1 − µ0 + C|] +
√
w(1− η)E[|z1 − µ0|]
=
η
σ
[√
σ2 + τ2
√
2
pi
exp
(
− (µ− µ0 + C)
2
2(σ2 + τ2)
)
+ (µ− µ0 + C)
(
1− 2Φ
(
−µ− µ0 + C√
σ2 + τ2
))]
+
1− η
σ
[√
σ2 + τ2
√
2
pi
exp
(
− (µ− µ0)
2
2(σ2 + τ2)
)
+ (µ− µ0)
(
1− 2Φ
(
− µ− µ0√
σ2 + τ2
))]
= η
[√
2
pi
(1− I20 )−1/2 exp
(
−1
2
s21(1− I20 )
)
+ s1
(
1− 2Φ
(
−s1(1− I20 )1/2
))]
+ (1− η)
[√
2
pi
(1− I20 )−1/2 exp
(
−1
2
s22(1− I20 )
)
− s2
(
1− 2Φ
(
s2(1− I20 )1/2
))]
,
where s1 = (µ+ C − µ0)/σ and s2 = (µ0 − µ)/σ. Therefore,
I2m = 1−
2/pi
(Qm/n)2
P−→ 1−
{
η
[
(1− I20 )−1/2 exp
(
−1
2
s21(1− I20 )
)
+
√
pi
2
s1
(
1− 2Φ
(
−s1(1− I20 )1/2
))]
+ (1− η)
[
(1− I20 )−1/2 exp
(
−1
2
s22(1− I20 )
)
−
√
pi
2
s2
(
1− 2Φ
(
s2(1− I20 )1/2
))]}−2
.
Notice that s2 = C/σ − s1 and Equation (B.1) can be rewritten as
ηΦ
(
−s1(1− I20 )1/2
)
+ (1− η)Φ
(
(C/σ − s1)(1− I20 )1/2
)
= 0.5; (B.2)
that is, s1 is the solution to Equation (B.2). This completes the proof.
B.2 Asymptotic distribution of the publication bias mea-
sure TS
Let X1, . . . , Xn be iid random variables and denote the kth central moment βk =
E(X1 − β)k, where β = E(X1). Also, denote the sample kth central moment mk =
n−1
∑n
i=1(Xi − X¯)k, where X¯ = n−1
∑n
i=1Xi. We have the following lemma regarding
the asymptotic distribution of the sample kth central moment.
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Lemma 1. If X1, . . . , Xn are iid with mean β and β2k <∞ for k ≥ 1, then
mk − βk = 1
n
n∑
i=1
[
(Xi − β)k − βk − kβk−1(Xi − β)
]
+ op(n
−1/2).
as n→∞.
Proof of Lemma 1. See page 72 in [181].
Now, let us back to the notation in the main text. Specifically, let xi = (s
2
i +τ
2)−1/2
and zi = yi(s
2
i + τ
2)−1/2. The regression test is zi = α + µxi + i, where i’s are iid
following a distribution with mean zero; α̂ and µ̂ are the least squares estimates of
α and µ respectively, and the residuals ̂i = yi − µ̂xi − α̂. Also, βk = E(1 − β)k is
the kth central moment of i’s, where β = E(1) = 0, and mk = n
−1∑n
i=1(i − ¯)k.
The true skewness of i’s is γ = β3/β
3/2
2 . Let m̂k = n
−1∑n
i=1(̂i − ¯̂)k be the sample
kth central moment by plugging in the residuals ̂i, where ¯̂ = n
−1∑n
i=1 ̂i = 0. The
sample skewness of  = (1, . . . , n)
T is Skew() = m3/s
3, where s =
√
nm2/(n− 1),
and TS = Skew(̂) is obtained by plugging ̂ = (̂1, . . . , ̂n)
T in Skew().
Proof of Proposition 4. First, we show that
√
n(Skew() − γ) D−→ N(0, v) as n → ∞,
where
v = 9 +
35
4
β−32 β
2
3 − 6β−22 β4 + β−32 β6 +
9
4
β−52 β
2
3β4 − 3β−42 β3β5.
Because Skew() = [(n−1)/n]3/2m3/m3/22 , Skew() have the same asymptotic distribu-
tion as m3/m
3/2
2 . By Lemma 1, we have[
m2
m3
]
−
[
β2
β3
]
=
1
n
n∑
i=1
[
2i − β2
3i − β3 − 3β2i
]
+ op(n
−1/2).
Therefore,
√
n
([
m2
m3
]
−
[
β2
β3
])
D−→ N
([
0
0
]
,
[
β4 − β22 β5 − 4β2β3
β5 − 4β2β3 β6 − β23 − 6β2β4 + 9β32
])
.
Denote the asymptotic covariance matrix above as Σ. Let g(r, s) = s/r3/2, then
g′(r, s) =
(−32sr−5/2, r−3/2)T. By the delta method,
√
n(g(m2,m3)− g(β2, β3)) D−→ N(0, [g′(β2, β3)]TΣ[g′(β2, β3)]);
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that is, √
n(Skew()− γ) D−→ N (0, v) .
Second, we show that
√
n(TS − Skew()) D−→ 0 as n → ∞. We write Skew() =
[(n − 1)/n]3/2f(δ), where f(δ) = m3/m3/22 is a continuous and differentiable function
of δ = (δ1, δ2, δ3, δ4, δ5)
T = (¯2, ¯3, ¯ · 2, 2, 3)T; here, k = n−1∑ni=1 ki . Specifically,
f(δ) = (δ5 − 3δ3 + 2δ2)(δ4 − δ1)−3/2; it is free of n. Also, TS = Skew(̂) = [(n −
1)/n]3/2f(δ̂), where δ̂ =
((
¯̂
)2
,
(
¯̂
)3
, ¯̂ · ̂2, ̂2, ̂3
)T
, and ̂k = n−1
∑n
i=1 ̂
k
i . Because the
average of the residuals is ¯̂ = 0, we have δ̂ =
(
0, 0, 0, ̂2, ̂3
)T
. By multivariate Taylor
expansion,
f(δ̂) = f(δ) + [h(δ)]T(δ̂ − δ) +Op(‖δ̂ − δ‖2),
where h(δ) = 5f(δ) is the gradient of f(δ) and ‖·‖ is the Euclidean norm. Specifically,
h(δ) =

h1(δ)
h2(δ)
h3(δ)
h4(δ)
h5(δ)

=

3
2(δ5 − 3δ3 + 2δ2)(δ4 − δ1)−5/2
2(δ4 − δ1)3/2
−3(δ4 − δ1)3/2
−32(δ5 − 3δ3 + 2δ2)(δ4 − δ1)−5/2
(δ4 − δ1)3/2

.
Since δ1, δ2, δ3
P−→ 0, δ4 P−→ β2 > 0, and δ5 P−→ β3, we have hj(δ) = Op(1) for
j = 1, . . . , 5. Now, we focus on
δ̂ − δ =
(
−¯2,−¯3,−¯ · 2, ̂2 − 2, ̂3 − 3
)T
.
Due to ¯ = Op(n
−1/2), we have δ̂1 − δ1 = −¯2 = Op(n−1), δ̂2 − δ2 = −¯3 = Op(n−3/2),
and δ̂3 − δ3 = −¯ · 2 = Op(n−1/2). Note that
̂i = (α− α̂) + (µ− µ̂)xi + i,
and α̂−α = Op(n−1/2), µ̂−µ = Op(n−1/2). Also, by the assumption that xi’s have finite
third moment and the weak law of large numbers, 1n
∑n
i=1 x
k
i = Op(1) for k = 1, 2, 3.
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Consequently, we have
δ̂4 − δ4 = ̂2 − 2
=
1
n
n∑
i=1
[(α− α̂) + (µ− µ̂)xi + i]2 − 1
n
n∑
i=1
2i
= (α− α̂)2 + (µ− µ̂)2
∑n
i=1 x
2
i
n
+ 2(α− α̂)(µ− µ̂)
∑n
i=1 xi
n
+ 2(α− α̂)¯+ 2(µ− µ̂)
∑n
i=1 xii
n
= Op(n
−1),
and
δ̂5 − δ5 = ̂3 − 3
=
1
n
n∑
i=1
[(α− α̂) + (µ− µ̂)xi + i]3 − 1
n
n∑
i=1
3i
= (α− α̂)3 + (µ− µ̂)3
∑n
i=1 x
3
i
n
+ 3(α− α̂)2(µ− µ̂)
∑n
i=1 xi
n
+ 3(α− α̂)(µ− µ̂)2
∑n
i=1 x
2
i
n
+ 3(α− α̂)2¯+ 3(µ− µ̂)2
∑n
i=1 x
2
i i
n
+ 6(α− α̂)(µ− µ̂)
∑n
i=1 xii
n
+ 3(α− α̂)2 + 3(µ− µ̂)
∑n
i=1 xi
2
i
n
= 3(α− α̂)2 + 3(µ− µ̂)
∑n
i=1 xi
2
i
n
+Op(n
−1)
= Op(n
−1/2).
Therefore, Op(‖δ̂ − δ‖2) = Op(n−1), implying
f(δ̂)− f(δ) = [h(δ)]T(δ̂ − δ) +Op(n−1)
=
5∑
j=1
hj(δ)(δ̂j − δj) +Op(n−1)
= h3(δ)(δ̂3 − δ3) + h5(δ)(δ̂5 − δ5) +Op(n−1)
= 3(δ4 − δ1)3/2 · ¯ · 2 + (δ4 − δ1)3/2
[
3(α− α̂)2 + 3(µ− µ̂)
∑n
i=1 xi
2
i
n
]
+Op(n
−1)
= 3(δ4 − δ1)3/2
{
[(α− α̂) + ¯] 2 + (µ− µ̂)
∑n
i=1 xi
2
i
n
}
+Op(n
−1)
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Note that
∑n
i=1 ̂i = 0, so (α− α̂) + ¯ = (µ̂− µ)
∑n
i=1 xi
n . Consequently,
f(δ̂)− f(δ) = 3(δ4 − δ1)3/2
{
(µ̂− µ)
∑n
i=1 xi
n
2 − (µ̂− µ)
∑n
i=1 xi
2
i
n
}
+Op(n
−1)
= 3(δ4 − δ1)3/2(µ̂− µ)
{∑n
i=1 xi
n
2 −
∑n
i=1 xi
2
i
n
}
+Op(n
−1)
= Op(n
−1/2)
{
[E(x1) +Op(n
−1/2)][β2 +Op(n−1/2)]
− [E(x121) +Op(n−1/2)]
}
+Op(n
−1)
= Op(n
−1/2)
{
[E(x1)β2 +Op(n
−1/2)]− [E(x1)β2 +Op(n−1/2)]
}
+Op(n
−1)
= Op(n
−1).
This leads to
√
n(f(δ̂)−f(δ)) D−→ 0; hence,√n(TS−Skew()) D−→ 0, and
√
n(TS−γ) D−→
N(0, v).
Finally, we show that v̂
P−→ v. By continuous mapping theorem, it is sufficient to
show that m̂k
P−→ βk for k = 2, . . . , 6. Recall that βk = E(k1) and m̂k = n−1
∑n
i=1 ̂
k
i .
Since ̂i = (α − α̂) + (µ − µ̂)xi + i = i + Op(n−1/2), we have m̂k = n−1
∑n
i=1(i +
Op(n
−1/2))k = n−1
∑n
i=1 
k
i + op(1) = βk + op(1); that is, m̂k
P−→ βk. By Slutsky’s
theorem,
√
n(TS − γ)/
√
v̂
D−→ N(0, 1); this completes the proof.
Proof of Corollary 1. Under H ′′0 , we have i ∼ N(0, σ2), so β2k = (2k − 1)!!σ2k and
β2k−1 = 0 for k ≥ 1. Here, c!! = c · (c−2) · (c−4) · · · is the double factorial. Specifically,
β2 = σ
2, β4 = 3σ
4, and β6 = 15σ
6. In the proof of Proposition 1, we showed that
√
n(TS − γ) D−→ N(0, v). Under H ′′0 , v is simplified as v = 9− 6(σ2)−2 · 3σ4 + (σ2)−3 ·
15σ6 = 6. This completes the proof.
B.3 Properties of pairwise and network meta-analyses
Proof of Proposition 6. For simplicity, let P = (K − 2)(K − 1)/2, the dimension of ef,
so A is P × (K− 1). First, if there are two distinct transformation matrices A1 and A2
such that ef = A1eb and ef = A2eb, then (A1 −A2)eb = 0. Let A1 = (a11, . . . ,a1P )T
and A2 = (a21, . . . ,a2P )
T. Since A1 6= A2, there is at least one k = 1, . . . , P such that
a1k 6= a2k. Consequently, (a1k − a2k)Teb = 0; this implies evidence cycles in eb and
contradicts the definition of basic parameters.
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Second, to investigate the entries of A = (a1, . . . ,aP )
T, consider the pth indirect
treatment contrast in ef (p = 1, . . . , P ), denoted as dhk (h < k); it corresponds to the
vector ap = (ap1, . . . , ap,K−1)T in A. Due to the network’s connectivity, treatments h
and k must be linked through a certain path; the argument in the above paragraph
implies that the path is unique. Suppose that this unique path contains M + 1 vertices
(M ≥ 2), say `0 = h, `1, . . . , `M−1, `M = k. Consequently, iteratively using the evidence
consistency equation, the indirect treatment contrast dhk can be obtained from M direct
treatment contrasts; that is, dhk = d`0`1 + d`1`2 + · · · + d`M−1`M . Recall that eb =
(e1, . . . , eK−1)T contains all direct treatment contrasts. For each i = 1, . . . ,M , there is
some eji (ji = 1, . . . ,K − 1) such that d`i−1`i = xieji , where xi = 1 if `i−1 < `i and
xi = −1 if `i−1 > `i. Consequently, we can write dhk =
∑M
i=1 xieji . On the other hand,
dhk = a
T
peb =
∑K−1
j=1 apjej . Therefore, if j /∈ {j1, . . . , jM}, apj = 0; if j = ji for some i,
apj = xi. This completes the proof.
Proof of Theorem 2. Both the Lu–Ades and Smith models use the evidence consistency
equation (i.e., ef = Aeb) to impute the indirect treatment contrasts, so the posterior
distributions of ef produced by the two models are entirely determined by eb. Since
Theorem 1 showed that the two models produce identical posterior distributions of eb,
the posterior distributions of ef must also be identical. Furthermore, we make regularity
assumptions that ϕf(t) and p(ef | D) are in LP space. Given ef’s characteristic function
ϕf(t), its posterior distribution is
p(ef | D) = 1
(2pi)P
∫
RP
e−it
Tefϕf(t) dt;
see Equation (10.6.3) in [182]. Note that
ϕf(t) = E
(
eit
Tef | D
)
= E
(
eit
TAeb | D
)
= E
(
ei(A
Tt)Teb | D
)
= ϕb(A
Tt).
Since p(eb | D) =
∏K−1
j=1 p(ej | Dj), for s = (s1, . . . , sK−1)T, we have
ϕb(s) = E
(
eis
Teb | D
)
= E
(
ei
∑K−1
j=1 sjej | D
)
=
K−1∏
j=1
E
(
eisjej | D) = K−1∏
j=1
∫
R
eisjejp(ej | Dj) dej .
This completes the proof.
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Proof of Theorem 3. We retain the notation µ˜j , yj , ξj (j = 1, . . . ,K − 1), µ, y, and ξ
defined in the proof of Theorem 1 for treatment networks without evidence cycles; how-
ever, now σ is a scalar, not a vector, representing the common heterogeneity standard
deviation of all treatment contrasts. Consequently, under the assumption of equal het-
erogeneity standard deviations, the Lu–Ades random-effects model gives the posterior
distribution of eb as:
pLA(eb | D) =
∫∫
p(eb, σ,µ | D) dσ dµ
∝
∫∫
f(y | eb, σ,µ, ξ)p(eb)p(σ)p(µ) dσ dµ
=
∫∫ 
K−1∏
j=1
f(yj | ej , σ, µ˜j , ξj)p(ej)p(µ˜j)
 p(σ) dµ dσ
=
∫ 
K−1∏
j=1
∫
f(yj | ej , σ, µ˜j , ξj)p(ej)p(µ˜j) dµ˜j
 p(σ) dσ.
Like the proof of Theorem 1, the first two steps above are consequences of the properties
of conditional probability and the likelihood of the outcome measure y; these are also
valid for the Smith random-effects models. The third step is due to the partition of
studies in the network without cycles, i.e., S = ⋃K−1j=1 Sj , and the outcome measures
yj in studies Sj depending on ej but not the other basic parameters in eb. This
study partition also naturally holds when the Smith random-effects models are used for
different sets of studies Sj . Therefore, by simultaneously using the Smith random-effects
models conditional on the common heterogeneity standard deviation σ, the posterior
distribution of eb is also
pS(eb | D) ∝
∫∫ 
K−1∏
j=1
f(yj | ej , σ, µ˜j , ξj)p(ej)p(µ˜j)
 p(σ) dµdσ
=
∫ 
K−1∏
j=1
∫
f(yj | ej , σ, µ˜j , ξj)p(ej)p(µ˜j) dµ˜j
 p(σ) dσ.
That is, pLA(eb | D) = pS(eb | D). This completes the proof.
Proof of Proposition 7. Among all connected networks with K treatments, we consider
the network which has the largest number of acyclic comparisons. This network may
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not be unique, but it must contain no evidence cycles. Otherwise, the removal of
certain comparisons in evidence cycles would add acyclic comparisons; this contradicts
the fact that this network has the most acyclic comparisons among all networks with
K treatments. As this network does not have cycles, it is a spanning tree and contains
K − 1 treatment comparisons. Hence, the number of acyclic comparisons does not
exceed K − 1; i.e., J ≤ K − 1.
Proof of Theorem 4. If there is evidence inconsistency in the sub-network consisting of
S?, let w? be the inconsistency factors. Consequently, the functional parameters e?f in
the sub-network are determined by e?b and w
?. The remaining proof is similar to that
of Theorem 1. In the Smith and Lu–Ades fixed-effects models, let µ = (µ1, . . . , µN )
T be
the study-specific baseline effects, µ˜j = (µi; i ∈ Sj)T be the baseline effects in studies
Sj , and µ? = (µi; i ∈ S?)T be those in studies S?. Denote yj = (yik; i ∈ Sj , k ∈ Ti)T,
ξj = (ξik; i ∈ Sj , k ∈ Ti)T, and y? = (yik; i ∈ S?, k ∈ Ti)T, ξ? = (ξik; i ∈ S?, k ∈ Ti)T.
We have
p(eb | D) =
∫∫
p(eb,µ,w
? | D) dµdw?
∝
∫∫
f(y | eb,µ,w?, ξ)p(eb)p(µ)p(w?) dµdw?
=
∫∫
f(y? | e?b,µ?,w?, ξ?)p(e?b)p(µ?)p(w?) dµ? dw?
×
J∏
j=1
∫
f(yj | ej , µ˜j , ξj)p(ej)p(µ˜j) dµ˜j
∝ p(e?b | D?)
J∏
j=1
p(ej | Dj).
The notation in the equation above is similar to the notation in the proof of Theorem 1,
and p(w?) is the prior of w?.
In the random-effects models, further denote σj as the heterogeneity standard de-
viation of the acyclic treatment comparison ej (j = 1, . . . , J), and let σ
? be the
vector of heterogeneity standard deviations in the sub-network consisting of S? and
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σ = (σ1, . . . , σJ , (σ
?)T)T be the vector of heterogeneity standard deviations in the en-
tire network. As in the foregoing, we have
p(eb | D) =
∫∫∫
p(eb,σ,µ,w
? | D) dσ dµdw?
∝
∫∫∫
f(y | eb,σ,µ,w?, ξ)p(eb)p(σ)p(µ)p(w?) dσ dµdw?
=
∫∫∫
f(y? | e?b,σ?,µ?,w?, ξ?)p(e?b)p(σ?)p(µ?)p(w?) dσ? dµ? dw?
×
J∏
j=1
∫∫
f(yj | ej , σj , µ˜j , ξj)p(ej)p(σj)p(µ˜j) dσj dµ˜j
∝ p(e?b | D?)
J∏
j=1
p(ej | Dj).
If all evidence cycles are consistent, the inconsistency factors w? can be simply
ignored in the equations above. This completes the proof.
